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Abstract
Cell cycle regulation lies at the heart of all developmental decisions, and aberrant
regulation represents an important step in the onset of tumourigenesis. Alterations in cell cycle
regulators are known to play a critical role in promoting tumour formation in a wide variety of
tissues. The cyclin-like protein Spy1 is capable of binding and activating CDK2 and promoting
progression through G1/S phase of the cell cycle. Spy1 can also target the cell cycle inhibitor p27
for degradation, and it has been shown to override cellular checkpoints and apoptotic pathways in
response to DNA damage leading to enhanced cell survival. Previous data has shown that Spy1
levels are tightly regulated throughout mammary gland development, and high levels are
associated with breast cancer, as well as cancer of the brain and liver. This suggests a role for
Spy1 in normal mammary development as well as in the development of tumourigenesis.
Transgenic and gene targeted models represent an ideal system in which to study altered protein
expression on development and tumour initiation. This work describes the development of three
novel model systems to study altered Spy1 expression on normal and abnormal development of
the mammary gland. Using the newly generated MMTV-Spy1 mouse we have demonstrated that
elevated levels of Spy1 increases mammary tumour susceptibility, and interestingly liver tumour
susceptibility. We demonstrate that levels of Spy1 are downregulated in the event of DNA
damage and the tumour suppressor p53 may be responsible for mediating this event. If p53 is
unable to keep levels of Spy1 in check this can lead to uncontrolled cell proliferation, a hallmark
of oncogenesis, and may contribute to tumour initiation. Thus for the first time, we demonstrate a
role for Spy1 in mediating tumour susceptibility, highlighting the importance of maintaining
proper checkpoint responses. Our work demonstrates that Spy1 could prove to be an attractive
diagnostic marker and therapeutic target in the treatment of various forms of cancer, helping to
eradicate this deadly disease.
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Chapter 1
General Introduction

1

Introduction
The Cell Cycle
The cell cycle lies at the heart of all developmental decisions and provides precise control
over the balance between quiescence, proliferation, differentiation and apoptosis (Schafer, 1998;
Vermeulen et al., 2003). The cell cycle is divided into 4 distinct phases, G1, S, G2 and M phase
(Schafer, 1998; Vermeulen et al., 2003). During G1 phase, the cell receives cues that trigger
preparation for DNA synthesis and allow cells to progress through to S phase of the cell cycle,
which is characterized by DNA synthesis (Donjerkovic and Scott, 2000; Schafer, 1998;
Vermeulen et al., 2003). Following S phase, cells enter into G2 where they prepare for the final
stage in cell division, mitosis. After successful completion of mitosis, the cell can either
terminally differentiate, re-enter the cell cycle, or enter G0, a state of quiescence characterized by
reversible cell cycle arrest if the proper cues are received (Schafer, 1998; Vermeulen et al., 2003).
Throughout the cell cycle, checkpoints can be activated to halt progression in unfavourable
circumstances, such as in the event of DNA damage or improper DNA replication. Additionally,
when the cell reaches the end of its lifespan or in response to certain stresses, cells can enter a
state of irreversible cell cycle arrest known as senescence (Acosta and Gil, 2012). Progression
and inhibition of the cell cycle is tightly controlled by the activity of cyclins, cyclin dependent
kinases (CDKs) and cyclin dependent kinase inhibitors (CKIs) (Nakayama, 1998; Roussel, 1999;
Schafer, 1998). Activation and inhibition of these regulatory proteins provides tight control over
entry and exit of each stage of the cell cycle.

Cyclins and CDKs
Progression through the cell cycle is controlled by a number of regulatory proteins.
Binding of cyclins to their binding partners, CDKs, and phosphorylation and de-phosphorylation
of key residues on the CDK, activates the cyclin-CDK complex enabling phosphorylation of key
substrates known to control cellular division. Protein levels of cyclins are transient and cycle
2

throughout the duration of the cell cycle, with levels increasing only when necessary (Evans et
al., 1983; Pines, 1991; Vermeulen et al., 2003). CDKs are serine/threonine kinases that are
expressed ubiquitously through the cell cycle and are modulated through post-transcriptional
modifications such as activating and inhibitory phosphorylation (Malumbres and Barbacid, 2005;
Schafer, 1998; Vermeulen et al., 2003). Different cyclin-CDK complexes are required for
progression at each stage of the cell cycle. For example, Cyclin E-CDK2 plays a key role in
regulating the transition from G1 to S phase of the cell cycle while Cyclin B-CDK1 initiates entry
into mitosis (Schafer, 1998; Vermeulen et al., 2003). Full activation of CDKs requires binding of
the appropriate cyclin binding partner and key phosphorylating and de-phosphorylating events.
Binding of cyclins to CDKs is regulated by key regions located on the cyclin and CDK
(Malumbres and Barbacid, 2005; Pavletich, 1999; Schafer, 1998; Vermeulen et al., 2003).
Cyclins have a characteristic conserved region of approximately 150 amino acids known as the
cyclin box, which plays a critical role in mediating binding with the appropriate CDK (Kobayashi
et al., 1992; Noble et al., 1997). CDKs contain a PSTAIRE helix which makes contact with the
cyclin box (Morgan, 1997; Pavletich, 1999). Binding of the cyclin alters the conformation of the
CDK such that the T-loop phosphorylation site becomes accessible and relieves partial blocking
of the catalytic cleft (Jeffrey et al., 1995; Pavletich, 1999). Further conformational changes are
achieved after T-loop phosphorylation on Thr160 (CDK2)/Thr161 (CDK1) by CDK activating
kinases (CAK) (Jeffrey et al., 1995; Pavletich, 1999; Russo et al., 1996; Solomon et al., 1992).
For full activation of the cyclin-CDK complex, the inhibitory phosphorylation on Thr14/Tyr15 by
Myt1 is removed by the phosphatase Cdc25 (Lew and Kornbluth, 1996; Nigg, 1995). Three
isoforms of Cdc25 exist and function in distinct phases of the cell cycle (Donzelli and Draetta,
2003; Karlsson-Rosenthal and Millar, 2006). Cdc25A promotes entry into S phase and
progression through the G2/M transition and dephosphorylates Cyclin E-CDK2, Cyclin A-CDK2
and Cyclin B-CDK1 (Donzelli and Draetta, 2003; Karlsson-Rosenthal and Millar, 2006). Cdc25B
and Cdc25C however, only dephosphorylate Cyclin B-CDK1 and therefore promote entry into
3

mitosis (Donzelli and Draetta, 2003; Karlsson-Rosenthal and Millar, 2006). In this state, the
cyclin-CDK complex is fully activated and will phosphorylate target substrates to promote
progression through the cell cycle.

Cell Cycle Inhibition: Cyclin Dependent Kinase Inhibitors
In response to DNA damage or environmental stressors, cyclin dependent kinase
inhibitors (CKIs) will inhibit the kinase activity of cyclin-CDK complexes to halt progression of
the cell cycle (Nakayama, 1998). Two classes of CKIs exist, the INK4 family of inhibitors and
Cip/Kip family. Each family of proteins inhibits cyclin-CDK activity in a unique fashion. The
INK4 family consists of p15, p16, p18 and p19, and this class of inhibitors binds monomeric
CDK4 or 6 effectively altering the conformation of the CDK so that Cyclin D can no longer bind
(Canepa et al., 2007; Sherr and Roberts, 1995). The inability of Cyclin D to bind to its CDK
binding partner renders the kinase inactive preventing progression through G1 phase of the cell
cycle. Additionally, these inhibitors have been shown to play important roles in regulating
senescence and alterations or mutations could contribute to the development of cancer (Canepa et
al., 2007; Roussel, 1999).
The Cip/Kip family of inhibitors consists of p21WAF1/Cip1, p27kip1, and p57kip2 (Nakayama,
1998). In contrast to the INK4 family of inhibitors, Cip/Kip members inhibit a broader range of
CDKs and instead bind the cyclin-CDK complex (Nakayama, 1998; Pavletich, 1999). Binding to
the cyclin-CDK complex can induce conformational changes and prevent access to the catalytic
cleft thereby preventing cyclin-CDK activity (Pavletich, 1999). Binding of these inhibitory
proteins is mediated through the presence of a conserved hydrophobic patch on the cyclin
containing the MRAIL motif, which is also responsible for substrate recognition (Chen et al.,
1996; Schulman et al., 1998). Members of this family of inhibitors are known to play crucial roles
in regulating normal developmental processes to prevent aberrant rates of proliferation. Levels of
p27 are tightly regulated via ubiquitin-mediated proteolysis and levels rapidly decrease in late G1
4

and S phase (Nakayama, 1998; Pagano et al., 1995). p27 primarily inhibits the cell cycle during
G1 and thus plays a critical role in mediating cellular proliferation (Donjerkovic and Scott, 2000;
Nakayama, 1998). This is demonstrated by the phenotype seen in mice lacking p27; without p27,
mice are significantly larger than control littermates and multiple organs exhibit significant
hyperplasia, highlighting the importance of p27 in regulating cell proliferation (Fero et al., 1996;
Nakayama et al., 1996). The cell cycle inhibitor p21 can be upregulated and activated through
p53 dependent and independent pathways and p21 is known to play a critical role for p53
dependent cell cycle arrest in G1 in response to DNA damage (el-Deiry et al., 1994). Expression
of p21 is not solely dependent on p53, although its upregulation in response to DNA damage
events occurs in a p53-dependent fashion (el-Deiry et al., 1994; Gartel and Tyner, 2002; Macleod
et al., 1995). In addition to its role in growth arrest in response to DNA damage, p21 may also
play a role in regulating exit from the cell cycle to promote differentiation (Steinman et al., 1994).
Exit from the cell cycle is a key component in terminal differentiation, thus precise control over
cell cycle entry and exit is critical for the expansion and maintenance of various cell populations
within the body. These regulators play a crucial role in proper development and prevent aberrant
growth and proliferation, a hallmark of cancer.

DNA Damage Response
DNA within a cell is exposed to a variety of insults and can be damaged either through
normal intrinsic events or from environmental stimuli such as UV irradiation or exposure to
harmful chemical substances. Regardless of how the DNA has been damaged, the cell must
activate pathways to repair or remove the damage, or risk accumulation of the damaged DNA
which could ultimately lead to carcinogenic events. Cell cycle checkpoints during G1/S and
G2/M can detect various forms of DNA damage and induce cell cycle arrest allowing the
appropriate repair machinery to be activated (Sancar et al., 2004). In the event that the DNA
cannot be repaired, the cell can undergo senescence to stop proliferation of the cell thereby
5

preventing subsequent expansion of a potentially dangerous population, or apoptotic pathways
can be activated to eliminate the cell completely.
DNA damage is recognized by serine/threonine kinases ataxia telangiectasia mutated
(ATM) and ataxia telangiectasia and Rad 3 related (ATR) which activate checkpoint pathways
and recruit the appropriate repair machinery to the site of damage for repair to occur (Sancar et
al., 2004; Smith et al., 2010). These kinases each recognize and respond to different types of
DNA damage, with ATM becoming activated in response to double strand breaks and ATR
responding to damage resulting from UV exposure (Hurley and Bunz, 2007; Sancar et al., 2004;
Smith et al., 2010). Upon activation of ATR and ATM, protein kinases Chk1 and Chk2 are
subsequently phosphorylated and activated by ATR and ATM respectively (Hurley and Bunz,
2007; Lukas et al., 2003; Smith et al., 2010). Rapid cell cycle arrest is achieved through
phosphorylation of Cdc25A leading to its ubiquitin-mediated degradation (Donzelli and Draetta,
2003; Mailand et al., 2000; Mailand et al., 2002). Without active Cdc25A, cyclin-CDK
complexes remain inactive allowing for cell cycle arrest and DNA repair to occur (Donzelli and
Draetta, 2003; Mailand et al., 2000; Smith et al., 2010). Additionally, phosphorylation of p53 will
lead to accumulation of p53 and sustained cell cycle arrest (Meek, 2004; Sakaguchi et al., 1998;
Shieh et al., 1997). Under normal circumstances, levels of p53 are held in check by the E3
ubiquitin ligase Mdm2, which blocks transcriptional activity of p53 and targets it for degradation
(Meek, 2004; Sakaguchi et al., 1998; Shieh et al., 1997). Phosphorylation of p53 on Ser15 and
Ser20 disrupts the interaction between p53 and Mdm2 leading to stabilization of p53 (Kruse and
Gu, 2009; Meek, 2004; Sakaguchi et al., 1998; Shieh et al., 1997). p53 can subsequently activate
target genes such as p21, which can further inhibit the cell cycle in G1 phase, or in the event that
the damage cannot be repaired, can activate apoptotic pathways (He et al., 2005; Meek, 2004).
Thus, p53 serves as a master regulator of the DNA damage response, mediating activation of the
appropriate repair pathways and response to damage as required by the severity of damage.
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The DNA repair response is a complex set of pathways with a large number of regulators
that identify the sites and types of DNA damage, recruit repair machinery, halt cell cycle
progression and repair the DNA. Examining levels and phosphorylation status of many of these
repair pathway proteins can indicate the level of damage and if an effective DNA repair response
has occurred. Histone H2A variant (H2AX) is a reliable marker when examining activation of
repair in response to DNA double stranded breaks (Dickey et al., 2009). In response to double
stranded breaks, H2AX phosphorylation on Ser139 is mediated by ATM, and once
phosphorylated is known as γH2AX (Dickey et al., 2009; Paull et al., 2000; Rogakou et al.,
1998). γH2AX is found at the site of double stranded breaks and is thought to help recruit repair
machinery to the site of damage by allowing the DNA to become less condensed enabling easier
access for repair proteins (Dickey et al., 2009; Kinner et al., 2008; Paull et al., 2000). Studies
have shown that H2AX is phosphorylated rapidly after damage, with phosphorylation evident 1 to
3 minutes after damage and levels of phosphorylation directly related to the severity of damage
(Dickey et al., 2009; Paull et al., 2000; Podhorecka et al., 2010). Increased levels of γH2AX have
been found in various types of cancer cells as well as in senescent cells indicating that these cells
have accumulated damage over time (Das et al., 1989; Dickey et al., 2009; Lee et al., 2008;
Sedelnikova and Bonner, 2006). Rodent models in which tumours have been induced by the
carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) have found increased levels of γH2AX in
the tumours indicating that the development of tumours is in part due to accumulated damage
(Lee et al., 2008). DMBA causes DNA adduct formation once its carcinogenic metabolite
covalently binds to DNA (Das et al., 1989; Melendez-Colon et al., 1999). This triggers the DNA
repair pathway activated in response to double stranded breaks (Costa et al., 2003; Dickey et al.,
2009; Paull et al., 2000; Podhorecka et al., 2010). In circumstances of extensive adduct formation,
such as in the case of exposure to DMBA, the repair machinery cannot keep up with the amount
of damage and damage begins to accumulate. The cell continues to divide and levels of γH2AX
increase as time progresses. Ultimately, the unrepaired damage leads to deleterious mutations in
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the DNA, causing tumourigenesis (Dickey et al., 2009). These findings highlight the importance
of an intact and efficient DNA repair pathway in the prevention of oncogenesis.

Thus, tight regulation over the cell cycle is imperative in maintaining the genomic
integrity of the cell, and in preventing unwanted, deleterious mutations from occurring. Entry and
exit from each stage of the cell cycle is tightly controlled by a number of cell cycle regulators that
each play a key role in ensuring the cell cycle proceeds in an effective manner. Progression
through the cell cycle is required to expand or replenish cell populations, while exit from the cell
cycle is needed to allow for terminal differentiation to occur. Inhibition during times of damage is
critical for maintaining the health an organism, as unchecked damage can accumulate over time
ultimately leading to tumourigenesis. A complete understanding of all of the regulators at play is
required to fully elucidate the mechanisms which control normal growth and development and
will ultimately expand understanding of the mechanisms responsible for tumour initiation and
progression.

Speedy/RINGO: A Family of Cell Cycle Regulators
Speedy/RINGO: Discovery, Function and Family Members
The discovery of Speedy/RINGO, or Spy1, was initially made in a rad1 deficient strain of
S.pombe that typically arrest at the G2/M transition in response to DNA damage (Lenormand et
al., 1999). Using this model, researchers identified and isolated Xenopus genes from a Xenopus
cDNA library that were able to overcome the G2/M arrest in response to damage, thereby
isolating genes involved in cell cycle regulation (Lenormand et al., 1999). Through this screen,
one clone was identified to confer resistance to UV radiation, and was coined Speedy, or Spy1
(Lenormand et al., 1999). Spy1 was found to be expressed in stage IV oocytes with levels
remaining fairly constant until the onset of gastrulation, where at that point, levels became
undetectable (Lenormand et al., 1999). Spy1/RINGO mRNA translation is repressed by binding
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of Pumilio2, an RNA binding protein, to its 3’UTR and 5’end of the cap structure until
progesterone stimulation causes dissociation of Pumilio2 from Spy1/RINGO mRNA, leading to
translation (Cao et al., 2010; MacNicol and MacNicol, 2010; Padmanabhan and Richter, 2006).
These results show that Spy1 is present in Xenopus oocytes as maternal mRNA, and therefore
could play a role in cell cycle regulation.
Stage IV oocytes are arrested at the G2/M boundary, and stimulation with progesterone
triggers progression through this stage to allow for the completion of the first stage of meiosis
(Sagata et al., 1989). Mos and mitogen activated protein kinase (MAPK) have also been shown
to stimulate oocyte maturation and inhibition of either mos or MAPK resulted in a block of
progesterone-induced maturation indicating the essentiality of both factors in this process
(Nebreda and Hunt, 1993). To test if Spy1 was capable of regulating cell cycle dynamics, Spy1
mRNA was injected into stage IV oocytes and progression past the G2/M boundary was
monitored. Injection of Spy1 mRNA not only induced release from G2 arrest and rapid oocyte
maturation, but it did so approximately 2-fold faster than seen in oocytes induced with mos
mRNA or progesterone (Ferby et al., 1999; Lenormand et al., 1999). To further validate the role
of Spy1 in oocyte maturation, depletion of Spy1 from stage IV oocytes with antisense
oligonucleotides significantly delayed oocyte maturation in response to progesterone,
highlighting the importance of this protein in this process (Ferby et al., 1999). Additionally, Spy1
injection triggered cdc2 kinase activity and MAPK activation quicker than that seen in
progesterone induced or mos injected oocytes (Ferby et al., 1999; Lenormand et al., 1999). When
oocytes were treated with a MEK inhibitor to effectively inhibit the MAPK pathway, the ability
of Spy1 to induce oocyte maturation was significantly delayed indicating a requirement for
MAPK activation in Spy1 mediated oocyte maturation (Lenormand et al., 1999). The ability of
Spy1 to release oocytes from the G2/M arrest established it as a cell cycle regulator. The question
remained however, whether or not Spy1 was capable of interacting with other cell cycle
regulatory proteins. Co-injection of Spy1 and CDK2 mRNA followed by co-immunoprecipitation
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demonstrated that these two proteins were capable of directly binding to one another (Lenormand
et al., 1999). CDK2 activity was also greatly up-regulated as a result of Spy1 injection as
compared to mos injection or progesterone stimulation (Lenormand et al., 1999). In addition to
promoting cell cycle progression, Spy1 may stimulate the translation of other mRNA important
for oocyte progression by activating Musashi, a known stem cell factor which is responsible for
translation of the mos mRNA required for oocyte maturation (Arumugam et al., 2012;
Charlesworth et al., 2006; MacNicol and MacNicol, 2010).Thus the newly discovered Spy1
protein was shown to be capable of inducing the G2/M transition in Xenopus oocytes, thus
establishing a new family of cell cycle proteins.
The cloning of the human homologue of Spy1 was made using a testis cDNA library
identifying proteins that were homologous to Xenopus-Spy1 (X-Spy1) (Porter et al., 2002). The
resulting match yielded 40% homology to X-Spy1 but also contained a central region with 70%
homology (Porter et al., 2002). To confirm this clone was indeed the human homologue to XSpy1, human Spy1 was injected into Xenopus oocytes to determine its ability to trigger oocyte
maturation. Although slower than X-Spy1, human Spy1 induced oocyte maturation upon
injection therefore confirming that the newly identified clone was indeed the human homologue
of Spy1 (Porter et al., 2002). A panel of deletion mutants of X-Spy1 were generated to test which
region of the protein was essential for its activity. It was found that the central region, the most
highly conserved portion of the protein, was essential for Spy1 activity (Porter et al., 2002).
Human Spy1 is expressed in a wide variety of human tissues, with levels relatively high
in the testis (Cheng et al., 2005b; Porter et al., 2002). Additionally, Spy1 is expressed in a wide
variety of immortalized cell lines (Cheng et al., 2005b; Porter et al., 2002). Since X-Spy1 is an
important cell cycle regulator in triggering release from the G2/M arrest, analysis of the
distribution of Spy1 expression during the cell cycle was assessed. Spy1 was expressed only in
G1/S phase of the cell cycle (Dinarina et al., 2009; Porter et al., 2002) and is localized to the
nucleus where it is capable of binding and activating CDK2, as seen with X-Spy1 (Porter et al.,
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2002). Increased levels of Spy1 led to a significant increase in the proliferative capacity of the
cells, increasing cellular proliferation and shortening G1 phase of the cell cycle (Porter et al.,
2002). The ability of Spy1 to enhance proliferation was dependent on CDK2, as inhibition of
CDK2 inhibited the ability of Spy1 to enhance cellular proliferation (Porter et al., 2002). Spy1 is
an essential player in normal cell proliferation as depletion of Spy1 from the cell significantly
decreased rates of cell proliferation (Porter et al., 2002). Overall, Spy1 was established to be a
critical player in the cell cycle machinery of mammalian cells.
After the discovery of human Spy1, further searches yielded new family members in the
Speedy/RINGO family of proteins (Table 1) (Cheng et al., 2005b; Dinarina et al., 2005). To date,
no homologues have been identified in yeast, worms, flies or plants; however, a potential
homologue has been identified in Ciona intestinalis (Cheng et al., 2005b). The discovery of this
homologue in this primitive branch of chordates suggests that homologues may exist in all
vertebrates, as modern day vertebrates branched off from Ciona intestinalis (Cheng et al., 2005b).
To date, 5 family members in total have been identified (Cheng et al., 2005b; Dinarina et al.,
2005). All share homology in the central core of amino acids, the Speedy/RINGO (S/R) box,
which is essential for binding to CDKs, but differ outside of this central region of similarity
(Cheng et al., 2005b; Dinarina et al., 2005). Speedy/RINGO A is expressed in a wide variety of
human tissues and immortalized cell lines (Cheng et al., 2005b; Dinarina et al., 2005; Porter et al.,
2002). Additionally, there are 2 isoforms of Speedy/RINGO A, Spy1 A1 and Spy1 A2 which
differ in their C-terminal region, with Spy1 A1 being the longer isoform (Cheng et al., 2005b).
Analysis of the two isoforms demonstrated Spy1 A1 to be identical to the originally identified
human Spy1, and will be referred to as Spy1 throughout (Cheng et al., 2005b). The Spy1 protein
can be divided up into three basic regions (Figure 1). The central portion of the protein, the S/R
box, is responsible for CDK binding, which has been previously demonstrated (Cheng et al.,
2005b; Dinarina et al., 2005; Porter et al., 2002). The N terminal region was found to be
responsible for regulating protein stability or degradation, while the C terminal region was noted
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to be required for CDK activation (Cheng et al., 2005b; Dinarina et al., 2005). Given that the
originally identified human Spy1 protein is capable of binding and activating CDK2, the CDK
binding preference of Spy1A was analysed. Spy1 is capable of binding and activating both CDK2
and CDK1, consistent with previous data (Cheng et al., 2005b; Dinarina et al., 2005).
The remaining family members in the Speedy/RINGO family of proteins all possess
similarities in the sequence of the S/R box, but differ in expression and binding to the CDKs
(Cheng et al., 2005b; Dinarina et al., 2005). Speedy/RINGO B has been shown to be expressed
solely in the testis of mice, and cannot promote oocyte maturation when injected into Xenopus
oocytes; however it can accelerate this process in the presence of progesterone, indicating the
basic function of the protein may be conserved (Cheng et al., 2005b; Dinarina et al., 2005). When
binding specificity to CDK partners was analysed, Speedy/RINGO B was found to bind
preferentially to Cdk1 (Cheng et al., 2005b; Dinarina et al., 2005). In contrast to Speedy/RINGO
B, Speedy/Ringo C is able to bind both CDK1 and CDK2 and is expressed in a wider range of
tissues (Cheng et al., 2005b; Dinarina et al., 2005). Speedy/RINGO C is found in tissues such as
the liver, placenta and bone marrow, which may indicate a role in polyploidization as these tissue
frequently exhibit polyploidy (Cheng and Solomon, 2008; Cheng et al., 2005b; Dinarina et al.,
2005; Mouron et al.). Less is known about Speedy/RINGO D, although it is known to be
expressed in mice (Cheng et al., 2005b; Dinarina et al., 2005). In contrast to the other well-known
family members, Speedy/RINGO E actually impairs cell cycle progression in the Xenopus oocyte
system despite its known ability to bind CDKs 1, 2, and 5 (Cheng et al., 2005b; Dinarina et al.,
2008; Dinarina et al., 2009). Thus, the Speedy/RINGO family of proteins represents a novel class
of cell cycle regulatory proteins that play a distinct role in the regulation of cell cycle progression.

12

Name

CDK Binding Partner

Expression

Speedy/RINGO A

CDK1, CDK2

Ubiquitous

Speedy/RINGO B

CDK1

Testis

Speedy/RINGO C

CDK1, CDK2

Liver, placenta, testis, bone
marrow, small intestine, kidney

Speedy/RINGO D

Unknown

Unknown

Speedy/RINGO E

CDK1, CDK2, CDK5

Unknown

Table 1: Speedy/RINGO family members

M102 F107
T15 S22 T33

D90 Y106

N

E136

D135

E137

C

S/R Box

Degradation

68

CDK Binding

200

CDK Activation

Figure 1: Schematic of Speedy/RINGO structure depicting location and function of
conserved regions with important residues for degradation and CDK binding indicated.
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Spy1 and Cell Cycle Regulation
Spy1 is capable of inducing oocyte maturation in Xenopus oocytes and stimulating
cellular proliferation in mammalian cell culture systems, indicating a key role in mediating cell
cycle progression (Ferby et al., 1999; Lenormand et al., 1999; Porter et al., 2002). The ability of
Spy1 to bind to CDKs through a conserved stretch of amino acids known as the Speedy/RINGO
(S/R) box is at least in part responsible for cell cycle progression (Cheng et al., 2005b; Dinarina et
al., 2009; Porter et al., 2002). Mutation of three key amino acid residues within this region
abolished binding of Spy1 to CDK2 highlighting the importance of this region in mediating the
Spy1-CDK2 interaction (Dinarina et al., 2009). While Spy1 can bind and activate CDKs, it is able
to do so in a unique manner. Spy1 is capable of binding and activating CDK2 in the absence of
the activating T loop phosphorylation demonstrated by Spy1’s ability to activate mutants of
CDKs that are unable to be phosphorylated on Thr161 and Thr160 (Cheng et al., 2005a;
Karaiskou et al., 2001). Spy1 is also less sensitive to inhibitory phosphorylation on Thr14/Tyr15
(Karaiskou et al., 2001). Addition of Myt1 kinase, which is known to phosphorylate the Thr14
residue, was shown to have a reduced inhibitory effect on Spy1-CDK activity, demonstrating that
Spy1 is less sensitive to the inhibitory effects of these phosphorylation sites (Karaiskou et al.,
2001). Thus, Spy1 is capable of activating CDKs in a manner that does not rely on the classical
phosphorylating and de-phosphorylating events required for cyclin activation of CDKs. Despite
this, the manner in which Spy1 and CDK binding occurs may be similar to that of cyclin-CDK
binding. Mutation of amino acid residues Ile49 and Arg50 in the PSTAIRE region of CDK2
prevented Spy1 binding to CDK2 (Dinarina et al., 2005). These residues are also important for
mediating Cyclin A binding to CDK2 indicating that Spy1 may in fact be binding in a similar
manner as the classical cyclins (Dinarina et al., 2005; Karaiskou et al., 2001). The ability of Spy1
to activate CDKs in the absence of the CDK classical phosphorylation status may, however, be
due in part to the ability of Spy1 to alter CDK conformation to a state that is normally induced by
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T loop phosphorylation, negating the requirement of this phosphorylation event (Karaiskou et al.,
2001).
CDK-cyclin complexes are known to phosphorylate canonical substrates consisting of the
sequence (S/T)PX(K/R) (Errico et al., 2010). Classic CDK-cyclin complexes prefer a basic
residue such as lysine or arginine to be located at the +3 position in relation to the
phosphorylation site (Holmes and Solomon, 1996). In contrast, Spy1-CDK complexes can
tolerate a wide variety of residues located at the +3 position and can phosphorylate non-canonical
substrates of CDKs (Cheng et al., 2005a). Since the Thr160 residue makes contact with the +3
residue, it is possible that the ability of Spy1 to induce activation in the absence of Thr160
phosphorylation may alter substrate specificity (Cheng et al., 2005a). It is also conceivable that
the binding of Spy1 to CDK2 may induce a different conformation than CDK-cyclin complexes,
which may also contribute to its ability to phosphorylate non canonical substrates well (Cheng et
al., 2005a). Taken together, the ability of Spy1 to uniquely activate CDKs and phosphorylate both
canonical and non-canonical substrates contributes to its functionality in regulating cell cycle
progression.
Cyclin dependent kinase inhibitors, CKIs, play a crucial role in regulating cell cycle
progression, negatively affecting progression by inhibiting cyclin-CDK complexes. This may be
required in the event of DNA damage whereby the cell needs to halt cell cycle progression to
allow for the appropriate repair pathways to occur. The CKI p21 works to inhibit cell cycle
progression at the G1/S phase of the cell cycle by binding and inhibiting cyclin-CDK complexes
(Bartek and Lukas, 2001; He et al., 2005). Addition of p21 inhibits CDK2-Cyclin A activity but
CDK2-Spy1 activity is not inhibited, indicating that Spy1 is less susceptible to inhibition by p21
(Karaiskou et al., 2001). The decreased sensitivity to p21 inhibition may be due in part to Spy1
lacking the hydrophobic patch of the MRAIL motif found on cyclins that allows for p21
inhibition of CDKs (Karaiskou et al., 2001). In support of this theory, it was demonstrated that
addition of Spy1 with CDK1 and p21 led to a significant reduction in the amount of p21 bound to
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CDK1 as compared to the addition of Cyclin B1 (Karaiskou et al., 2001). This data supports that
Spy1 is less sensitive to inhibition by p21 which may be due in part to decreased binding affinity.
While Spy1 has been shown to have reduced binding affinity to p21, it has been shown to
bind directly to another CKI, p27 (Porter et al., 2003). The CKI p27 is a member of the Cip/Kip
family and binds CDK2-Cyclin E, and CDK4-Cyclin D complexes to inhibit their activity, thus
halting cell cycle progression. In a yeast two-hybrid screen, Spy1 was shown to bind to p27;
further analysis revealed that Spy1 interacts with the CDK binding region on p27 (Porter et al.,
2003).

Together, Spy1, CDK2 and p27 are able to form a complex; Spy1 is capable of

overcoming a p27-induced cell cycle arrest and increasing turnover of p27 in G1/S phase of the
cell cycle (McAndrew et al., 2007; Porter et al., 2003). Increased p27 turnover in the presence of
Spy1 is due to the ability of Spy1/CDK2 to phosphorylate p27 on Thr187, targeting p27 for
degradation (McAndrew et al., 2007). This phosphorylation event is dependent on the ability of
Spy1 to both bind and activate CDK2, and requires the C terminal region of Spy1 for CDK2
activation (Cheng et al., 2005b; McAndrew et al., 2007). In addition to its ability to target p27 for
degradation, addition of Spy1 protects CDK2-Cyclin E complexes from p27 inhibition
(McAndrew et al., 2007). Thus, Spy1 could further drive cell cycle progression in part due to its
ability to overcome p27-induced cell cycle arrest, target p27 for degradation, and protect CDK2Cyclin E complexes from inhibition (McAndrew et al., 2007; Porter et al., 2003). This could
provide a unique mechanism whereby Spy1 facilitates cell cycle progression and overcomes
checkpoints in the event of DNA damage, an event which could have drastic consequences in the
context of cancer initiation and progression.
Cyclins are subject to tight regulation of expression levels during the cell cycle. Similar
to cyclins, Spy1 expression has also been shown to be regulated in a cell cycle specific manner
and the presence of PEST sequences suggests it may have a short half-life (Al Sorkhy et al., 2009;
Dinarina et al., 2009; Lenormand et al., 1999; Porter et al., 2002). Levels of Spy1 were shown to
be higher in G1 phase of the cell cycle and were down regulated during G2/M (Al Sorkhy et al.,
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2009; Dinarina et al., 2009). A panel of Spy1 deletion mutants were studied to determine the
regions of Spy1 responsible for mediating its degradation. Loss of the first 57 amino acids
prevented Spy1 degradation, indicating that the N terminus is required for mediating Spy1
degradation (Al Sorkhy et al., 2009). Further analysis of the N terminal region identified three
key amino acid residues responsible for mediating Spy1 degradation (Al Sorkhy et al., 2009).
Mutation of Thr15, Ser22, and Thr33 prevented the ubiquitination and subsequent degradation of
Spy1 (Al Sorkhy et al., 2009). This mutant also showed decreased levels of phosphorylation and
was capable of enhancing proliferation, even above that seen with wild-type Spy1 (Al Sorkhy et
al., 2009). Additionally, Spy1 degradation has been shown to be regulated via two different E3
ubiquitin ligases, namely the SCF-Skp2 complex and Nedd4 (Al Sorkhy et al., 2009; Dinarina et
al., 2009). Expression of Skp2 is inversely correlated with that of Spy1, and reduction of Skp2
levels leads to an increase in Spy1 levels, suggesting that the SCF-Skp2 complex could be
involved in degradation of Spy1 (Dinarina et al., 2009). An alternative mechanism of degradation
was shown to be through Nedd4 (Al Sorkhy et al., 2009). Addition of MG132 led to an increase
in Spy1 protein levels and a decrease in ubiquitination indicating a ubiquitin proteasome system
was responsible for Spy1 degradation (Al Sorkhy et al., 2009; Dinarina et al., 2009). A search of
possible E3 ubiquitin ligases yielded Nedd4 (Al Sorkhy et al., 2009). Co-immunoprecipitation
experiments showed direct binding of Spy1 to Nedd4 and increased Nedd4 led to a reduction in
Spy1 protein levels (Al Sorkhy et al., 2009). Spy1 protein levels are controlled by a variety of
cellular mechanisms and are tightly controlled during the cell cycle. This likely serves to prevent
early activation and prevent cell cycle progression under unwanted circumstances.

Spy1 and the DNA Damage Response
In the event of DNA damage, cell cycle checkpoints are activated, halting cell cycle
progression allowing for the damage to be repaired. If the damage cannot be repaired, apoptotic
pathways can be activated leading the cell death. Spy1 was initially isolated in a strain of rad1
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deficient yeast and was able to confer resistance to UV damage allowing for progression through
the cell cycle (Lenormand et al., 1999). This initial discovery demonstrated that in addition to its
ability to promote cell cycle progression, Spy1 may also override cell cycle checkpoints in the
event of DNA damage. Indeed, it was shown that in the case of exposure to DNA damaging
agents or after exposure to UV, cells with elevated levels of Spy1 showed increased cell survival
(Barnes et al., 2003; Gastwirt et al., 2006). The ability of Spy1 to promote cell survival is
dependent on both its interaction and activation of CDK2 and is p53-dependent (Barnes et al.,
2003; Gastwirt et al., 2006; McAndrew et al., 2009). Upon DNA damage, increased interaction
between Spy1 and CDK2, as well as increased CDK2 activity, is essential for Spy1 mediated
increases in cell survival (Barnes et al., 2003; Gastwirt et al., 2006). Cell cycle checkpoint
activation at both S and the G2/M phase of the cell cycle was also inhibited as no changes were
observed in either DNA synthesis or in the levels of phosphorylated histone 3 (Gastwirt et al.,
2006). Overexpression of Spy1 results in decreased phosphorylation of key mediators of DNA
damage signaling, such as H2AX, RPA32 and Chk1 indicating impaired DNA damage signaling
(Gastwirt et al., 2006). Knockdown of Spy1 levels decreases cell survival in the presence of DNA
damage, indicating a potential role for Spy1 in the normal repair process (Barnes et al., 2003;
McAndrew et al., 2009). Thus, given Spy1’s ability to promote cell cycle progression, Spy1 may
serve as a mediator between cell cycle progression and checkpoint activation (McAndrew et al.,
2009). In the event of damage, elevated levels of Spy1 could continue to promote cellular
proliferation allowing for the accumulation of deleterious mutations, thereby playing a role in
cancer initiation and progression.

Indeed, elevated levels of Spy1 have been found in breast, brain and liver cancers, among
others, highlighting the importance of this protein in maintaining the balance between cell cycle
progression and inhibition (Al Sorkhy et al., 2012; Ke et al., 2009; Lubanska et al., 2014; Zucchi
et al., 2004). Elucidating the mechanism by which Spy1 regulates growth and development in
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normal developmental systems will provide further insight into the role it may play in the
initiation and progression of tumourigenesis.

The Mammary Gland
The mammary gland is an excellent study system as the majority of development occurs
post-natally allowing for investigators to study normal developmental processes that regulate
growth and development of the gland (Figure 2) (Howlin et al., 2006; Richert et al., 2000). The
gross structure of the murine mammary gland is composed of an extensive ductal network
composed of primary ducts as well as lateral branching which fills the fat pad (Hinck and
Silberstein, 2005; Richert et al., 2000). The hollow lumen of each duct is lined by luminal
epithelial cells which are surrounded by myoepithelial cells, the contractile cells within the gland
(Figure 3B) (Richert et al., 2000). During pregnancy, alveoli form and fill the fat pad, producing
and secreting milk proteins during lactation (Oakes et al., 2006; Richert et al., 2000). Once
lactation is complete, the gland involutes returning to its post-pubertal state where it awaits the
next round of pregnancy (Richert et al., 2000; Watson, 2006).
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Figure 2: The majority of mammary gland development occurs postnatal in a cyclic
fashion with repeated cycles of proliferation, differentiation, apoptosis and regeneration.
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Figure 3: Schematic representation of the structures of the mammary gland, A)
the terminal end bud and B) a mature duct. Yellow represents the highly proliferative
cap cells, green represents body cells, purple are the stem cells which reside in the
mature duct and orange represents progenitor cells. Mature luminal and myoepithelial cells are indicated in blue and red respectively.
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Development of the Murine Mammary Gland during Embryogenesis and Puberty
Development of the murine mammary gland begins mid-gestation and sets the stage for
rapid outgrowth of the rudimentary ductal tree formed during post-natal development. Embryonic
development of the murine mammary gland begins at embryonic day 10.5 with the formation of
mammary lines. Ectodermal cells migrate along this line and aggregate together to form
mammary placodes which dictate the location of the 5 pairs of mammary glands (Cowin and
Wysolmerski, 2010; Hens and Wysolmerski, 2005). At embryonic day 14.5, the placodes begin to
invaginate into the underlying mesenchyme to form mammary buds (Cowin and Wysolmerski,
2010; Hens and Wysolmerski, 2005; Richert et al., 2000). Ductal branching morphogenesis
generates a small number of ducts with a small number of side branches, and this process is
arrested at embryonic day 18.5 where the gland then remains developmentally arrested until the
onset of puberty (Cowin and Wysolmerski, 2010; Hens and Wysolmerski, 2005; Richert et al.,
2000). At the onset of puberty, the gland undergoes a period of development characterized by
rapid outgrowth of the ductal network, which is regulated in a hormone dependent manner, in
contrast to embryonic development which is regulated in a hormone independent manner
(Brisken and O'Malley, 2010; Richert et al., 2000). The driving force behind ductal elongation
during this period of development is the steroid hormone estrogen (Brisken and O'Malley, 2010;
Richert et al., 2000; Sternlicht, 2006). Estrogen signaling stimulates elongation of the
rudimentary ductal network formed during embryonic development allowing the duct to elongate
to fill the mammary fat pad (Brisken and O'Malley, 2010; Richert et al., 2000; Sternlicht, 2006).
Mice lacking estrogen receptor α are unable to respond to estrogen stimulation, fail to undergo
ductal morphogenesis, and the primitive ductal network remains in this form (Mallepell et al.,
2006). While estrogen may stimulate ductal morphogenesis and is essential for this process, the
driving force behind ductal elongation and bifurcation of the ducts are terminal end buds (TEBs)
(Hinck and Silberstein, 2005; Richert et al., 2000; Sternlicht, 2006). TEBs are bulbous structures
located on the ends of the elongating ducts and are known to be the site of the highest rates of
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proliferation within the mammary gland (Figure 3A) (Williams and Daniel, 1983). At
approximately 3 weeks of age at the onset of puberty, TEBs first appear and begin to drive
elongation of the ductal network (Hinck and Silberstein, 2005; Richert et al., 2000). At the
leading edge of TEBs are a population of undifferentiated pluripotent stem cells called the cap
cells, with the highest proliferative capacity of any cell population within the mammary gland
(Hinck and Silberstein, 2005; Richert et al., 2000; Williams and Daniel, 1983). Cap cells will
eventually give rise to the myoepithelial cells of the ducts but can also migrate into the inner
epithelial layer to give rise to luminal epithelial cells (Hinck and Silberstein, 2005; Richert et al.,
2000; Williams and Daniel, 1983). Beneath the cap cells are multiple layers of epithelial cells
which proliferate to help drive ductal elongation (Hinck and Silberstein, 2005; Richert et al.,
2000). As the TEBs progress through the fat pad, the innermost layer of epithelial cells undergo
apoptosis to produce a hollowed out lumen characteristic of the mammary ductal structure (Hinck
and Silberstein, 2005; Humphreys et al., 1996; Richert et al., 2000). Along the trailing edge of the
TEBs, cells differentiate, and myoepithelial cells help to produce the basement membrane known
to surround the ductal structures (Hinck and Silberstein, 2005; Richert et al., 2000; Williams and
Daniel, 1983). In addition to driving ductal elongation, TEBs are also capable of bifurcating to
produce additional branches on the ductal tree (Hinck and Silberstein, 2005; Richert et al., 2000).
This process produces the complex ductal structure characteristic of the mature mammary gland.
The TEBs guide and direct elongation of the ductal network through the fat pad; when they reach
connective tissue that has been generated by another epithelial structure, or once the edge of the
fat pad is detected, TEBs regress and terminal ducts are generated (Hinck and Silberstein, 2005;
Richert et al., 2000; Sternlicht, 2006). The filling of the fat pad signals the end of this phase of
development, which is usually completed between 10 and 12 weeks of age (Richert et al., 2000;
Sternlicht, 2006). Cyclic secretion of hormones during the estrous cycle, such as progesterone,
continues to stimulate lateral side branching and alveolar buds during post-pubertal development
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(Brisken and O'Malley, 2010; Richert et al., 2000; Robinson et al., 1995). The mammary gland
will remain in this state until the next stage of development, pregnancy, occurs.

Pregnancy and Lactation
The mammary gland exists in a highly dynamic state, ready to respond to changes in
hormone stimulation that occur with the onset of pregnancy (Oakes et al., 2006; Richert et al.,
2000). This stage of mammary development is characterized by an initial burst in proliferation,
followed by functional differentiation to generate the functional milk producing units of the
mammary gland, the alveoli (Anderson et al., 2007; Oakes et al., 2006; Richert et al., 2000;
Sternlicht, 2006). The initial stage of pregnancy consists of rapid expansion of the ductal network
leading to increased side branching and development of alveolar buds (Brisken, 2002; Oakes et
al., 2006; Richert et al., 2000). The steroid hormone progesterone is responsible for inducing
proliferation that leads to increased side branching as well as for inducing the formation of alveoli
(Brisken, 2002; Brisken and O'Malley, 2010). Mice lacking the progesterone receptor show
significant defects in pregnancy induced side branching as well as lobuloalveolar development
(Brisken et al., 1998; Humphreys et al., 1997). As pregnancy progresses, the epithelial to
adipocyte ratio increases and the number of lipid droplets is greatly diminished allowing for
expansion of the epithelial population to generate the functional units of the gland, the alveoli
(Anderson et al., 2007; Oakes et al., 2006; Richert et al., 2000). While the early stages of
pregnancy are characterized by proliferation, at mid-pregnancy the gland shifts to a state
predominated by differentiation. While progesterone plays a critical role in side branching, the
hormone prolactin plays a key role in differentiation and milk production through activation of
the Jak2-Stat5 pathway (Anderson et al., 2007; Brisken, 2002; Brisken et al., 1999; Brisken and
O'Malley, 2010; Gouilleux et al., 1994; Ormandy et al., 1997). Mice with loss of the prolactin
receptor in a gene knockout model display normal outgrowth and side branching, however, show
defects in differentiation and production of alveoli (Ormandy et al., 1997). The alveolar buds
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begin to progressively cleave and differentiate, generating individual alveoli that will acquire the
capacity to produce and secrete milk proteins (Anderson et al., 2007; Oakes et al., 2006; Richert
et al., 2000). Alveoli are composed of an inner layer of alveolar cells which line the hollow cavity
and are capable of secreting milk proteins (Anderson et al., 2007; Oakes et al., 2006; Richert et
al., 2000). Surrounding the alveolar cells is a discontinuous single cell layer of myoepithelial cells
which allow the inner alveolar cells to make contacts with the basement membrane which is
required for full differentiation to occur (Adams and Watt, 1993; Howlett and Bissell, 1993;
Richert et al., 2000). While the alveolar cells are responsible for milk production, the
myoepithelial cells are responsible for contracting to push the milk out of the alveoli into the
ducts (Richert et al., 2000). At the end of pregnancy and throughout lactation, the gland is filled
entirely with alveoli, and continues to produce and secrete milk proteins until the suckling
stimulus is removed. The gland then reverts back to its post-pubertal state.

Involution
During involution, remodelling of the gland reverts the gland back to its pre-pregnancy
state with the removal of alveolar cells and the reappearance of adipocytes (Richert et al., 2000;
Watson, 2006). This stage of development is characterized by apoptosis and can be divided into
two distinct phases (Richert et al., 2000; Watson, 2006). The first phase is initially reversible and
is characterized by flattening and shedding of the alveolar cells into the lumen and activation of
apoptotic pathways (Li et al., 1997; Richert et al., 2000; Watson, 2006). During this 48 hour stage
of development, no remodeling of the gland occurs; however at the onset of the second phase of
development while apoptosis is still occurring, remodelling of the gland begins to occur and this
process is now irreversible (Richert et al., 2000; Watson, 2006). The peak of apoptosis occurs at
approximately day 4 of involution when alveolar cells are detached from the alveolar structure
and have undergone programmed cell death (Quarrie et al., 1995; Richert et al., 2000). These
cells are cleared away by surrounding epithelial cells or macrophages that have invaded the area
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(Fadok, 1999; Richert et al., 2000). By day 4, the alveoli have collapsed, and are being cleared
away. At the same time adipocytes begin to refill to restore the original ratio of epithelial cells to
adipocytes that was altered during pregnancy and lactation (Richert et al., 2000; Watson, 2006).
Matrix metalloproteinases play a key role in the remodelling process by breaking down the
extracellular matrix to allow for detachment of the cells serving to trigger the apoptotic response
required for this stage of development (Green and Lund, 2005; Richert et al., 2000; Watson,
2006). By day 6 of involution, the alveoli have collapsed and the focus shifts to remodelling the
epithelium and stroma back to its pre-pregnant state (Richert et al., 2000; Strange et al., 1992).
Although massive remodelling of the gland needs to occur and apoptosis is extensive, systemic
hormones act as survival signals for the extracellular matrix and basement membrane structures
ensuring that the integrity of the gland is not fully disrupted (Li et al., 1997; Richert et al., 2000;
Watson, 2006). The entire gland is fully remodelled by day 21 and resembles its pre-pregnant
state; however it is known that the post-pregnant gland appears to be more differentiated when
compared to a nulliparous gland and may retain some alveoli that were generated during
pregnancy and lactation (Richert et al., 2000).
The mammary gland possesses the unique ability to undergo cyclic development
throughout life, and can completely remodel and regenerate itself after involution. This implies
the existence of stem or progenitor cell populations within the mammary gland that have the
capacity to reconstitute the various cell types within the gland.

Mammary Cell Populations and Hierarchy
The mammary gland retains a tremendous capacity for regeneration throughout the
duration of development due to populations of stem and progenitor cells that harness the potential
to reconstitute the gland during stages of remodelling. The entire mammary gland can be
reconstituted from the implantation of tissue fragments taken from any portion of the developed
mammary gland (Deome et al., 1959). Further work using flow cytometry analysis to isolate
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specific cell populations within the mammary gland demonstrated that the mammary gland can be
reconstituted in its entirety from the implantation of one stem cell into the cleared fat pad
(Kordon and Smith, 1998; Shackleton et al., 2006; Stingl et al., 2006). The stem cell population
known to have the ability to reconstitute a functional murine gland can be identified by the cell
surface markers CD49fhiCD29hiCD24+/medSca1low (Shackleton et al., 2006; Shehata et al., 2012;
Sleeman et al., 2007; Stingl et al., 2006). The stem cell population can undergo symmetric
division to replenish itself or asymmetric division to generate an identical daughter cell and a
more committed progenitor cell (Visvader and Lindeman, 2006; Visvader and Stingl, 2014). This
balance between symmetric and asymmetric division helps to maintain the correct number of cells
within the gland and allows for the massive expansion of epithelial cells seen during puberty and
pregnancy, as well as aids in remodelling of the gland during involution (Visvader and Lindeman,
2006; Visvader and Stingl, 2014). The mammary gland is thought to possess a hierarchy of cells
which arise from a common multipotent fetal mammary stem cell (Makarem et al., 2013; Spike et
al., 2012; Visvader and Stingl, 2014). The stem cell compartment in the mammary gland is not a
homogenous one, instead being comprised of both long and short term repopulating cells, with
the short term repopulating cells potentially playing a role in the transient but dramatic increase in
cell numbers associated with pregnancy (Asselin-Labat et al., 2010; Visvader and Lindeman,
2006; Visvader and Stingl, 2014). It is also thought that there may be a population of basal and
luminal stem cells that give rise to the progenitor cell populations, but further investigation is
required (Visvader and Lindeman, 2006; Visvader and Stingl, 2014). The number and type of
progenitors that exists within the mammary gland is also controversial; however, it is known that
progenitors of both the luminal and myoepithelial lineage exist (Visvader and Lindeman, 2006;
Visvader and Stingl, 2014). Myoepithelial progenitors give rise to mature myoepithelial cells.
The myoepithelial cells constitute the basal layer of ducts and alveoli. During puberty,
myoepithelial cells help to produce the basement membrane which surrounds the structures of the
gland; during pregnancy, these contractile cells respond to hormone stimulation to help expel
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milk from the alveoli into the ducts (Richert et al., 2000; Visvader and Lindeman, 2006; Visvader
and Stingl, 2014). Myoepithelial cells can be identified and extracted from the mammary cell
population based on surface marker expression of CD29hiCD49fhiCD24+EpCAMlo/med (Visvader
and Lindeman, 2006; Visvader and Stingl, 2014). In addition to myoepithelial cells, the gland is
also composed of cells of a luminal lineage which can be isolated based on the cell surface
expression of CD49floCD29loCD24+CD14-EpCAMhic-kit-Sca1+CD61-CD49b- and mature ductal
and alveolar cells can be isolated based on CD49floCD29loCD24+CD14-EpCAMhic-kitSca1+CD61-CD49b- and CD49floCD29loCD24+CD14-EpCAMhic-kit-Sca1lowCD61- respectively
(Shehata et al., 2012; Sleeman et al., 2007; Visvader and Lindeman, 2006; Visvader and Stingl,
2014). Ductal epithelial cells line the lumen of the ducts, while alveolar cells line the inside of the
alveoli and are capable of producing and secreting milk proteins during pregnancy. The hierarchy
may not be as straightforward as it seems. Luminal progenitors implanted into a cleared fat pad
can reconstitute the gland suggesting that luminal progenitors may retain a certain degree of
plasticity, and may have the potential to revert back to a more stem like state (Visvader and
Stingl, 2014). Injecting this population with certain basement membrane substrates may enhance
this phenotype, thus demonstrating the importance of the microenvironment on mammary cell
status (Shehata et al., 2012; Sleeman et al., 2007; Vaillant et al., 2011; Visvader and Stingl,
2014). Additionally, a population of parity-induced mammary epithelial cells was identified
(Chang et al., 2014; Visvader and Stingl, 2014; Wagner et al., 2002). This population of cells is
located within the luminal cell layer of the ducts and arises during pregnancy (Chang et al., 2014;
Visvader and Stingl, 2014; Wagner et al., 2002). They can survive the process of involution, and
can continue to reside within the ducts, lying dormant until a subsequent round of pregnancy to
give rise to alveoli (Chang et al., 2014; Visvader and Stingl, 2014; Wagner et al., 2002). Although
much remains to be learned about the hierarchy of cells within the gland, these cells demonstrate
a remarkable capacity for self-renewal and contribute to regenerative processes that allow the
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mammary gland to exist in a highly dynamic state, perpetuating multiple rounds of proliferation,
differentiation and self-renewal.

Breast Cancer: Incidence, Susceptibility and Subtypes
Breast cancer remains the leading cancer diagnosis in women with 1 in 9 Canadian
women expected to develop breast cancer in their lifetime (Canadian Cancer Society, 2014).
Despite recent improvements in screening procedures and treatment options, 1 in 30 women will
ultimately succumb to the disease making it the second most common cause of cancer related
deaths in women (Canadian Cancer Society, 2014). A number of factors can contribute to a
woman’s risk of developing breast cancer. For instance, it is known that late onset of
menstruation, early age at first full term pregnancy, breast feeding and early onset of menopause
can all help to decrease the risk of developing breast cancer (2002; Byers et al., 1985; Hsieh et al.,
1990; Kelsey et al., 1993; MacMahon et al., 1970; Russo et al., 2005). This is presumably
because these events decrease a woman’s exposure to cycling hormones. Additionally, the
cellular changes that occur during pregnancy and lactation result in a more differentiated
population of cells which may be less susceptible to transformation events that would ultimately
lead to the development of breast cancer (Britt et al., 2007). In contrast, puberty represents a
period of development characterized by rapid proliferation and represents a period of increased
susceptibility when exposed to harmful stimuli such as ionizing radiation (Preston et al., 2002).
Irradiated adult mice were less susceptible to the development of aggressive estrogen receptor
negative (ER-) tumours while juvenile mice that were irradiated developed tumours at a much
higher frequency, presumably due to an expansion in the mammary stem cell population (Tang et
al., 2014). Thus, environmental factors and lifestyle can contribute to a woman’s susceptibility of
developing breast cancer by potentially altering the population of cells that reside within the
mammary gland.

28

Complicating treatment of this disease are the various known subtypes of breast cancer.
At least five major subtypes of breast cancer have been identified and distinct cell types are
thought to serve as the cell of origin for each (Perou et al., 2000; Sorlie et al., 2001). Claudin-low
breast cancers are thought to arise from the mammary stem cells that sit at the top of the cellular
hierarchy within the mammary gland based on a similar gene expression profile (Prat et al.,
2010). Basal-like breast cancer is associated with a poor clinical outcome due in part to its
common status as a triple negative breast cancer, meaning it lacks estrogen, progesterone and
Her2 receptors (Liedtke et al., 2008; Rakha et al., 2008). Carriers for the BRCA1 mutation have
an increased tendency to develop breast cancer of this subtype, and while the cells display a basal
like phenotype, the cell of origin has been demonstrated to be the luminal progenitor (Lim et al.,
2009; Turner and Reis-Filho, 2006). The cell of origin for the remaining subtypes, luminal A,
luminal B and Her2-positive, have not been conclusively demonstrated. There is some evidence
to suggest that luminal A may arise from a mature luminal cell while luminal B and Her2-positive
may arise from cells higher up the cell hierarchy as the cell transitions from luminal progenitor to
mature luminal cell (Visvader and Stingl, 2014). A complete understanding of the populations
and cycling dynamics of cells within the mammary gland must be fully understood in order to
fully elucidate the cell of origin for all breast cancer subtypes and better target and treat the
disease.

Cell Cycle Regulators and the Mammary Gland
The mammary gland exists in a highly dynamic state, characterized by cyclic stages of
development requiring cells to be able to exert tight control over proliferation, differentiation and
apoptosis. Misregulation at any stage of development could lead to aberrant growth and
ultimately tumour initiation. Cell cycle regulators play a key role in regulating each stage of
development and transgenic model systems have elucidated and highlighted the importance of
tight control of the cell cycle during mammary gland development (Hennighausen and Robinson,
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2001). Knockout studies in mice have demonstrated the importance of cyclins and CDKs in
regulating both normal development and promoting tumourigenesis. Ablation of CDK2 leads to
decreased branching and proliferation during puberty, indicating a requirement for this CDK in
pubertal development (Ray et al., 2011). Study of the role of CDK2 in other stages of mammary
development has proven difficult given that the CDK2 null mouse is sterile and thus the female is
unable to go through the stages of pregnancy, lactation and involution (Berthet et al., 2003). It
was additionally shown through crosses with the MMTV-neu mouse model, which drives
expression of the transgene specifically within the mammary gland, that CDK2 is required for
ErbB2 induced tumourigenesis (Ray et al., 2011). Ablation of CDK2 resulted in a significant
decrease in tumour incidence as well as an increase in tumour latency (Ray et al., 2011).
Similarly, loss of Cyclin D1-CDK activity also exerted a protective effect from MMTV-neu
induced mammary tumours (Landis et al., 2006). Although loss of Cyclin D1-CDK kinase
activity proved to be detrimental for tumour development, it did not have any significant effects
on mammary development (Landis et al., 2006). Complete loss of Cyclin D1 causes severe
defects in pregnancy and lactation, with mothers unable to nurse their pups due to a reduction in
acinar development during pregnancy (Fantl et al., 1995). The reduction in acinar development
may be in part due to significant defects in the ability of the gland to undergo the proliferative
changes necessary for pregnancy and lactation (Sicinski et al., 1995). To further validate the key
role Cyclin D1 may play in regulating proliferation within the mammary gland mice were
engineered to overexpress Cyclin D1 specifically in the mammary gland. MMTV-Cyclin D1 mice
display increased rates of proliferation with increased lobuloalveolar development and ductal side
branching (Wang et al., 1994). MMTV-Cyclin D1 mice also develop mammary adenocarcinomas
at a significantly higher rate than control littermates, indicating that Cyclin D1 plays an important
role in regulating proliferative events in the mammary gland and misregulation of these processes
could lead to tumourigenesis (Wang et al., 1994). Thus, data from these models further highlight
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the importance of appropriate control of the cell cycle in mammary development and
tumourigenesis.
The transcription factor c-Myc is a master regulator of many cellular processes such as
proliferation and apoptosis and is elevated in a large number of breast cancer cases (Dang, 1999;
Escot et al., 1986). The MMTV-Myc mouse was developed to study the effects of aberrant Myc
expression in the mammary gland. Mice containing the transgene displayed significantly more
mammary adenocarcinomas and this was associated with multiple rounds of pregnancy (Stewart
et al., 1984). MMTV-Myc mice are unable to lactate due to tumour onset and burden. Thus, an
inducible overexpression model was generated to allow expression of c-Myc to be turned on in
the mammary gland under the control of doxycycline during specific periods of development.
Utilization of this model identified a 72 hour period of time during pregnancy that was
responsible for the lactation defect observed in these mice (Blakely et al., 2005). Aberrant
expression of c-Myc from day 12.5 to 15.5 of pregnancy induces precocious development of the
gland leading to accelerated differentiation, and early onset of lactation (Blakely et al., 2005).
Since the gland prematurely lactates, milk stasis triggers involution prior to the birth of the pups,
leaving the mother unable to nurse her young (Blakely et al., 2005). Thus c-Myc contributes to
the control of many developmental events that occur during mammary gland development.
Positive cell cycle regulation is crucial to the proper development of the mammary gland;
however, tumour suppressors must be activated during specific times of development and in cases
of aberrant growth to prevent the onset of tumourigenesis. The tumour suppressor p53 is mutated
in approximately half of all human breast cancers. Patients with germline mutations in p53 are
predisposed to developing cancer, with breast cancer being one of the leading forms (Akashi and
Koeffler, 1998; Coles et al., 1992). Deletion of p53 in mice leads to significant tumourigenesis,
with mice succumbing to tumour formation between 4 and 6 months of age, and lymphomas
being the primary cause of death (Jacks et al., 1994). Due to early mortality from lymphomas,
breast tumour development is not seen at high levels in these mice. To study the effects of loss of
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p53 on tumour development, p53 null epithelium was transplanted into the cleared fat pad of
wild-type hosts and mice were treated with hormone stimulation or carcinogens (Jerry et al.,
2000). Mice lacking p53 developed significantly more tumours highlighting the importance of
this tumour suppressor on preventing tumour initiation (Jerry et al., 2000). Developmentally, p53
has also been shown to regulate symmetric versus asymmetric division of the mammary stem cell
population, with loss of p53 promoting symmetric division (Cicalese et al., 2009). Therefore, loss
of p53 could promote expansion of a population of tumour initiating cells promoting the initiation
and progression of breast cancer. Tight control of p53 levels and activity is required to allow for
proper function and to prevent the onset of tumourigenesis.
Thus, cell cycle regulators play a critical role in regulating the developmental decisions
of the mammary gland and help to promote proper growth and development. Disruption of these
pathways can lead to aberrant growth and onset of tumourigenesis further highlighting the
importance of fully elucidating the mechanisms regulating growth and development of the
mammary gland.

Comparison of Murine and Human Mammary Gland Development
Development of the murine and human mammary gland is regulated by the same
developmental processes but the gross morphological structure contains important differences.
The mammary fat pad of the mouse contains far more adipocytes and less fibrous material than
that found in the human breast indicating that while the cellular hierarchy between species is
highly similar, they may require different environmental stimuli for proper development (Hovey
et al., 1999; Visvader, 2009). In addition to differences in the fat pad, gross morphological
differences also exist between mouse and human. In humans, the network of ducts is highly
segmented and ducts terminate into the functional units of the gland the terminal ductal lobular
units (TDLU) (Cardiff and Wellings, 1999; Visvader, 2009). In contrast, the ductal network of the
murine mammary gland is not segmented and grows in a more linear fashion (Cardiff and
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Wellings, 1999). Mice lack TDLUs but instead possess lobuloalveolar units which form during
each estrous cycle (Cardiff and Wellings, 1999; Visvader, 2009). Despite these differences, the
cellular composition of the structures remains the same and they are able to carry out the same
functions.
While the cellular hierarchy is similar, differences do exist in the expression profiles of
surface markers used to identify key lineages within the mammary cell hierarchy. For instance,
CD24 is used to identify cells strictly of a luminal lineage in humans but in mice, is used as a
pan-epithelial marker (Shackleton et al., 2006; Stingl et al., 2006; Visvader, 2009). In humans,
increased activity of the enzyme aldehyde dehydrogenase (ALDH) can be used to identify
populations of cells with increased stem/progenitor properties but is not used to identify
stem/progenitor populations of the mouse mammary gland (Ginestier et al., 2007; Visvader,
2009). Tumourigenesis in transgenic mouse models can recapitulate phenotypes seen in human
breast cancer samples indicating that the proposed cell of origin remains the same (Cardiff and
Wellings, 1999). Thus, while differences may exist in gross morphological structure between the
murine and human mammary gland, the cellular composition remains unchanged. Both normal
and abnormal development of the gland are controlled by the same driving factors, making the
murine mammary gland an ideal study system for comparison of the events occurring in the
human breast.

Spy1, Mammary Gland Development and Tumourigenesis
Levels of Spy1 protein were analyzed during mammary gland development to determine
if expression changed depending on the stage of development. Spy1 protein levels were found to
be high during proliferative phases of development such as during puberty and early pregnancy,
and were drastically downregulated during late pregnancy and lactation, a period of development
characterized by differentiation (Golipour et al., 2008). Interestingly, levels of Spy1 were
elevated at the onset of involution, a developmental stage characterized by apoptosis (Golipour et
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al., 2008). Downregulation of Spy1 levels during differentiation was confirmed using the HC11
model system, a mammary epithelial cell system that responds to the same differentiation stimuli
they would be exposed to in vivo and are capable of forming spheroid structures which mimic the
morphology seen in vivo (Ball et al., 1988). A differentiation time course also showed a decrease
in Spy1 levels at the onset of differentiation. Overexpression of Spy1 during differentiation of
HC11 cells accelerated the expression of β–casein, a milk protein commonly used as an indicator
of differentiation during mammary pregnancy and lactation (Golipour et al., 2008). Additionally,
cells with elevated levels of Spy1 displayed disorganized piles of cells and were unable to form
the organized spherical structures typically formed by mammary epithelial cells (Golipour et al.,
2008). In vivo overexpression of Spy1 via mammary fat pad transplantation of Spy1 expressing
HC11 cells caused increased ductal branching and PCNA staining, a marker of proliferation
(Golipour et al., 2008). Additionally, increased rates of tumourigenesis were found with increased
levels of Spy1 (Golipour et al., 2008); however, the HC11 cells utilized contain a mutated p53,
therefore one can only conclude that Spy1 may accelerate or help to promote tumour initiation
(Golipour et al., 2008). Using the non-degradable mutant of Spy1, Spy1-TST, it was
demonstrated that losing the ability to degrade Spy1 leads to increased onset of tumourigenesis
and an increased tumour volume as compared to wild-type Spy1, indicating that losing the ability
to degrade Spy1 at the G2/M checkpoint may contribute to the onset of tumourigenesis (Al
Sorkhy et al.). To further highlight the importance of Spy1 in breast cancer initiation and
progression, analysis of Spy1 levels in various forms of human breast cancer revealed
significantly higher levels of Spy1 in all forms analyzed over that of pair matched adjacent or
normal tissue (Al Sorkhy et al.). Spy1 levels were also found to be elevated in more aggressive
lines of human breast cancer cells and Spy1 was found to be one of the fifty most upregulated
genes in invasive ductal carcinoma of the breast (Al Sorkhy et al.; Zucchi et al., 2004). Given the
tight regulation of Spy1 protein levels during mammary gland development, the ability to
accelerate mammary tumourigenesis in vivo, and the high levels of Spy1 noted in breast cancer
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samples, it appears that Spy1 plays a key role in regulating normal mammary gland development.
Misregulation of Spy1 could lead to the onset of tumourigenesis, highlighting the importance of
further elucidating the role Spy1 plays during mammary gland development.

Liver
The liver is a vital organ comprising 2 to 5% of a person’s total body weight and plays a
wide variety of roles ranging from protein secretion, detoxification and cholesterol metabolism
among others (Bisteau et al., 2014; Si-Tayeb et al., 2010). The large number of functions the liver
performs means it is essential for survival, thus loss of function resulting from chronic injury or
hepatocellular carcinoma is devastating. Those diagnosed with primary liver cancer face a
survival rate of only 5 years and death due to liver cancer remains the second most common cause
of cancer related death worldwide (Canadian Cancer Society, 2014; World Health Organization,
2014). In addition to the devastating effects of hepatocellular carcinoma, non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH), diseases of the liver characterized
by increased fat, inflammation and damage have been on the rise in recent years (Dowman et al.,
2010; Takahashi et al., 2012; The National Digestive Diseases Information Clearinghouse, 2014).
To better treat these debilitating, and sometimes life threatening conditions, a more thorough
understanding of the molecular mechanisms regulating growth and development are required.

Murine Liver Development
The majority of liver development takes place embryonically, with specification of the
liver starting at approximately embryonic day 9 (Kung et al., 2010; Si-Tayeb et al., 2010; Zorn,
2008). The liver arises in the ventral foregut from the lateral domains of the endoderm (Tremblay
and Zaret, 2005). During foregut closure, the medial and lateral domains become fused; the
endoderm becomes specified to a hepatic fate due to FGF signaling from the cardiac mesoderm
and BMP signaling arising from the septum transverse mesenchyme (Gualdi et al., 1996;
35

Houssaint, 1980; Rossi et al., 2001; Serls et al., 2005; Si-Tayeb et al., 2010; Zorn, 2008). Wnt
signaling is crucial for proper differentiation of the specified tissue generating the hepatoblasts, or
bipotential cells within the foregut (Monga et al., 2003; Suksaweang et al., 2004; Tan et al., 2008;
Zorn, 2008). Wnt signaling also promotes the formation of the liver bud at approximately day 9.5
when the hepatoblasts form a columnar shape and invade into the septum transversum
mesenchyme (Si-Tayeb et al., 2010; Zorn, 2008). Once the liver bud has been formed, the
hepatoblasts continue to proliferate, and differentiation commences at embryonic day 13,
continuing even after birth until all cells have become mature differentiated cells (Kung et al.,
2010; Si-Tayeb et al., 2010; Zhao and Duncan, 2005). During this period of differentiation, the
liver also separates into separate lobes, and sinusoids and bile canaliculi appear (Si-Tayeb et al.,
2010). Hepatoblasts in contact with the portal vein will differentiate to form a bi-layer of biliary
precursors that will ultimately give rise to cholangiocytes which are characterized by expression
of cytokeratin 19 (CK19) (Germain et al., 1988; Lemaigre, 2003; Zorn, 2008). Hepatoblasts not
in contact with the portal vein will give rise to hepatocytes, characterized by expression of αfetoprotein (AFP) during fetal development and albumin (Alb) (Germain et al., 1988; Shiojiri,
1981; Zorn, 2008). Hepatocytes constitute approximately 70% of the liver and thus perform the
vast majority of all liver functions (Blouin et al., 1977; Si-Tayeb et al., 2010). By embryonic day
17, hepatocytes are arranged in their characteristic morphology arranged into hepatic chords with
their apical surface in contact with bile canaliculi (Zorn, 2008). The process of differentiation
continues after birth until most of the cells are unipotent and committed to either a mature
cholangiocyte or hepatocyte. Thus, the liver remains in a relatively quiescent state throughout
life, unless injury to the liver occurs, in which case proliferation can once again be activated to
reconstitute the liver tissues; additionally a reservoir of adult liver stem cells known as oval cells
can be stimulated to divide and differentiate into the various cells that constitute the liver.

36

Cell Cycle, Ploidy and Regeneration in the Liver
Hepatocytes of the liver remain in a state of quiescence throughout much of adult life;
however, it retains a remarkable capacity to regenerate itself in the event of liver injury.
Proliferation and differentiation of hepatocytes continues after birth up until approximately 4
weeks of age, in the case of mice (Celton-Morizur et al., 2009; Viola-Magni, 1972). Until 3
weeks of age, all of the hepatocytes within the liver are diploid (Gentric et al., 2012). At 3 weeks
of age when weaning occurs, the hepatocyte population switches from a mostly diploid
population to a mostly tetraploid population, with 70% of mouse hepatocytes being tetraploid
(Gentric et al., 2012; Severin et al., 1984). The switch in ploidy results from the activation of
altered cell division which leads to incomplete cytokinesis. In essence, the cleavage furrow is not
formed and the cell does not divide, leading to generation of bi-nucleated tetraploid cells (Gentric
et al., 2012). This process is regulated through insulin signaling regulation of the PI3-K/Akt
pathway, as inhibition of Akt at this stage of development increased the number of diploid
hepatocytes seen in the post-natal liver (Celton-Morizur et al., 2009). Thus, hepatocyte
polyploidization is a naturally occurring process which may serve important roles in maintaining
the function and integrity of the liver (Gentric et al., 2012). Polyploidy may serve as a protective
mechanism for hepatocytes as one of their primary functions is detoxification of harmful
substances (Gentric et al., 2012). Having increased DNA content may serve as a back-up in the
event of damage or mutation (Gentric et al., 2012). Additionally, polyploidy may also decrease
the energy demands on hepatocytes, especially in the case of regeneration when hepatocytes not
only need to divide but also maintain liver function during this process (Gentric et al., 2012).
Although hepatocytes rarely divide, in the event of regeneration they are capable of reentering the cell cycle to regenerate the entire mass of the liver through compensatory growth
mechanisms (Fausto and Campbell, 2003). Exit from G0 is a highly coordinated process
composed of priming of the hepatocytes to respond to growth factor signaling and coordination of
DNA replication and cellular division (Bisteau et al., 2014; Ehrenfried et al., 1997; Fausto and
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Campbell, 2003). Tumour necrosis factor signaling primes hepatocytes to exit from quiescence
and enables them to respond to growth factor signaling such as hepatocyte growth factor (HGF)
and epidermal growth factor (EGF) (Fausto and Campbell, 2003; Webber et al., 1998; Webber et
al., 1994). Once hepatocytes are capable of responding to mitogenic stimuli, Cyclin D1 levels are
upregulated, leading to activation of CDK4-Cyclin D complexes (Bisteau et al., 2014; Ehrenfried
et al., 1997). This triggers activation of the cell cycle which proceeds in the usual manner with
activation of the CDK2-Cyclin E complex followed by CDK2-Cyclin A and finally CDK1-Cyclin
B (Bisteau et al., 2014; Ehrenfried et al., 1997). Regeneration of the liver occurs with 2 highly
synchronized rounds of cellular proliferation, the first peak in DNA synthesis occurring
approximately 36 hours after initiation of the process, and the next occurring approximately 60
hours after regeneration commences (Bisteau et al., 2014; Ehrenfried et al., 1997; Fausto and
Campbell, 2003; Grisham, 1962). Within a week, the liver mass is restored to its original size
(Ehrenfried et al., 1997; Fausto and Campbell, 2003). While hepatocytes may be a differentiated
cell type typically held in a state of quiescence, they retain a remarkable capacity for
proliferation, highlighting the importance of understanding cell cycle regulation in liver
development and regeneration.

Diseases of the Liver: NAFLD and NASH
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are
conditions characterized by excess fat accumulation in the liver (Dowman et al., 2010; Jou et al.,
2008; Takahashi et al., 2012). They differ from each other in that NASH is also characterized by
increased inflammation and damage in the liver, representing the more severe disease (Dowman
et al., 2010; Jou et al., 2008; Takahashi et al., 2012). Both NAFLD and NASH resemble alcoholic
disease but are found in people with little to no alcohol intake (Dowman et al., 2010; Jou et al.,
2008; Takahashi et al., 2012). The incidence of fatty liver disease is currently on the rise
presumably due to the increased prevalence of obesity and type 2 diabetes (Farrell et al., 2009;
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Takahashi et al., 2012). There are currently no specific therapies to treat NAFLD/NASH and its
exact causes are still unclear, making it an important area of research.
Accumulation of fat within the liver can occur by a variety of mechanisms such as
increased fat synthesis, decreased fat export, decreased fat oxidation or increased fat delivery
(Bradbury and Berk, 2004; Dowman et al., 2010; Takahashi et al., 2012). All mechanisms
contribute to fat accumulation within the liver, constituting the first hit in development of
NAFLD/NASH (Dowman et al., 2010; Takahashi et al., 2012). Fat accumulation within the liver
can then activate inflammatory response pathways such as NFκB, leading to elevated expression
of inflammatory cytokines resulting in increased injury to the liver (Cai et al., 2005). The
proliferative capacity of mature hepatocytes begins to decline over time as a by-product of the
increased inflammatory response and oxidative stress that is a direct result of the increase in free
fatty acids (Dowman et al., 2010; Feldstein et al., 2004; Takahashi et al., 2012). Loss of
proliferative hepatocytes over time leads to increased amounts of apoptosis, significantly
damaging the liver and decreasing its ability to regenerate (Dowman et al., 2010; Jou et al., 2008;
Roskams et al., 2003). Additionally, fibrosis of the liver becomes apparent as the disease
progresses (Dowman et al., 2010; Jou et al., 2008). Fibrosis results in cases of severe injury when
the livers response is to deposit fibrous material, such as collagen, to repair the damage (Bataller
and Brenner, 2005; Friedman et al., 1985). In severe cases, the architecture of the liver is
compromised after decreases in blood flow and liver function lead to the development of cirrhosis
of the liver (Bataller and Brenner, 2005). Once the disease has progressed to this stage, the risk of
liver failure and hepatocellular carcinoma (HCC) rises greatly (Figure 4) (Bataller and Brenner,
2005; Dowman et al., 2010).
NASH is characterized by increased inflammation, fibrosis and increased rates of
apoptosis (Dowman et al., 2010; Takahashi et al., 2012). Given these characteristic changes,
expression of apoptotic regulators may be altered in this disease. Expression of p53 is upregulated
in fatty liver diseases with increased levels correlating with increased degrees of inflammation
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and fibrosis (Kodama et al., 2011; Panasiuk et al., 2006; Yahagi et al., 2004). Additionally, the
downstream target p21 is also upregulated indicating increased activity of p53 (Farrell et al.,
2009). p53 may be involved with progression of the disease by activating apoptotic pathways
leading to increased hepatocyte death (Farrell et al., 2009; Panasiuk et al., 2006). Levels of the
anti-apoptotic protein Bcl-XL were found to be downregulated in response to p53 expression in
cases of fatty liver disease indicating that elevation and activation of p53 may contribute to
further inflammation and injury to the liver thus playing a key role in progression of this disease
(Farrell et al., 2009; Panasiuk et al., 2006).
Although the molecular mechanisms that cause NAFLD and NASH are still poorly
understood, these findings highlight the importance of dissecting the molecular mechanisms that
regulate damage responses and apoptotic pathways to treat and prevent the progression of this
disease.

Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the leading diagnoses of cancer worldwide and
is the second leading cause of death due to cancer (Canadian Cancer Society, 2014). Diagnosis
with HCC has a very poor prognosis with a 5 year survival rate of only 20%. Incidences of HCC
are on the rise possibly due to an increase in the incidence of obesity, which is a known risk
factor for the development of HCC (Kant and Hull, 2011; Venook et al., 2010). Infection with
hepatitis B or C and chronic alcohol abuse can all lead to cirrhosis of the liver, which can
progress to HCC over time (Fattovich et al., 2004). Additionally, rates of HCC are higher in
males than females. Although the exact cause of this predisposition is unknown, it is
hypothesized that an increased inflammatory response specifically in males may lead to increased
inflammation and therefore, increased incidences of HCC (Naugler et al., 2007). Deregulation of
the cell cycle is also known to contribute to the onset of HCC (Aravalli et al., 2008; Pascale et al.,
2002). Cyclin D1 amplification is seen in 11 to 20% of HCC cases (Bisteau et al., 2014; Wang et
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al., 2013). Overexpression of Cyclin D leads to aneuploidy in hepatocytes, which can persist and
ultimately contribute to HCC initiation and overexpression of Cyclin D alone can initiate HCC
although with a long latency (Deane et al., 2001; Nelsen et al., 2005). Thus it appears that
additional genetic alterations are necessary to fully progress to HCC. The CKI p27 is known to
inhibit cell cycle re-entry in quiescent hepatocytes, preventing cell cycle entry until required
(Albrecht et al., 1998; Ilyin et al., 2003). Loss of p27 leads to acceleration of DNA replication but
only promotes tumour formation when livers have been chronically injured (Bisteau et al., 2014;
Hayashi et al., 2003; Sun et al., 2007a). Decreased levels of p27 are more often seen in advanced
or aggressive stages of disease and correlate with poor patient prognosis, indicating a critical role
for p27 in maintaining the quiescent state of hepatocytes (Ito et al., 1999; Matsuda et al., 2013;
Tannapfel et al., 2000). The transcription factor c-Myc is also known to contribute to HCC, as
mice expressing elevated levels develop tumours after a long latency (Beer et al., 2004;
Heindryckx et al., 2009; Thorgeirsson and Santoni-Rugiu, 1996). Additionally, inactivation of
Myc results in regression of the tumour and differentiation of tumour cells into hepatocytes and
biliary forming cells (Shachaf et al., 2004). Increased expression and activity of Myc may play a
key role in initiating tumour onset as well as help to sustain its growth throughout tumour
progression. These studies highlight the importance of regulated cell proliferation in preventing
the onset of liver tumourigenesis, emphasizing the tight control over proliferation that must be
exerted on hepatocytes to prevent oncogenesis.
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Figure 4: Liver disease progression from simple steatosis to hepatocellular carcinoma (HCC).
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Spy1 and the Liver
Cell cycle regulation has proven to play a key role in regulating normal liver
development, regenerative processes and tumour initiation and progression. High levels of the
cyclin-like protein Spy1 have been found in HCC samples compared to pair matched normal or
adjacent tissue and correlate with increased levels of the proliferation marker ki67 (Ke et al.,
2009). Additionally, levels of Spy1 were found to correlate with levels of α-fetoprotein, a protein
expressed during fetal development of the liver, which is known to be re-expressed in HCC (Ke et
al., 2009). Patients with increased levels of Spy1 also correlated with poorer prognosis. Thus
Spy1 may play an important role in cell cycle regulation in the liver and may contribute to
tumourigenesis in this system (Ke et al., 2009).

The Mouse as a Model Organism
Studies utilizing in vitro cell systems and transplantation of cell systems back into an in
vivo setting have shed great insight on a vast amount of regulatory mechanisms in normal and
abnormal tissue development. Although these approaches are valuable, a more realistic setting to
study the effects of altered protein expression would provide an even greater depth of knowledge
as the multitude of factors that influence and regulate growth and development would be present
in their natural state. The mouse represents an ideal model system to study the effects of altered
protein expression on either the organism as a whole or through targeted tissue approaches.
Humans and mice share approximately 99% of their genes, and have similar numbers of protein
coding genes, making the mouse an ideal system of study which can then be translated back to
humans (Guenet, 2005). Additionally, the ease of model generation and relatively quick
generation time makes the mouse an excellent candidate for the study of growth and
development. Furthermore, the genetics and physiology of the mouse are well characterized,
enabling detailed analysis of complex phenotypes that may arise from altering gene expression.
Mice can be generated through a targeted approach by knocking down or introducing mutations
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within a specific gene, or can be generated by introducing foreign DNA, called a transgene,
directly into the oocyte. Using either approach will result in a genetically modified animal that
can be used to assess phenotypic changes resulting from the alteration or addition of gene
expression.

Transgenic Model Systems
Each year hundreds of results are published which utilize transgenic model systems,
highlighting the importance of this approach in the study of development and oncogenesis.
Development of this approach began in the 1970s when experiments were conducted to generate
chimeric mice either through direct embryo aggregation or blastocyst injection (Brinster, 1974). It
wasn’t until 1980 that the first successful transgenic mouse was generated through pronuclear
injections (Gordon et al., 1980). Although this mouse did not express the transgene because the
sequence had become rearranged, it was the first demonstration of the pronuclear injection
technique which is the most successful, widely used technique today (Gordon et al., 1980). Just
one year later, the first transgenic mice capable of transgene expression were produced, and in
1982, the first mouse with a visible phenotype due to transgene expression was created (Brinster
et al., 1981; Palmiter et al., 1982). These seminal discoveries paved the way for researchers as
transgenic mouse models have become a staple of many studies involving development, cancer
initiation and progression and in the study of new drugs developed to target disease. Pronuclear
injection of a segment of double stranded DNA is the most widely used approach in the
generation of transgenic mouse models (Haruyama et al., 2009). In this approach, the gene of
interest is cloned into an expression vector containing a promoter that can drive expression of the
transgene in a tissue and sometimes, temporal specific manner (Hanahan et al., 2007; Haruyama
et al., 2009). The expression cassette must also contain an enhancer region and poly adenylation
sequence to ensure proper RNA transcription and translation (Haruyama et al., 2009). The
generated transgenic vector can be tested for expression in an in vitro setting before being
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digested to isolate the transgene fragment. The transgene is injected into a fertilized oocyte during
the pronuclear period (Brinster et al., 1985; Si-Hoe et al., 2001). This is the period immediately
following fertilization when the male and female pronuclei are both still visible (Brinster et al.,
1985; Si-Hoe et al., 2001). This ensures that the transgene integrates into the chromosome prior to
the first doubling of genetic material that occurs before the first cleavage event (Brinster et al.,
1985; Si-Hoe et al., 2001). If integration occurs after this point, a mosaic animal will be generated
in which many of the cells may not express the transgene (Brinster et al., 1985; Si-Hoe et al.,
2001). Integration of the transgene is a random event, thus it is highly unlikely that two founder
mice, mice resulting from pronuclear injection, will contain the same integration event (Bishop
and Smith, 1989). Additionally, it is difficult to determine how many copies of the transgene
integrate although many times, the transgene will integrate in a linear array called a concatamer
(Bishop and Smith, 1989). Although the number of copies of a transgene that integrate into the
genome cannot be controlled, transgene expression does not correlate with the number of
transgene copies inserted. Since integration is a random event, it is important to have multiple
founders to assess the phenotype of transgene expression in the early stages of analysis to rule out
the possibility of insertional mutagenesis (Woychik et al., 1985). Insertional mutagenesis occurs
when the phenotype seen is not due to the transgene itself, but rather that the transgene has
inserted within a functional endogenous gene and interrupted the function of this gene (Woychik
et al., 1985). Thus, it is imperative that multiple founders are analyzed to ensure that the
phenotype observed is due to the transgene itself, and not modification of endogenous gene
expression due to transgene insertion site. Once generated, transgenic mice can be utilized for a
wide range of applications making them an attractive model system for research.
From the date of injection of the transgene, generation and identification of transgenic
mice takes a minimum of 7 weeks, making it a relatively quick process. Using this approach,
investigators can generate mice in which a gene of interest is overexpressed in its endogenous
form and can introduce transgenes containing mutations or modification of their gene of interest.
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Recent advances allow the production of transgenic mice in which knockdown of a gene can be
achieved through the use of shRNA (Premsrirut et al.; Yahagi et al., 2004). Expression of these
transgenes, whether overexpression or knockdown, can be constitutive utilizing only the promoter
found within the transgene or transgene expression can be inducible through the use of
tetracycline transactivator (tTA) or reverse tetracycline transactivator (rtTA) systems (Furth et al.,
1994; Gossen and Bujard, 1992; Gossen et al., 1995; Hennighausen et al., 1995; Sun et al.,
2007b; Zhu et al., 2002). Both systems require a regulatory unit called a responsive element, and
an induction agent to work; this allows the generation of transgenic models in which expression
of a transgene can be rapidly shut off or induced enabling the study of transgenes during specified
times of development (Furth et al., 1994; Gossen and Bujard, 1992; Gossen et al., 1995;
Hennighausen et al., 1995; Sun et al., 2007b; Zhu et al., 2002). In both systems, the TetO
promoter is the responsive element that is bound by either tTA or rtTA, both of which are fusion
proteins of tetracycline (Furth et al., 1994; Gossen and Bujard, 1992; Gossen et al., 1995;
Hennighausen et al., 1995; Sun et al., 2007b; Zhu et al., 2002). Both systems make use of the
antibiotic tetracycline or its derivative doxycycline to either repress or induce expression (Furth et
al., 1994; Gossen and Bujard, 1992; Gossen et al., 1995; Hennighausen et al., 1995; Sun et al.,
2007b; Zhu et al., 2002). The difference lies in how the tTA or rtTA binds the TetO responsive
element. The tTA system is referred to as a tet-off system as addition of doxycycline causes a
conformational change in tTA leading to dissociation of tTA from the TetO responsive element
thereby repressing expression of the transgene (Furth et al., 1994). Thus in the absence of
doxycycline, the transgene is expressed in the tTA system (Figure 5A). The rtTA system works in
an opposite fashion. In the absence of doxycycline, the rtTA protein cannot bind to the TetO
responsive element; however, upon addition of doxycycline, rtTA now binds and induces rapid
expression of the transgene (Gossen et al., 1995). Removal of doxycycline leads to dissociation of
rtTA from the responsive element and the transgene is no longer expressed (Figure 5 B). Use of
either the tet-off or tet-on system allows for tighter control of transgene expression and for rapid
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induction or suppression of expression during specified periods of time (Furth et al., 1994; Sun et
al., 2007b; Zhu et al., 2002). Additionally, this system can be combined with tissue specific
promoters driving expression of tTA or rtTA allowing for both temporal and spatial control of
transgene expression (Gunther et al., 2002; Zhang et al., 2010). Thus, transgenic model systems
represent a powerful tool in which expression can be controlled both spatially and temporally to
study altered gene expression in a natural in vivo setting.
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Figure 5: Mechanism of A) tet-off and B) tet-on systems. In the tet-off system, the
presence of doxycycline (Dox) prevents binding of the tetracycline transactivator
(tTA) to theTet operator (TetO) therefore preventing transgene expression. In the teton system, doxycycline is required for binding of the reverse tetracycline
transactivator (rtTA) to TetO and transgene expression.
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Gene Targeted Mice
The 2007 Nobel Prize in Physiology or Medicine was awarded to Mario Capecchi, Oliver
Smithies and Martin Evans, all of whom pioneered technology now commonly used for the
generation of gene targeted mouse models (Abbott, 2007). Capecchi and Smithies independently
discovered that a new section of DNA could be introduced into the genome by flanking the
segment with matching regions of DNA from the region to be targeted (Smithies et al., 1985;
Thomas and Capecchi, 1986). This early work was conducted in mammalian cell culture where it
proved to be highly successful. It wasn’t until Evans demonstrated how to isolate embryonic stem
(ES) cells from 3.5 day old mouse blastocysts and inject them back into a blastocyst of a different
strain that the true potential of this technique could be realized (Evans and Kaufman, 1981).
Evans’ work demonstrated that injection of ES cells into a recipient blastocyst could incorporate
and become established into the germline creating a chimeric mouse (Bradley et al., 1984; Hall et
al., 2009). Using ES cells, alterations at the level of the genome could now be introduced directly
into ES cells and subsequently be used in blastocyst injections establishing gene targeted mice
(Doetschman et al., 1987; Thomas and Capecchi, 1987). This technique takes advantage of the
cell’s own DNA repair machinery. Although rates of successful recombination are much lower
than seen with successful random integration in the generation of transgenic mice, this technique
harnesses greater power in its ability to completely ablate gene function and introduce mutations
at the level of the genome. This eliminates the possibility of insertional mutagenesis that can be
seen with random integration (Hall et al., 2009; Muller, 1999). Gene targeting can be used in a
variety of applications to study the effects of altered gene expression. It is commonly used to
study the effects of loss of gene function through the direct inactivation of a gene. This can be
accomplished directly through the generation of one mouse, or can be accomplished in a
conditional fashion such as in the study of genes which can cause embryonic lethality, or to study
loss of function during specified times of development (Nagy, 2000; Wagner et al., 1997). In
addition to loss of function studies, targeted approaches can also be utilized to introduce
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mutations directly into the genome to study the effects of these mutations on development and
disease processes, which aid in our understanding of identified mutations in human disease (Hall
et al., 2009; Muller, 1999).
While this technique can be utilized in a number of different ways, generation of gene
targeted mice follows the same basic approach. Homologous recombination lies at the basis of
this system. A segment of linear DNA containing regions of homology, known as homologous
arms, on both the 5’ and 3’ end is electroporated into ES cells typically from a substrain of
129/SV mice (Hall et al., 2009; Muller, 1999). The homologous arms direct recombination to the
appropriate location in the genome and allow for introduction of a modified gene segment which
lies between the regions of homology. To increase rates of successful recombination, a total of 6
to 14kb of homology is typically required in a targeting vector made up of a one longer arm of
homology and one short arm (Deng and Capecchi, 1992; Hasty et al., 1991; Muller, 1999). Since
hundreds of cells are electroporated, a method of negative and positive selection is employed to
better detect cells which may have underwent proper homologous recombination (Mansour et al.,
1988; Muller, 1999). Placed next to one of the homologous arms outside of the regions of
homology, is the HSV thymidine kinase gene (TK) (Hall et al., 2009; Muller, 1999). This acts as
a negative selection marker, since only random integration events will have the TK cassette (Hall
et al., 2009; Muller, 1999). Those cells which have undergone proper homologous recombination
will survive when grown in the presence of the antiviral medication gancyclovir, while any cells
which have undergone random integration will die in its presence due to inhibition of DNA
synthesis by the TK gene (Daher et al., 1990; Hall et al., 2009; Muller, 1999). A neomycin
selectable marker is used as a means of positive selection, as cells containing the neo marker will
survive when grown in the presence of neomycin (Hall et al., 2009; Mansour et al., 1993; Muller,
1999; Schwartzberg et al., 1989). The neo marker is placed between the arms of homology and
thus is part of the modified gene segment that is introduced during homologous recombination
(Hall et al., 2009; Muller, 1999). In some cases, the neo marker is introduced into a critical exon,
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interrupting expression and consequently generates a loss of function model (Hall et al., 2009;
Muller, 1999). In cases of knock in models where mutations are introduced or when conditional
models are being generated, care must be taken to ensure the neo marker is inserted into an
intronic region that will not interrupt endogenous gene function prior to the gene being knocked
out (Hall et al., 2009; Muller, 1999). Additionally, the neo marker is typically inserted in the
opposite orientation of the gene of interest to eliminate the possibility that its promoter will
influence expression of any downstream genes or to avoid transcription of exons located
downstream of the neo marker (Hall et al., 2009; Muller, 1999). Thus, addition of positive and
negative selection markers greatly aids in the screening process when searching for cells which
have undergone successful homologous recombination.
The modified gene segment between the homologous arms can either introduce a gene
mutation via a mutated version of the endogenous gene, completely disrupt gene function by
interrupting a critical exon or deleting a segment of the gene, or a conditional approach can be
utilized whereby loxP sites are placed flanking a critical exon of the gene (Hall et al., 2009;
Muller, 1999; Nagy, 2000). In a complete knockout, the open reading frame of the gene is
completely disrupted eliminating function during embryogenesis. At times, this can be deleterious
to the growth of the organism leading to embryonic lethality. To circumvent this, conditional
approaches can be utilized to shut off gene function at later stages of development (Hall et al.,
2009; Muller, 1999; Nagy, 2000). Additionally, conditional approaches offer a further level of
spatial and temporal control. Most conditionally targeted mice make use of the Cre/loxP system
(Hall et al., 2009; Muller, 1999; Nagy, 2000; Sauer, 1998; Wagner et al., 1997). Cre recombinase
is from the P1 bacteriophage that will excise a segment of DNA flanked on either side by loxP
sites, 34bp sequences composed of 13bp inverted repeats which flank an 8bp asymmetric
sequence of DNA (Hamilton and Abremski, 1984; Nagy, 2000). These sequences are placed in
the same direction around an essential exon such that when Cre recombinase is expressed, the
flanked area of DNA is removed, leaving behind one loxP site, thereby disrupting gene function
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(Hall et al., 2009; Nagy, 2000; Voziyanov et al., 1999). Care must be taken to place the loxP sites
in introns so that endogenous function is not interrupted prior to the expression of Cre
recombinase, allowing the gene to maintain its endogenous expression and function up until that
point (Hall et al., 2009; Nagy, 2000). Using this approach, a floxed mouse containing the loxP
sites is generated. To ablate gene function, this mouse must be crossed with a transgenic mouse
expressing Cre recombinase, typically under the control of a tissue specific promoter (Hall et al.,
2009; Nagy, 2000; Wagner et al., 1997). Mice resulting from this cross containing both the floxed
allele and the Cre transgene will undergo Cre mediated excision of the gene of interest generating
the conditional knockout mouse.
Development of gene targeted mice typically takes one year from the date of
electroporation until homozygous mice are generated. Although this time frame is considerably
longer than that required for the generation of transgenic mice, the advantages this system
provides over transgenic approaches outweigh the length of time required for model development.
Gene targeted mice are an excellent tool for studying known mutations, and loss of function in
human disease to enhance our understanding of the developmental processes that cause disease,
as well as to generate more effective therapies in the treatment of human disease.

Mammary Specific Mouse Model Systems
The study of mammary development and tumour biology was revolutionized by the
advent of transgenic model systems which drive specific expression within the mammary gland
(Callahan and Smith, 2000; Cardiff and Kenney, 2011; Hutchinson and Muller, 2000). Studies in
the 1930s identified a factor present in a mother’s milk that could be transmitted to their offspring
and ultimately cause breast tumourigenesis (Callahan and Smith, 2000; Cardiff and Kenney,
2011; Hutchinson and Muller, 2000). The ‘milk factor’ was later named the mouse mammary
tumour virus (MMTV), and was found to cause mammary tumours through insertional
mutagenesis, whereby insertion of MMTV caused activation of oncogenes (Callahan and Smith,
52

2000; Cardiff and Kenney, 2011; Nusse and Varmus, 1982). These activated genes were later
identified as Wnt1, Fgf3 and Notch (Cardiff and Kenney, 2011; Dickson et al., 1990; Jhappan et
al., 1992; Nusse and Varmus, 1982). Although other tissues within the mouse become infected
with MMTV, tumours are only seen in mammary tissue, suggesting that the cyclic nature of the
gland may contribute to tumourigenesis (Cardiff and Kenney, 2011). A seminal discovery in
breast cancer research came in 1984 when the first transgenic mouse model utilizing the MMTV
promoter was described (Callahan and Smith, 2000; Cardiff and Kenney, 2011; Stewart et al.,
1984). The transcription factor c-Myc was placed under the control of the MMTV promoter and
transgenic mice were generated through established protocols (Stewart et al., 1984). Mice
containing the MMTV-Myc transgene developed mammary tumours by 10 to 19 months of age
demonstrating the oncogenic properties of Myc (Stewart et al., 1984). Utilization of the MMTV
promoter expanded this area of research and currently, the MMTV promoter remains the most
widely used promoter in the study of breast development and tumourigenesis.
The MMTV promoter contains a hormone responsive element, directing expression
mainly to mammary epithelium, although there has been documented expression in other tissues
such as the salivary gland; this suggests either activation during embryonic development or low
levels of activity in other tissues (Callahan and Smith, 2000; Cardiff and Kenney, 2011). The
MMTV promoter is active throughout mammary development with increased expression during
pregnancy, when surges of hormones further stimulate activity of the promoter (Callahan and
Smith, 2000; Cardiff and Kenney, 2011). Thus the MMTV promoter represents a useful tool in
the study of altered gene expression on normal and abnormal development of the mammary
gland.
Transgenic systems in which genes are placed under the control of the MMTV promoter
to drive increased expression are widely utilized. Since the generation of the MMTV-Myc mouse,
this system has been used extensively to study the effects of increased expression on breast
tumour initiation. MMTV driven expression of Cyclin D1 has demonstrated its involvement in
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regulating proliferative stages of development as MMTV-Cyclin D1 mice exhibit proliferative
abnormalities and display increased lobuloalveolar development during puberty (Wang et al.,
1994). In addition to its role in driving increased protein expression, the MMTV promoter has
been utilized to generate conditional knockouts to enable the study of loss of function on
mammary development and tumourigenesis (Hutchinson and Muller, 2000). Brca1 null mice are
embryonic lethal preventing the study of this gene on breast cancer initiation (Hakem et al.,
1996). Since Brca1 has been implicated in breast cancer patients demonstrating germline
mutations in this gene, studying the effects of loss of function are essential to understanding this
subset of breast cancer. Using the MMTV-Cre mouse, a floxed Brca1 mouse was generated and
was used to study its role in tumour initiation (Xu et al., 1999). Using this approach, loss of Brca1
was found to lead to the development of genetically unstable mammary tumours with a long
latency period, highlighting the significance of this tumour suppressor in maintaining genomic
integrity (Xu et al., 1999).
The MMTV promoter represents an excellent system to drive gene expression
specifically to the mammary epithelium. Use of this mammary specific promoter has
revolutionized our understanding of important regulators in mammary development and
tumourigenesis and proves to be a reliable tool to study breast cancer initiation and progression.
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Hypothesis and Objectives
Mouse model systems to address the role of Spy1 in development and tumour initiation
and progression do not currently exist. This work will describe the generation of transgenic and
gene targeted mouse models to address the effects of altered protein expression on development
and tumourigenesis, specifically within the mammary gland.
We hypothesize that tight regulation of Spy1 protein levels is essential for proper
mammary gland development and aberrant regulation is an important step for breast cancer
initiation.
This hypothesis will be addressed through the following objectives:


Generate and characterize transgenic mouse model systems to overexpress Spy1
specifically within the mammary gland



Elucidate the role of Spy1 in breast cancer susceptibility and tumour initiation



Generate a gene targeted mouse model for the conditional knockout of Spy1 within the
mammary gland

This work will provide new study systems that will aid and enhance our understanding of
the role Spy1 plays in development and tumourigenesis. Data obtained from this study may
ultimately contribute to our understanding of the molecular factors influencing breast cancer
initiation and progression. This work offers promise for the development of novel diagnostic
and therapeutic targets that will contribute to the eradication of this disease.
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Chapter 2
MMTV-Spy1 Mice Demonstrate Increased Susceptibility
to Mammary Tumourigenesis
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Introduction
The ability of a cell to sense and repair DNA damage is crucial to prevent the
accumulation of DNA damage, deleterious mutations, and progression to carcinogenesis. The
DNA damage response pathway is a large network of signaling cascades that trigger cell cycle
arrest once damage is detected (Sancar et al., 2004). Upon cell cycle arrest, the appropriate repair
mechanism is activated, and once damage is repaired, the cell is allowed to re-enter the cell cycle.
If the damage is extensive, the cell has the option to trigger apoptosis, removing the cell from the
population and thereby eliminating the deleterious mutation. The tumour suppressor p53 lies at
the heart of this process and plays a critical role in regulating cell growth and repair (Bartek and
Lukas, 2001; Meek, 2004; Sakaguchi et al., 1998). In the event of DNA damage, levels of p53
begin to accumulate within the cell leading to cell cycle arrest and DNA repair (Meek, 2004;
Sakaguchi et al., 1998; Shieh et al., 1997). In cases of irreparable damage, p53 can trigger
apoptosis, leading to removal of the cell thereby preventing the accumulation of damaged cells
which could ultimately lead to carcinogenesis (Meek, 2004; Sancar et al., 2004). Thus p53 plays a
crucial role as a cell cycle regulator. This is highlighted by the observation that over 50% of
human cancers contain a mutation of p53, indicating that loss or abrogation of p53 function may
confer an advantage to cancerous cells (Soussi et al., 2006). Additionally, individuals with LiFraumeni syndrome, a disease characterized by germline mutations in p53, are at an increased
risk of developing cancer, with the most common types including bone, breast and cancers of soft
tissue (Akashi and Koeffler, 1998). Mouse models with germline knockout of p53 develop
normally however develop spontaneous tumours at an increased rate (Donehower et al., 1992;
Hutchinson and Muller, 2000; Jacks et al., 1994; Purdie et al., 1994). Taken together, this
highlights the importance of the proper function of all proteins which mediate cell cycle
progression, arrest and DNA repair in preventing the onset of tumourigenesis.
Spy1 is an atypical cyclin-like protein capable of promoting progression through G1/S
phase of the cell cycle by binding and activating Cdk2 independent of the canonical
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phosphorylation status (Cheng et al., 2005; Karaiskou et al., 2001; Porter et al., 2002). Spy1 was
initially discovered in a screen for genes that would confer resistance to UV radiation in a rad1
deficient strain of S.pombe, indicating a critical role for Spy1 in the DNA damage response
(Lenormand et al., 1999). Upon exposure to DNA damaging agents, Spy1 has been to shown to
increase cell survival, and this effect is dependent on its ability to bind and activate CDK2
(Barnes et al., 2003; Gastwirt et al., 2006). Endogenously, Spy1 levels increase following damage
and knockdown of Spy1 decreases cell survival after exposure to DNA damaging agents (Barnes
et al., 2003; Gastwirt et al., 2006; McAndrew et al., 2009). Proper activation of checkpoint
signaling is crucial for both repair and apoptotic events following damage. Overexpression of
Spy1 inhibits both S and G2/M phase checkpoint activation, allowing for continued cell division
in the presence of damage (Gastwirt et al., 2006). Spy1 prevents phosphorylation of key
mediators of the DNA damage response (DDR) such as H2AX, Chk1 and RPA32 thereby
inhibiting the activity of proper checkpoint responses (Gastwirt et al., 2006; McAndrew et al.,
2009). Spy also overrides apoptosis, and its ability to do so is dependent on p53 (McAndrew et
al., 2009). Thus, Spy1 serves as an important mediator of the DDR in maintaining the proper
balance of cellular proliferation and may play a crucial role in the transition from precancerous to
cancerous cell.
Previous data have demonstrated that Spy1 protein levels are tightly regulated through
the course of mammary gland development (Golipour et al., 2008). Levels are high during
proliferative stages of development and are drastically downregulated at the onset of
differentiation (Golipour et al., 2008). Interestingly, levels once again rise at the onset of
involution, a period of development characterized by apoptosis (Golipour et al., 2008).
Overexpression of Spy1 leads to precocious development of the mammary gland and disrupts
normal morphogenesis (Golipour et al., 2008). When overexpressed in an in vivo setting, Spy1
accelerates mammary tumourigenesis (Golipour et al., 2008). To further highlight this finding,
Spy1 has been found to be one of the 50 most upregulated genes in invasive ductal carcinoma of
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the breast, and is elevated in human breast cancer samples (Al Sorkhy et al., 2012; Zucchi et al.,
2004). In addition to breast cancer, elevated levels of Spy1 have been implicated in cancer of the
brain, liver, and lymphoma (Hang et al., 2012; Ke et al., 2009; Lubanska et al., 2014). Although
these data point to a critical role for Spy1 in regulating normal mammary development as well as
tumour initiation, it is still not known what effects increased levels of Spy1 have on normal
development of the mammary gland in an in vivo setting, or if Spy1 on its own is sufficient to
drive tumourigenesis.
Herein, we describe the development of the first transgenic mouse model for Spy1
whereby we direct overexpression specifically to the mammary gland using the MMTV promoter.
Using this model, we can study for the first time, the effects of altered Spy1 expression on normal
and abnormal development of the mammary gland in a natural in vivo setting. Using a mouse
strain resistant to mammary tumourigenesis, we show that the MMTV-Spy1 mice develop
normally and show no gross alterations in mammary development.

Treatment with 7,12-

dimethlybenz(a)anthracene (DMBA) demonstrates that the MMTV-Spy1 mice are significantly
more susceptible to mammary tumour formation and exhibit alterations in their DDR pathways.
Increased susceptibility to tumourigenesis may in part be due to the interaction of Spy1 with the
tumour suppressor p53 and its ability to overcome checkpoint responses in the event of DNA
damage. Thus this data demonstrates that Spy1 is an important factor in breast cancer
susceptibility and may play a key role in tumour initiation, due in part to its ability to override the
DNA damage response.
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Materials and Methods
Construction of Transgene
The MMTV-Spy1 transgene was prepared as follows. Site directed mutagenesis was
utilized to create an additional EcoRI site in Flag-Spy1A-pLXSN (Porter et al., 2003) to allow for
subsequent removal of the Spy1 coding sequence using EcoRI digestion. The MMTV-SV40TRPS-1 vector (kind gift from Dr Gabriel E DiMattia) was digested with EcoRI to remove the
TRPS-1 coding sequence to allow for subsequent ligation of the Spy1 coding sequence into the
MMTV-SV40 backbone.

Generation and Maintenance of MMTV-Spy1 Transgenic Mice
The MMTV-Spy1 vector was digested with XhoI and SpeI to isolate the MMTV-Spy1
transgene fragment and remove the remainder of the vector backbone. The transgene was sent to
the London Regional Transgenic and Gene Targeting Facility where pronuclear injections were
performed in B6CBAF1/J hybrid embryos.

Identification of founders and subsequent

identification of positive pups was performed by PCR analysis. PCR was performed by adding
50ng of genomic tail DNA to a 25µL reaction (1x PCR buffer, 2mM MgSO4, 0.2mM dNTP,
0.04U/µL

UBI

Taq

Polymerase,

[5’CCCAAGGCTTAAGTAAGTTTTTGG

3’

0.4µM
],

0.4µM

forward
reverse

primer
primer

[5’

GGGCATAAGCACAGATAAAACACT 3’], 1% DMSO) (NCI Mouse Repository). Cycling
conditions were as follows: 94°C for 3 minutes, 40 cycles of 94°C for 1 minute, 55°C for 2
minutes, and 72°C for 1 minute, and a final extension of 72°C for 3 minutes.

Mice were

maintained following the Canadian Council on Animal Care Guidelines under the animal
utilization protocol 10-16 approved by the University of Windsor.
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Primary Cell Harvest and Culture
Mammary tissue of the inguinal gland was dissected and primary cells were isolated as
described (Mroue and Bissell, 2013). Briefly, tissue was digested in a collagenase solution, and
the resulting suspension was spun at 1500rpm for 10 minutes. To ensure a clean epithelial
culture, a series of 4 to 10 pulses were performed at 1500rpm while the resulting pellet from each
pulse was monitored for the presence of organoids and single cells. For mammosphere formation
assays, cells were seeded in ultra-low attachment 6 well plates at a plating density of 20,000 cells
per mL in media containing 20ng/mL bFGF, 20ng/µL EGF, 100µg/mL gentamycin, 1% P/S in
DMEM-F12. Mammospheres were allowed to form for 7 days before quantification. Cells were
also seeded on attachment plates in media containing 5% fetal bovine serum, 5ng/mL EGF,
5µg/mL insulin, 50µg/mL gentamycin, 1% P/S in DMEM-F12 for BrdU incorporation assays
conducted 1 week after isolation of the cells.

Cell Culture
Human embryonic kidney cells, HEK-293 (CRL-1573; ATCC) and NIH/3T3 cells, were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; D5796; Sigma Aldrich)
supplemented with 10% fetal bovine serum (FBS; F1051; Sigma Aldrich) and 10% calf serum
(C8056; Sigma Aldrich) respectively, and 1% penicillin/streptomycin. U-2 OS and Saos-2,
human osteosarcoma cells (provided by Dr. J. Hudson, University of Windsor) and human colon
carcinoma cell lines, HCT116 p21+/+, p21-/-, p53-/-, and Chk2-/- (provided by Dr. B. Vogelstein,
Johns Hopkins) were maintained in McCoy’s 5A 1X medium (10-050-CV; Cellgro-Mediatech)
with 10% FBS and 1% penicillin/streptomycin. Mouse mammary epithelial cells, HC11
(provided by Dr. C. Shemanko) were maintained in RPMI supplemented with 10% newborn calf
serum, 5µg/mL insulin, 10ng/mL EGF and 1% penicillin/streptomycin. All cell lines were
maintained at 5% CO2 at 37˚C. A BioRad TC10 Automated Cell Counter was used to assess cell
viability via trypan blue exclusion.
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Plasmids
The pEIZ plasmid was a kind gift from Dr B. Welm, and the pEIZ-Flag-Spy1 vector was
generated as previously described (Lubanska et al., 2014). pCS3 and Myc-Spy1-pCS3 plasmids
were generated as previously described (Porter et al., 2002), and the p53-GFP backbone was
purchased from Add-Gene (11770) and was utilized in p53 overexpression experiments in
mammary cell lines. The Flag-p53-pcDNA3 construct was purchased from Addgene (#10838)
and was used in p53 overexpression experiments in all other cell lines.

Transfection and Infection
Transfection of all mammary cell lines was performed as follows. Plasmids were
transiently transfected using 25µg of polyethylenimine (PEI) and 12ug of plasmid DNA. PEI and
DNA were allowed to incubate at room temperature for 10 minutes in base media before being
added to the plate. Transfection reagent was left on for 16-18 hours before being removed. HC11
cells were transfected in serum and antibiotic free media.
For transfection of NIH3T3, U-2 OS, Saos2 and HCT116 cell lines, jetPRIME
transfection reagent (CA89129-922; VWR) was utilized. Briefly, 4µg DNA was added to 200µl
of jetPRIME buffer and subsequently vortexed. 4µl jetPRIME was then added and the mixture
was vortexed again and incubated at room temperature for 10 minutes. Following incubation, the
mixture was added to the plate in a drop wise fashion and cells were incubated at 37⁰C for at least
24 hours.
Transfection of primary mouse cell lines with sip53 and siRNA control (Santa Cruz) was
performed using siRNA Transfection Reagent (Santa Cruz) as per manufacturer’s instructions.
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UV Irradiation
Media was removed from exponentially growing cells and cells were washed once with
1X PBS and subjected to ultraviolet (UV) radiation using a GS Gene Linker (Bio Rad).
Immediately following irradiation, fresh medium was added to the cells.

DMBA Treatments
Mice were given 1mg of DMBA (Sigma Aldrich) in 100µL of a sesame:corn oil mixture
(4:1 ratio) via oral gavage once per week. Treatment began when mice reached 8 weeks of age
and were continued for 6 consecutive weeks. After completion of the treatment, mice were
monitored on a weekly basis for the presence of tumours via palpitations. Mice were humanely
sacrificed when tumours were noted, and all mice were sacrificed by 8 months of age regardless
of tumour formation. Tissues were collected from sacrificed mice and were flash frozen for
immunoblotting and qRT-PCR analysis, or were fixed in formalin for immunohistochemistry.

Histology and Immunostaining
Tissue was collected and fixed in 10% neutral buffered formalin. Tissue was dehydrated
through a series of ascending ethanol concentrations and was subsequently cleared in xylene.
Following clearing in xylene, samples were embedded in paraffin wax and sectioned into 5µm
thick sections using Leica RM2125RT. Prior to staining, sections were rehydrated through a
series of descending ethanol concentrations and heat mediated antigen retrieval was performed
using 10mM sodium citrate buffer pH 6.0. Endogenous peroxidase activity was blocked with a
3% H2O2 solution diluted in methanol, and sections were blocked for 1 hour at room temperature
in a humidified chamber with Mouse on Mouse (MOM) blocker (Biocare Medical) or 3% BSA0.1% Tween-20 in 1x PBS for antibodies with mouse or rabbit secondary antibodies respectively.
Sections were incubated in primary antibody diluted in blocking solution overnight at 4°C,
followed by 3 washes with 1x PBS. Secondary antibody at a concentration of 1:750 was diluted
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in blocking solution and sections were incubated in secondary antibody for 1 hour at room
temperature in a humidified chamber. Sections were washed and subsequently incubated with
ABC reagent as per manufacturer’s instructions (Vectastain ABC Kit; 30 min in ABC reagent).
Following addition of the ABC reagent, sections were stained with DAB following
manufacturer’s instructions (DAB Peroxidase Substrate Kit, Vector Laboratories), and were
counterstained with haematoxylin (Vector Laboratories). Sections were dehydrated through a
series of descending ethanol concentrations and were coverslipped using Permount toluene
solution (Fisher Scientific), and imaged using the LEICA DMI6000 inverted microscope with
LAS 3.6 software.

Quantitative Real Time PCR Analysis
RNA was isolated using Qiagen RNeasy Plus Mini Kit as per manufacturer’s instructions.
cDNA was synthesized using Superscript II (Invitrogen) as per manufacturer’s instructions.
SYBR Green detection (Applied Biosystems) was used to perform real time PCR and was
performed and analyzed using Viia7 Real Time PCR System (Life Technologies) and software.
Primers used were as follows:
Flag-Spy1 Forward: 5’TGACAAGAGGCACAATCAGATGT 3’
Flag-Spy1 Reverse: 5’ CAAATAGGACGCTTCAGAGTAATGG3’
Human p53 Forward: 5’ CCTGAGGTTGGCTCTGACTGTAC 3’
Human p53 Reverse: 5’ TGGAGTCTTCCAGTGTGATGATG 3’
Human Spy1 Forward: 5’ TTGTGAGGAGGTTATGGCCATT 3’
Human Spy1 Reverse: 5’ GCAGCTGAACTTCATCTCTGTTGTAG 3’
Mouse GAPDH Forward: 5’ GATGCCCCCATGTTTGTGAT 3’
Mouse GAPDH Reverse: 5’ GTGGTCATGAGCCCTTCCA 3’
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Protein Isolation and Immunoblotting
Flash frozen tissue was thawed and cut into small pieces. An appropriate amount of tissue
lysis buffer (50mM Tris-HCl pH 7.5, 1% NP-40, 0.25% Na-deoxycholate, 1mM EGTA, 0.2%
SDS, 150mM NaCl) with protease inhibitors (leupeptin 2g/mL, aprotinin 5g/mL, PMSF
100g/mL) was added to the tissue. Tissue and lysis buffer were homogenized on ice using a
Fisher Scientific Sonic Dismembrator 50. Homogenized tissue was flash frozen in liquid nitrogen
and subsequently thawed on ice. Samples were centrifuged at 13000rpm for 20 minutes at 4°C.
Supernatant was collected and centrifuged again at 13000rpm for 20 minutes at 4°C to remove
any excess fat from the lysate. Supernatant was collected and stored at -20°C until future use.
Cells were lysed with TNE buffer (50mM Tris, 150mM NaCl, 5mM EDTA) with protease
inhibitors (leupeptin 2g/mL, aprotinin 5g/mL, PMSF 100g/mL). Cells were lysed for 20
minutes on ice, vortexing every 5 minutes. Cells were centrifuged at 4°C at 10,000rpm for 10
minutes, and supernatant was collected and stored at -20°C until further use.
Protein concentrations were assessed using the Bradford assay as per manufacturer’s
instructions, and equal amounts of protein were prepared for loading. Equal amounts of protein
were loaded on a 10%-SDS polyacrylamide gel and were transferred to PVDF membranes at 30V
for 2 hours using wet transfer method. Membranes were blocked for 1 hour at room temperature
in 1% BSA and were incubated in primary antibody overnight at 4°C. Membranes were washed
three times in tris-buffered saline-tween 20 (TBST), 10 minutes each, following primary antibody
incubation. Secondary antibody, at a concentration of 1:10,000, was used for 1 hour at room
temperature and membranes were washed three times in TBST for 5 minutes each following
secondary antibody incubation. Visualization was conducted using chemiluminescent peroxidase
substrate (Pierce) as per manufacturer’s instructions, and images were captured on Alpha
Innotech HD 2 using AlphaEase FC software.

92

Antibodies
For western blot analysis, all primary antibodies were used at a concentration of 1:1000.
Antibodies include Actin (Millipore), Spy1 (Abcam), and p53 (Abcam). Mouse IgG (Sigma
Aldrich) and Rabbit IgG (Sigma Aldrich) were used at a concentration of 1:10,000. For
immunohistochemical analysis, all primary antibodies were used at a concentration of 1:200 and
were as follows, γH2AX (Millipore), Spy1 (Abcam), and ki67 (Abcam). Biotinylated anti-mouse
(Vector Laboratories) and biotinylated anti-rabbit (Vector Laboratories) were used at a
concentration of 1:750.

BrdU Incorporation Assay
15,000 cells per well were seeded in a 96 well plate. BrdU (BD Pharmingen) was added
24 hours later to a final concentration of 10µM and cells were incubated in media containing
BrdU for 24 hour at 37°C, 5% CO2. Media containing BrdU was removed and cells were washed
three times with 1x PBS. Cells were fixed in 4% PFA for 15 minutes and were washed twice with
1xPBS. Cells were incubated for 20 minutes at 37°C in 2M HCl and subsequently washed once
with 1x PBS. Cells were incubated for 45 minutes with Anti-BrdU (BD Biosciences) in 0.2%
Tween in 1x PBS. Cells were washed with 1x PBS and incubated with anti-mouse IgG and
hoescht at a 1:1000 dilution in 1x PBS for 1 hour at room temperature. Cells were washed one
time with 1x PBS followed by a wash with distilled water. Cells were stored at 4°C in 50%
glycerol until ready to image using the LEICA DMI6000 inverted microscope.

Whole Mount Analysis
Briefly, the inguinal gland was spread onto a positively charged slide and left in Clarke’s
Fluid (75% ethyl alcohol, 25% acetic acid) overnight. The following day, glands were placed in
70% ethyl alcohol for 30 minutes before being stained in carmine alum (0.2% carmine, 0.5%
potassium sulphate) overnight. Glands were destained for 4 to 6 hours with destaining solution
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(1% HCl, 70% ethyl alcohol) and were subsequently dehydrated in ascending concentrations of
alcohol (15 minutes each 70, 95, 100% ethyl alcohol) before being cleared in xylene overnight.
Slides were mounted with Permount toluene solution (Fisher Scientific) before being examined
on a Leica MZFLIII dissecting microscope (University of Windsor) and images were captured
using Northern Eclipse software.
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Results
Generation of MMTV-Spy1 transgenic mouse model system.
To study the effects of increased Spy1 expression within the mammary gland, a
transgenic mouse model expressing Spy1 under the control of the MMTV-LTR promoter was
generated. The Flag-Spy1 coding sequence was extracted from the previously described FlagSpy1-pLXSN vector and was cloned into an MMTV-SV40 backbone (Figure 1A). Founder mice
of the B6CBAF1/J background were identified via PCR analysis. Of the mice screened, three
were identified as founders through the presence of an 825bp fragment, and all three were able to
successfully transmit the transgene to their progeny (Supplemental Figure 1A). To determine if
the MMTV-Spy1 mice expressed increased levels of Spy1 within the mammary gland, tissue was
collected from 6 week old mice MMTV-Spy1 mice and their control littermates. Analysis of both
mRNA and protein levels revealed that the MMTV-Spy1 mice contained significantly higher
levels of Spy1 as compared to control littermates (Figure 1 B, C). Western blot analysis of other
tissues did not show elevated levels of Spy1 in MMTV-Spy1 mice (Supplemental Figure 1B, C).
Previous data demonstrated that increased levels of Spy1 can disrupt the normal
morphology of the mammary gland as well as promote accelerated development in vivo through
the use of mammary fat pad transplantation (Golipour et al., 2008). To assess if the MMTV-Spy1
mice displayed any developmental abnormalities, whole mount and immunohistochemical
analysis was conducted during puberty. Although immunohistochemical analysis revealed
expression of Spy1 within the mammary gland, histopathological analysis only revealed slight
phenotypic changes in the gland such as slight thickening of the ductal walls (Figure 1 D, E).
Gross morphology of the gland was not altered in whole mount analysis (Supplemental Figure
2A, B) and through histological analysis. Additionally, all MMTV-Spy1 female mice successfully
nursed their litters, even following multiple rounds of pregnancy, indicating that the
overexpression of Spy1 does not significantly alter normal mammary gland development.
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Spy1 increases mammary tumour susceptibility.
Spy1 has been shown to increase cell proliferation in a variety of cell types when
exogenously expressed (Al Sorkhy et al., 2012; Porter et al., 2002). To determine if Spy1 alters
the proliferative characteristics of mammary epithelial cells in the MMTV-Spy1 mice, primary
mammary epithelial cells were isolated from the inguinal glands of control and MMTV-Spy1
mice and were treated with BrdU. Cells extracted from MMTV-Spy1 mice displayed a
significantly higher percentage of BrdU positive cells indicating increased proliferation (Figure
2A). In addition to its ability to enhance proliferation, Spy1 has also been demonstrated to alter
stem cell characteristics in primary neural cells (Lubanska et al., 2014). Spy1 overexpression
causes increased neurosphere formation in primary neural cells, as well, it has been demonstrated
to promote stem cell self-renewal and tip the balance towards symmetric division in brain tumour
cells (Lubanska et al., 2014). To determine if Spy1 alters the stem cell population within a
mammary system, primary mammary epithelial cells were once again isolated from the inguinal
glands of control and MMTV-Spy1 mice and were plated to select for mammosphere formation.
MMTV-Spy1 mammary cells formed significantly more mammospheres than control cells
indicating a potential role for Spy1 in regulating the mammary stem cell population (Figure 2B).
Although elevated levels of Spy1 do not promote gross morphological changes in mammary
development, they are capable of altering the characteristics of the cells within the gland.
Although cells extracted from MMTV-Spy1 mammary glands exhibit significant changes
in both proliferative capacity and their ability to self-renew, MMTV-Spy1 mice develop normally
and do not develop spontaneous tumours. Previous data has demonstrated that exogenous
expression of Spy1 via mammary fat pad transplantation promotes mammary tumour formation,
and increased levels of Spy1 have been implicated in breast cancer in addition to liver and brain
(Al Sorkhy et al., 2012; Golipour et al., 2008; Ke et al., 2009; Lubanska et al., 2014). To assess
whether or not elevated levels of Spy1 may affect tumour susceptibility, MMTV-Spy1 mice were
treated with the known carcinogen 7,12-dimethlybenz(a)anthracene (DMBA). DMBA is
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commonly used in rodent models to study the onset and timing of mammary tumour formation
(Hoshino et al., 2007; Lee et al., 2008). MMTV-Spy1 mice and their control littermates were
treated with DMBA once per week for 6 consecutive weeks during puberty (Figure 2C). Mice
were monitored on a weekly basis for tumour formation. Over 90% of MMTV-Spy1 mice
developed tumours as compared to only 50% of control mice (Figure 2D). Additionally, over
80% of MMTV-Spy1 mice developed mammary tumours, significantly more than the
approximately 30% of control mice which developed mammary tumours (Figure 2D).
Interestingly, although not significant, ovarian tumours were noted only in MMTV-Spy1 mice
(Figure 2D). While not significant, it was noted that MMTV-Spy1 mice began to develop
tumours earlier than their control littermates (Figure 2E). Tumour tissue was sent for pathological
analysis, and a wide range of tumour sub-types were noted (Figure 2F). When tumour subtype
was further analysed, MMTV-Spy1 mice had significantly more malignant mammary tumours
over littermate controls (Figure 2G). Overall, this data demonstrates that elevated levels of Spy1
increases susceptibility to mammary tumour formation.
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Spy1 expression disrupts the DDR in the presence of DMBA.
Spy1 was initially discovered in a screen for genes that could confer resistance to
ultraviolet (UV) radiation in a rad-1 deficient strain of yeast (Lenormand et al., 1999). Given that
DMBA is known to damage DNA, we sought to determine if the increased susceptibility
observed was due to Spy1’s ability to overcome the DDR and apoptosis (Barnes et al., 2003;
Gastwirt et al., 2006; McAndrew et al., 2009). Mice were treated with DMBA at the time when
the tumour treatment protocol would begin, and tissue was collected 48 hours later and analysed
for alterations in known DNA damage response proteins. We observed that Spy1 was indeed
significantly overexpressed in 8 week old MMTV-Spy1 mice with and without DMBA (Figure
3A). Levels of p53 were examined as p53 is a potent tumour suppressor and plays a key role in
regulating many of the cellular processes involved in the DNA damage response (Meek, 2004).
MMTV-Spy1 mice were found to have significantly increased levels of p53 in response to
DMBA as compared to control littermates (Figure 3B). To determine if there was lingering DNA
damage or a delay in the repair of damage, immunohistochemical analysis was performed to look
for the presence of γH2AX, a well-established marker of DNA damage (Dickey et al., 2009; Paull
et al., 2000; Sedelnikova and Bonner, 2006). Significantly more γH2AX positive cells were noted
in MMTV-Spy1 mice indicating a lack of repair in response to DMBA (Figure 3C). Since Spy1
accelerates proliferation in mammary epithelial cells, expression of ki67, a known marker of
proliferation, was determined in glands of MMTV-Spy1 mice and their control littermates to see
if Spy1 induced accelerated proliferation in response to DMBA. Immunohistochemical analysis
did not show any significant difference in the proliferative capacity of the cells (Figure 3D). This
data demonstrates that elevated levels of Spy1 are capable of overriding DNA repair pathways
leading to accumulation of DNA damage.
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Spy1 can override p53 in response to DNA damage.
The observed increase in p53 in response to DMBA in MMTV-Spy1 mice suggests a
relationship between Spy1 and p53 in the DNA damage response. To further investigate this
relationship, HC11 and NIH/3T3 cells, containing mutated p53 and wild-type p53 respectively,
were transfected with Spy1, p53 or a combination of both and proliferation was assessed via
trypan blue analysis (Figure 4A). Even in the presence of p53, Spy1 was still able to increase cell
proliferation, although this was only significant in NIH/3T3 cells. Thus, the ability of Spy1 to
enhance proliferation in the presence of p53 supports that Spy1 can overcome p53 induced cell
cycle arrest.

Levels of Spy1 are tightly regulated in the DNA damage response.
To examine the endogenous regulation of Spy1 in response to DNA damage, U-2 OS
cells, which have wild-type p53, were exposed to 30J/m2 or 50J/m2 of UV and levels of Spy1 and
p53 protein were analysed (Figure 4B). In response to DNA damage, levels of Spy1 decreased,
and further quantification revealed reciprocal expression of Spy1 and p53 protein levels. When
Spy1 was exogenously expressed in multiple cells lines (U-2 OS, NIH/3T3, HCT116 parental and
HCT116 p21-/-) with varying alterations in repair pathways, downregulation of Spy1 was also
observed in response to UV (Figure 4C), although this effect was not significant in HCT116
parental or p21-/- cell line this downregulation is consistent with what was observed for
endogenous Spy1 levels. These results support that Spy1 levels are downregulated in many cell
types following DNA damage.

p53 negatively regulates Spy1 protein levels.
Levels of Spy1 and p53 demonstrate a reciprocal relationship in response to DNA
damage. To assess if p53 is capable of triggering the downregulation of Spy1 protein levels, U-2
OS, HEK293, and NIH/3T3 were transfected with Spy1, p53 or Spy1 and p53 and levels of Spy1
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protein were quantified (Figure 5). In every cell system studied, expression of p53 was sufficient
to trigger downregulation of Spy1 protein levels, indicating that Spy1 downregulation in response
to DNA damage may in part be mediated by p53.
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Spy1 overcomes UV- induced cell cycle arrest.
To further investigate the relationship between Spy1 and p53, primary cells were isolated
from MMTV-Spy1 mice and their control littermates. Levels of p53 were decreased using siRNA
(Figure 6A) and cells were treated with UV to determine the effects of Spy1 mediated
proliferation in the presence or absence of both p53 and UV. MMTV-Spy1 cells lacking p53 had
a significantly higher number of BrdU positive cells (Figure 6B). This indicates that in the
absence of p53 and the presence of damage, Spy1 is capable of promoting cellular proliferation.
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Discussion
Development of the transgenic MMTV-Spy1 mouse has yielded new insight into the role
Spy1 may have in tumour initiation and susceptibility. The MMTV-Spy1 mouse on the
B6CBAF1/J background develops normally, showing no overt phenotypic differences when
compared to control mice. Contrary to data in the HC11 cell line showing disrupted twodimensional acinar development suggesting a defect in functional differentiation (Golipour et al.,
2008), MMTV-Spy1 mice are capable of successfully nursing their young even through multiple
rounds of pregnancy. Mammary development appears to occur normally in these mice, even with
increased levels of Spy1. When primary cells are extracted from the mammary glands of control
and MMTV-Spy1 mice, Spy1 expressing cells exhibit increased rates of proliferation and formed
significantly more

mammospheres than control cells. This indicates that although

morphologically there does not appear to be any difference in mammary development, Spy1
alters characteristics of mammary epithelial cells which could trigger subtle changes in the gland.
Previous data demonstrated that overexpression of Spy1 through mammary fat pad
transplantation led to accelerated ductal development, and increased tumourigenesis (Golipour et
al., 2008). MMTV-Spy1 mice do not display any significant changes in ductal development and
do not develop spontaneous mammary tumours, even after multiple rounds of pregnancy. The
reason for this phenotypic difference may lie in the p53 status of the cell line utilized in the fat
pad transplantation experiment. HC11 cells contain a mutated p53 which would abrogate its
function, and thus from those early experiments, it can only be said that Spy1 may increase
susceptibility to tumourigenesis, and does not necessarily initiate it on its own (Merlo et al.,
1993). Data from the MMTV-Spy1 mouse suggests that this is in fact the case as treatment of
MMTV-Spy1 mice with the known carcinogen DMBA leads to significant formation of
mammary tumours over control littermates, indicating that Spy1 increases susceptibility to
mammary tumour formation.
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Mouse strain is also known to play a large role in mammary tumour susceptibility. The
MMTV-Spy1 mouse was generated on a resistant background of mouse, the B6CBAF1/J.
C57BL6/J mice are highly resistant to various forms of tumourigenesis and are known to be
resistant to MMTV infection (Beutner et al., 1996; Davie et al., 2007). Lack of developmental
phenotype and spontaneous tumour formation could be due to mouse strain. To confirm this, the
MMTV-Spy1 mouse has been backcrossed on the more susceptible FVB background to test the
effects of aberrant Spy1 expression on spontaneous tumour formation in a susceptible genetic
background (Supplemental Figure 3). This background did however allow us to truly test a
susceptibility phenotype as the B6CBAF1/J stain of mouse is resistant to mammary tumour
formation.
Spy1 is known to override the DNA damage response, and can override apoptosis in a
p53 dependent manner (Barnes et al., 2003; Gastwirt et al., 2006; McAndrew et al., 2009). Levels
of p53 were examined in mice treated with DMBA and were found to be significantly increased
in MMTV-Spy1 mice treated with DMBA, along with a significant increase in the number of
γH2AX cells. Increased levels of γH2AX can signify latent unrepaired damage, or perhaps a
delay in the repair response to DNA damage. To examine the relationship between Spy1 and p53
more closely, we turned our attention to in vitro cell systems, using a variety of cell lines which
were of varying p53 statuses and contained differences in various DNA repair pathways. We
found that Spy1 overcomes a p53-mediated cell cycle arrest. During the DDR, levels of Spy1 are
decreased in opposition to p53 levels, and overexpression of p53 was shown to decrease Spy1
protein levels. Lack of significance for various cell lines may be due in part to the p53 status of
the cell line, or defects in repair mechanisms which could alter the cellular response to increased
levels of Spy1. This data highlights a role for p53 mediation of Spy1 levels in the normal DDR.
In the event of damage, p53 levels rise, and by a yet unknown mechanism, are able to trigger the
downregulation of Spy1 protein levels, allowing for the DDR to work unhindered. Once the
repair is completed, Spy1 levels once again rise and can trigger cell cycle progression, allowing
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the cell to resume proliferation. Thus Spy1 may be a key player in mediating the DDR and
triggering cell cycle re-entry.
In the event of DNA damage, wild-type p53 levels would increase and become activated
to keep Spy1 levels in check to allow for the appropriate repair. In the fat pad transplant model,
overexpression of Spy1 is sufficient to trigger tumourigenesis (Golipour et al., 2008). This may
be due to inactivated p53, which would prevent Spy1 degradation and allow for sustained levels
of Spy1 and continued proliferation in the presence of DNA damage, genomic instability, or
detrimental mutations, leading to the development of tumourigenesis. Following treatment with
DMBA in the MMTV-Spy1 model, Spy1 itself may act as a stressor in addition to the damage
caused from the DMBA. Initially, wild-type p53 would be present and would keep Spy1 levels in
check to allow for repair of damage. Over time, p53 may become mutated or inactivated,
preventing its wild-type function, rendering it incapable of downregulating Spy1 levels. In this
case, Spy1 would lead to continued proliferation in the presence of deleterious damage and
mutations and could continue to promote cell survival in the absence of p53 (Figure 7). Thus the
ability of Spy1 to initiate tumourigenesis may be dependent on loss of p53 function, highlighting
a key role for Spy1 in promoting tumour initiation and progression in breast cancer subtypes
which frequently display loss of p53 activity.
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Chapter 3
The Role of Spy1 in Liver Steatosis and Susceptibility to
Hepatocellular Carcinoma
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Introduction
Hepatocellular carcinoma, HCC, is one of the leading causes of cancer related death
worldwide, with a five year survival rate of only 20% (Canadian Cancer Society, 2014; World
Health Organization, 2014). Prognosis is poor mainly due to the limited treatment options and the
central role the liver plays in basic human functions such as detoxification and cholesterol
metabolism. A variety of factors contribute to susceptibility to HCC including hepatitis B or C
infection, chronic alcoholism and cirrhosis of the liver (Fattovich et al., 2004). Cirrhosis of the
liver can be caused by long term alcohol abuse triggering accumulation of lipid droplets within
the liver leading to increased inflammation and fibrosis (Bataller and Brenner, 2005).
Manifestation of this condition can also occur through progression of non-alcoholic fatty liver
disease (NAFLD) to non-alcoholic steatohepatitis (NASH), which occur in the absence of
alcoholism (Dowman et al., 2010; Takahashi et al., 2012; The National Digestive Diseases
Information Clearinghouse, 2014). Incidence of HCC is currently on the rise and may be
attributed to increased rates of obesity which play a contributing factor in the onset of NASH
(The National Digestive Diseases Information Clearinghouse, 2014). A more thorough
understanding of this disease would help to elucidate the molecular mechanism underlying the
onset and initiation of HCC.
NAFLD is characterized by increased fat accumulation in the liver (The National
Digestive Diseases Information Clearinghouse, 2014). In and of itself, this condition is not
typically harmful, and symptoms may be absent. Changes in diet, and increased weight loss can
help to reverse this condition (Dowman et al., 2010; Jou et al., 2008; Takahashi et al., 2012; The
National Digestive Diseases Information Clearinghouse, 2014). Fat accumulation in the liver
becomes more dangerous when it begins to trigger inflammatory response pathways leading to
injury and damage to the liver (Cai et al., 2005; Dowman et al., 2010; Jou et al., 2008). Over
time, the level of damage sustained by the hepatocytes diminishes their capacity to proliferate,
leaving them unable to regenerate the injured and damaged areas of the liver, and increasing rates
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of apoptosis (Dowman et al., 2010; Feldstein et al., 2004; Takahashi et al., 2012). When the
ability to regenerate damaged areas is lost, injury is sustained and the liver begins to deposit
fibrous material such as collagen, further perpetuating the condition (Bataller and Brenner, 2005;
Dowman et al., 2010; Friedman et al., 1985; Jou et al., 2008). Over time, fibrosis of the liver
leads to severely compromised liver blood flow and function, which increases the risk of liver
failure and developing HCC (Bataller and Brenner, 2005; Dowman et al., 2010).
In normal circumstances, hepatocytes possess a remarkable capacity for regeneration
(Fausto and Campbell, 2003). In the event of injury or loss of tissue, the quiescent hepatocyte
population is primed to respond to mitogenic signals to stimulate re-entry into the cell cycle
(Bisteau et al., 2014; Ehrenfried et al., 1997; Fausto and Campbell, 2003; Webber et al., 1998;
Webber et al., 1994). The hepatocytes undergo two rounds of highly synchronized DNA
replication and division to reconstitute the injured area or to compensate for lost tissue (Bisteau et
al., 2014; Ehrenfried et al., 1997; Fausto and Campbell, 2003; Grisham, 1962). In models of
partial hepatectomy, the liver is capable of sustaining loss of two-thirds of the overall tissue mass
and can regenerate this mass within a week demonstrating the remarkable proliferative capacity
of hepatocytes (Bisteau et al., 2014; Fausto and Campbell, 2003; Michalopoulos, 2007). With
NASH and severe cases of injury, the hepatocytes lose their ability to proliferate and regenerate
the injured tissue, eventually succumbing to apoptosis further increasing the amount of damaged
tissue (Dowman et al., 2010; Farrell et al., 2009; Panasiuk et al., 2006). One regulator of
activation of the apoptotic pathway is the tumour suppressor p53 (Meek, 2004). p53 acts as a
master regulator of the DNA damage response and apoptosis in response to damage and
inflammation (Meek, 2004; Sakaguchi et al., 1998; Sancar et al., 2004). Fatty liver diseases have
been found to have increased levels of p53 which correlate positively with the amount of
inflammation present, thus indicating that increased inflammation in NASH could trigger upregulation and activation of p53 leading to increased rates of apoptosis (Farrell et al., 2009;
Kodama et al., 2011; Panasiuk et al., 2006; Yahagi et al., 2004). Furthermore, p21, a target
124

protein of p53, was found to be up-regulated in fatty liver disease along with p53 indicating
activation of p53 signaling pathways (Farrell et al., 2009). Levels of anti-apoptotic proteins, such
as Bcl-XL were found to be decreased, further indicating that inflammation can trigger upregulation of p53 leading to increased rates of apoptosis, and further perpetuating disease
progression (Panasiuk et al., 2006).
Damage response pathways and cell cycle regulation play a critical role in hepatocyte
proliferation in response to injury and inflammation. The cyclin-like protein Spy1 is capable of
binding and activating CDK2 in the absence of canonical phosphorylation, leading to increased
CDK2 activity and enhanced progression through the cell cycle (Cheng et al., 2005; Karaiskou et
al., 2001; Lenormand et al., 1999; Porter et al., 2002). Additionally, Spy1 overrides DNA damage
response checkpoints, promoting cell cycle progression in the presence of damage (Barnes et al.,
2003; Gastwirt et al., 2006; McAndrew et al., 2009). Spy1 also overrides apoptosis in a p53dependent manner (Gastwirt et al., 2006; McAndrew et al., 2009). Thus, Spy1 plays a critical role
in regulating cell cycle progression and response to damage. Previous reports have found Spy1
levels to be high in HCC when compared to pair matched normal tissue, and increasing levels
correlated with increasing severity of disease and poor prognosis (Ke et al., 2009). Levels of Spy1
also correlated positively with the proliferation marker ki67, highlighting the importance of this
protein in promoting cell cycle progression (Ke et al., 2009). Thus it appears that Spy1 may play
a critical role in tumour initiation and progression in the liver.
Herein we describe a surprising phenotype in the previously described MMTV-Spy1
mice. Male mice containing the transgene were found to develop tumours in the liver at a
significantly higher rate than their control littermates. Additionally, histological analysis revealed
the presence of increased fat accumulation in livers of male MMTV-Spy1 mice. We describe a
potential role for Spy1 in increasing liver cancer susceptibility, potentially by triggering the onset
of NAFLD/NASH, leading to increased damage and inflammatory response signaling, and
continued cellular proliferation in the presence of damage.
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Materials and Methods
Maintenance of MMTV-Spy1 Transgenic Mice
MMTV-Spy1 mice were generated as described in Chapter 2. Briefly, the Spy1 coding
sequence was cloned in the MMTV-SV40 vector backbone and sent to the London Regional
Transgenic and Gene Targeting Facility for pronuclear injections into B6CBAF1/J hybrid
embryos. Mice were maintained on a B6CBAF1/J background. Genotyping was performed via
PCR analysis. PCR was performed by adding 50ng of genomic tail DNA to a 25µL reaction (1x
PCR buffer, 2mM MgSO4, 0.2mM dNTP, 0.04U/µL UBI Taq Polymerase, 0.4µM forward
primer

[5’CCCAAGGCTTAAGTAAGTTTTTGG

3’

],

0.4µM

reverse

primer

[5’

GGGCATAAGCACAGATAAAACACT 3’], 1% DMSO) (NCI Mouse Repository). Cycling
conditions were as follows: 94°C for 3 minutes, 40 cycles of 94°C for 1 minute, 55°C for 2
minutes, and 72°C for 1 minute, and a final extension of 72°C for 3 minutes.

Mice were

maintained following the Canadian Council on Animal Care Guidelines under the animal
utilization protocol 10-16 approved by the University of Windsor.

Plasmids
The pCS3 and Myc-Spy1 pCS3 plasmids were utilized in overexpression experiments
and were generated as previously described (Porter et al., 2002). For knockdown experiments,
pLKO.1 (Addgene) and pLKO.shSpy1.2 were utilized and were generated as described (Porter et
al., 2002).

Cell Culture and Transfection
HepG2 cells (a kind gift from Dr. Hudson, University of Windsor) were maintained in
Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% FBS and 1%
penicillin/streptomycin at 37°C, 5% CO2. HepG2 cells were transfected using polyethylenime
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(PEI) branched reagent (Sigma). Briefly, 40µg of PEI and 10µg of plasmid were incubated
together for 10 minutes before adding to a 10cm plate.

Histology and Immunostaining
Tissue was collected and fixed in 10% neutral buffered formalin. Tissue was dehydrated
in ascending concentrations of ethanol, and cleared in xylene prior to embedding in paraffin wax.
Samples were sectioned at 5 uM using the Leica RM2125RT. For haematoxylin and eosin stain,
sections were rehydrated in descending concentrations of ethanol, washed in distilled water and
stained with haematoxylin (Vector Laboratories). Sections were washed using running tap water,
and were subsequently stained with eosin (Sigma Aldrich) before being dehydrated through
ascending concentrations of ethanol. For immunohistochemistry, slides were deparaffinized in
xylene, rehydrated through a descending series of ethanol concentrations and heat mediated
antigen retrieval was performed with 10mM sodium citrate buffer pH 6.0. Following this,
endogenous peroxidase activity was blocked using 3% H2O2 diluted in methanol. Sections were
blocked in Mouse on Mouse (MOM) blocker (Biocare Medical) or 3% BSA-0.1% Tween-20 in
1x PBS for mouse and rabbit secondary antibodies respectively. Sections were incubated
overnight at 4°C in primary antibody diluted in the appropriate blocker. Following 3 10 minute
washes with 1xPBS, sections were incubated with secondary antibody (1:750) for 1 hour in a
humidified chamber. Sections were subsequently incubated with ABC reagent as per
manufacturer’s instructions (Vectastain ABC Kit). Next, sections were stained with 3,3'diaminobenzidine (DAB) following manufacturer’s instructions (DAB Peroxidase Substrate Kit,
Vector Laboratories), and were counterstained with haematoxylin (Vector Laboratories). Sections
were then dehydrated in a series of ascending ethanol concentrations, coverslipped with Permount
toluene solution (Fisher Scientific) and visualized using the LEICA DMI6000 inverted
microscope with LAS 3.6 software.
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Quantitative Real Time PCR Analysis
RNA was isolated from flash frozen tissue using TRIzol reagent (Life Technologies) as
per manufacturer’s instructions, while RNA isolation from cell pellets was conducted using the
Qiagen RNeasy Plus Mini Kit as per manufacturer’s instructions. Superscript II (Invitrogen) was
used to synthesize cDNA from the obtained RNA samples as per manufacturer’s instructions.
Real Time PCR was performed using Sybr Green Detection (Applied Biosystems) on the Viia7
Real Time PCR System (Life Technologies) and software. Primer sequences were as follows:
Flag-Spy1 Forward: 5’TGACAAGAGGCACAATCAGATGT 3’
Flag-Spy1 Reverse: 5’ CAAATAGGACGCTTCAGAGTAATGG3’
Human GAPDH Forward: 5’ GCACCGTCAAGGCTGAGAAC 3’
Human GAPDH Reverse: 5’ GGATCTCGCTCCTGGAAGATG 3’
Human Spy1 Forward: 5’ TTGTGAGGAGGTTATGGCCATT 3’
Human Spy1 Reverse: 5’ GCAGCTGAACTTCATCTCTGTTGTAG 3’
Mouse GAPDH Forward: 5’ GATGCCCCCATGTTTGTGAT 3’
Mouse GAPDH Reverse: 5’ GTGGTCATGAGCCCTTCCA 3’

Protein Isolation and Immunoblotting
Flash frozen tissue was thawed and an appropriate amount of tissue lysis buffer (50mM
Tris-HCl pH 7.5, 1% NP-40, 0.25% Na-deoxycholate, 1mM EGTA, 0.2% SDS, 150mM NaCl)
with protease inhibitors (leupeptin 2g/mL, aprotinin 5g/mL, PMSF 100g/mL) was added to
the tissue. Tissue was then homogenized on ice in the tissue lysis buffer with the Fisher Scientific
Sonic Dismembrator 50. The homogenized tissue was flash frozen in liquid nitrogen and thawed
on ice before being spun at 13,000rpm for 20 minutes at 4°C. Supernatant was isolated and spun
again at 13,000rpm for 20 minutes at 4°C. To ensure equal protein loading, Bradford analysis was
performed as per manufacturer’s instructions to assess protein concentration. Equal amounts of
protein were prepared for loading in a 10% SDS-polyacrylamide gel and were transferred to a
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PVDF membrane at 30 volts for 2 hours using the wet transfer method. Membranes were
subsequently blocked in 2% milk for 1 hour at room temperature before incubation with primary
antibody overnight at 4°C. Following incubation with primary antibody, membranes were washed
with TBST 3 times for 10 minutes each followed by incubation with secondary antibody
(1:10000) for 1 hour at room temperature. Membranes were washed again with TBST 3 times, 5
minutes each and visualization of the signal was conducted using chemiluminescent peroxidase
substrate (Pierce) as per manufacturer’s instructions. Images were captured on Alpha Innotech
HD 2 using AlphaEase FC software.

BrdU Incorporation Assay
Cells were seeded in a 96 well plate at a seeding density of 10,000 cells per well and were
allowed to adhere overnight. Following adherence to the plate, cells were incubated in media
containing 10µM BrdU (BD Pharmingen) for 16-18 hours. Media was removed and cells were
washed with 1X PBS. Cells were subsequently fixed with 4% paraformaldehyde for 15 minutes
and were washed with 1X PBS before incubation at 37°C in 2M HCl for 20 minutes. Cells were
washed with 1X PBS and incubated with Anti-BrdU (BD Biosciences) in 0.2% Tween in 1X PBS
for 45 minutes. After incubation, cells were washed with 1x PBS and incubated with anti-mouse
IgG and hoescht at a 1:1000 dilution in 1X PBS for 1 hour at room temperature. Cells were then
washed with 1X PBS followed by distilled water and were stored in 50% glycerol at 4°C until
imaging and analysis.

Oil-Red O Staining
HepG2 cells were seeded at a density of 10,000 cells per well in a 96 well plate and left
to adhere to the plate overnight. Cells were washed with 1X PBS and were subsequently fixed
using 10% neutral buffered formalin for 30 minutes at room temperature. Following fixation,
cells were washed with distilled water and were incubated in 60% isopropanol for 5 minutes.
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Cells were subsequently stained with a 60% working solution of Oil-Red O (Sigma Aldrich) for
10 minutes and were washed with distilled water until water was clear. Images were obtained
using the Leica DMI6000B Inverted Microscope and were analyzed using ImageJ software.
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Results
Male MMTV-Spy1 exhibit an increase in Spy1 and increased tumourigenesis.
MMTV-Spy1 mice were generated on a B6CBAF1/J background to study the effects of
increased Spy1 protein levels on mammary development and tumourigenesis. Given that the
MMTV promoter can show residual activity in other tissue types, as well as in males, nonproductive MMTV-Spy1 male breeders and their control littermates were sacrificed once they
reached one year of age. Upon sacrifice, it was noted that MMTV-Spy1 males over one year of
age displayed a significant increase in liver tumour formation as compared to control littermates
of the same age (Figure 1A). Liver tissue was extracted from aged males and Spy1 expression
levels were found to be significantly increased in liver tissue from MMTV-Spy1 males (Figure
1B). When levels of Spy1 were examined in aged female mice, the same trend was not noted
(Figure 1C), indicating that expression of Spy1 and tumour onset is specific to male MMTVSpy1 mice.

Elevated levels of Spy1 lead to increased fat accumulation and increased nuclear size.
Progression to HCC can be attributed to a number of factors such as hepatitis B or C
infection or NAFLD/NASH (Fattovich et al., 2004). Both NAFLD and NASH are characterized
by increased lipid accumulation within the liver which ultimately leads to increased inflammation
and fibrosis, contributing to the development of HCC (Bataller and Brenner, 2005; Cai et al.,
2005; Dowman et al., 2010; Takahashi et al., 2012; The National Digestive Diseases Information
Clearinghouse, 2014). To determine if elevated levels of Spy1 leads to morphological changes in
the liver of aged mice, liver tissue was collected, fixed and stained to assess the pathology of the
livers (Figure 1D). It was found that MMTV-Spy1 mice displayed increased fat accumulation that
although not significant, could play a contributing role in the initiation of liver tumourigenesis
(Figure 1D, E). Additionally, the area of hepatocyte nuclei was measured and found to be
significantly increased in the livers of MMTV-Spy1 mice (Figure 1F). Enlargement of hepatocyte
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nuclei could signify a number of molecular mechanisms, such as cellular senescence or
polyploidy, that could contribute to tumour onset in MMTV-Spy1 mice (Gonzalez-Reimers et al.,
1987; Nakajima et al., 2010). Thus, MMTV-Spy1 male mice display elevated levels of Spy1
which correlates with a significant increase in nuclear area, and although not, significant,
increased fat accumulation.
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Increased levels of Spy1 does not alter expression of known markers of HCC.
Spy1 accelerates cell cycle progression both by binding and activating CDK2, as well as
triggering degradation of the cell cycle inhibitor p27, thereby relieving inhibition on G1/S phase
of the cell cycle (Cheng et al., 2005; McAndrew et al., 2007; Porter et al., 2002; Porter et al.,
2003). Given the tight relationship between Spy1 and p27 we sought to determine if p27 levels
were reduced in the livers of MMTV-Spy1 mice. Analysis of protein expression revealed that
although the trend of p27 protein demonstrated reduced levels in MMTV-Spy1 livers, these
differences were not statistically significant (Figure 2A). We next looked further into other
known cell cycle regulators and examined expression levels of c-Myc in livers of MMTV-Spy1
mice to determine if altered Myc expression levels could be contributing to tumourigenesis. Myc
is known to play crucial roles in cell cycle regulation and can stimulate tumourigenesis in livers
of Myc transgenic mouse models (Beer et al., 2004; Shachaf et al., 2004). Additionally, previous
data has shown that Spy1 lies downstream of Myc, making it an ideal candidate for disruption of
expression levels and suggesting a unique interaction between Spy1 and Myc (Golipour et al.,
2008). We found no significant difference in the expression of Myc between control littermates
and MMTV-Spy1 mice, indicating that altered Spy1 protein levels do not affect cell cycle
mediators which are known effectors of Spy1 (Figure 2B).
Albumin is expressed in mature hepatocytes and is commonly used as marker to delineate
the population of mature hepatocytes within the liver (Germain et al., 1988; Zorn, 2008). Cases of
HCC are known to have decreased levels of albumin indicating a possible step back in
differentiation or alterations in the hepatocyte population during tumour progression (Ljubimova
et al., 1997). Spy1 has been shown to affect differentiation of mammary epithelial cells, causing
disrupted morphology and early expression of differentiation markers indicating a potential
failure of these cells to functionally differentiate (Golipour et al., 2008). Albumin levels were
examined to determine if Spy1 was capable of altering the differentiation status of hepatocytes
within the liver. No significant difference in albumin expression was noted between control and
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MMTV-Spy1 aged mice (Figure 2C). Spy1 expression does not alter expression of a subset of
known cell cycle mediators and proteins known to influence tumour onset and status.

Up-regulation of damage response pathways in MMTV-Spy1 mice.
Fatty liver diseases such as NASH can lead to up-regulation of inflammatory and damage
pathways in response to increased damage and injury the liver sustains due to increased fat
accumulation (Dowman et al., 2010; Takahashi et al., 2012; The National Digestive Diseases
Information Clearinghouse, 2014). Studies have shown that levels of the tumour suppressor p53
are increased in cases of NASH positively correlating with the degree of inflammation (Kodama
et al., 2011; Panasiuk et al., 2006; Yahagi et al., 2004). Given that Spy1 is known to play a role in
the DNA damage response, and the relationship between NASH and p53, we sought to determine
if elevated levels of p53 correlate with changes in this response pathway. Analysis of p53 levels
via immunohistochemistry revealed a significant increase in the levels of p53 protein in MMTVSpy1 male livers as compared to control (Figure 3A). Next, levels of p21, a known downstream
target of p53, were analysed. Once again, MMTV-Spy1 livers showed a significant increase in
p21 protein levels indicating that p53 expression was not only elevated, but its activity could also
be increased (Figure 3B). A side effect of increased inflammation and damage is increased levels
of apoptosis to remove severely damaged cells from the population. Levels of anti-apoptotic
proteins are known to be decreased in cases of NASH, and p53 is capable of activating apoptotic
pathways, therefore we next examined the rate of apoptosis in MMTV-Spy1 livers (Panasiuk et
al., 2006). Through immunohistochemistry, we showed a significant increase in the levels of
active caspase 3, a central player in the apoptotic pathway commonly used to indicate increased
amounts of apoptosis (Figure 3C). Thus, MMTV-Spy1 mice show significantly elevated levels of
proteins known to be involved in inflammatory and apoptotic pathways in response to NASH.
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Alteration of Spy1 levels in a HCC cell line causes changes in proliferation and fatty acid
accumulation.
MMTV-Spy1 mice exhibit increased incidence of HCC, increased fat accumulation, and
up-regulation of key mediators in the apoptotic response pathway. To determine the direct effects
of increased Spy1 levels on characteristics of HCC, we utilized the well characterized HepG2
HCC cell line. Using these cells, we overexpressed Spy1 (Figure 4A) and examined the effects of
elevated Spy1 on accumulation of fat within hepatocytes and proliferative capacity of the cells.
Using Oil Red O staining, a technique commonly used for the staining of accumulated lipid
droplets, we show that overexpression of Spy1 increases lipid accumulation in HepG2 cells
(Figure 4B). Additionally, through BrdU staining, we show that elevated levels of Spy1
significantly increases the percentage of BrdU positive cells (Figure 4C). In contrast, knockdown
of Spy1 (Figure 5A) leads to a significant decline in Oil Red O staining (Figure 5B), and a
decrease in the percentage of BrdU positive cells (Figure 5C). Thus, Spy1 appears to play a
pivotal role in maintaining elevated rates of proliferation and promoting and maintaining lipid
accumulation.
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Discussion
The MMTV-Spy1 transgenic mouse model was initially generated to study the effects of
aberrant Spy1 expression on mammary gland development and tumourigenesis. The MMTV
promoter is well documented and has been shown to induce expression of the transgene in various
tissue types with the most common organs affected being secretory organs such as the salivary
gland (Callahan and Smith, 2000; Cardiff and Kenney, 2011). There have been however,
documented cases of transgene expression in the liver (Wagner et al., 2001). Surprisingly, we find
a significant increase in rates of liver tumour formation in MMTV-Spy1 male mice. Indeed,
increased levels of Spy1 were found in aged MMTV-Spy1 male livers and interestingly,
transgene expression was not noted in livers of aged females, further indicating male specific
transgene expression within the liver. MMTV driven transgene expression has been found in
other male tissues, such as male reproductive organs (Parker et al., 1987; Rollini et al., 1992).
Androgen responsive elements have been noted within the MMTV promoter thus indicating the
possibility that androgen stimulation could lead to male specific liver expression of the transgene
(Parker et al., 1987; Rollini et al., 1992). Although MMTV-Spy1 males did develop significantly
more tumours than control mice, tumours were still found in controls. CBA mice are known to
have increased susceptibility to HCC, and since the MMTV-Spy1 mouse is maintained on a
B6CBAF1/J background, we would expect to see tumour formation in wild-type animals as well
(Bilger et al., 2004; Smith et al., 1973). Our data supports that overexpression of Spy1 is
enhancing the susceptibility phenotype of this genetic background of mice.
Histological analysis revealed key differences in MMTV-Spy1 and control liver tissue.
Nuclear area in livers of MMTV-Spy1 mice was found to be significantly larger than those of
control livers. Increased nuclear area could be caused by either increased ploidy in hepatocytes or
senescence (Gonzalez-Reimers et al., 1987; Nakajima et al., 2010). To determine if nuclear size is
increased due to increased ploidy of hepatocytes, primary cells from the livers of MMTV-Spy1
and control mice could be extracted and analyzed via flow cytometry to assess DNA content.
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Additionally, immunohistochemical analysis could be utilized through the use of a Feulgen stain,
which directly stains DNA. The amount of stain colour and intensity of the stain is directly
proportional to the amount of DNA present, therefore, if increased staining was observed this
would indicate increased DNA content and ploidy. Since Spy1 is capable of promoting cell cycle
progression, it is plausible that increased amounts of Spy1 could in fact be triggering elevated
rates of DNA replication leading to increased DNA content in hepatocytes. In addition to
increased ploidy, increased nuclear size is also known to occur during senescence (Mitsui and
Schneider, 1976; Rodier and Campisi, 2011). In cases of NAFLD/NASH, increases in nuclear
size correlate with elevated expression of p21, which is seen in the MMTV-Spy1 mice (Nakajima
et al., 2010). Senescent cells have been shown to increase in size, and studies have proven that
senescent cells are capable of promoting malignancy in premalignant epithelial cells in vivo
indicating that the potential presence of senescent cells could in fact contribute to tumour onset
(Krtolica et al., 2001). Determining the precise cause of the observed increase in nuclear size
would shed light on how Spy1 may be causing enhanced tumourigenesis in MMTV-Spy1 mice.
Livers of MMTV-Spy1 mice also displayed increased levels of fat. Although the
difference was not statistically significant, this manifestation could have profound consequences
on the development of HCC and play a key role in its progression. NASH is characterized by
increased fat droplets in the liver, and is known to be a risk factor for tumour development (The
National Digestive Diseases Information Clearinghouse, 2014). Thus, even though the increase in
number of mice with fatty liver is not significant, small changes in fat accumulation could play a
key role in the significant increase in liver tumours seen. The predominating factor in progression
from NASH to HCC is the damage inflammation causes in the liver as a result of fat
accumulation. Fatty acids trigger an inflammatory response, leading to increased injury to the
liver that hepatocytes would typically be able to repair (Dowman et al., 2010; Feldstein et al.,
2004; Jou et al., 2008). In cases of severe injury, hepatocytes ultimately senesce or undergo
apoptosis diminishing the ability of the liver to repair injured areas of tissue (Dowman et al.,
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2010; Takahashi et al., 2012). Elevated levels of p53 have been found in cases of NASH and
positively correlate with increasing degrees of inflammation (Farrell et al., 2009; Kodama et al.,
2011; Panasiuk et al., 2006; Yahagi et al., 2004). Activation of p53 triggers up-regulation of its
downstream target p21, which arrests the cell cycle, and ultimately, p53 will lead to apoptosis of
damaged hepatocytes (Farrell et al., 2009; Yahagi et al., 2004). MMTV-Spy1 mice display
characteristics of a severely diseased liver. We see increased levels of p53 and p21 as well as
increased amounts of active caspase-3 indicating significant injury and inflammation, and a
decline in the regenerative potential of the liver due to apoptosis. To confirm progression of the
disease to fibrosis of the liver, trichrome staining would need to be completed to verify the
presence of collagen which is deposited by stellate cells in response to inflammation.
Since Spy1 causes enhanced cell cycle progression, it could act as a stressor in and of
itself, triggering and enhancing activation of p53 which would halt cell cycle progression and
return the hepatocytes to a normal state of quiescence. In an already transformed cell line, we
show that overexpression of Spy1 significantly increases levels of proliferation and lipid droplet
accumulation, while knockdown of Spy1 has the opposite effect, leading to both decreased BrdU
incorporation and Oil Red O staining. This provides further support for the theory that Spy1 could
be acting as a stressor, leading to activation of stress response pathways and triggering
inflammatory response pathways that would lead to development and progression of NASH.
Severe cases of NASH would ultimately lead to a decline in liver function, and ultimately liver
failure or HCC.
Spy1 has been demonstrated to mediate mammary tumour susceptibility using the
MMTV-Spy1 transgenic model and treatment with known carcinogens. Here we describe a
potential role for Spy1 in mediating susceptibility to liver tumour formation and promoting severe
liver disease. Elevated levels of Spy1 increase proliferation, and trigger lipid accumulation in
established HCC cells. In vivo, although not significant we see lipid accumulation in addition to
significant up-regulation of markers associated with severe cases of NASH which can lead to the
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development of HCC. Thus it appears that Spy1 plays a pivotal role in mediating liver tumour
initiation and could prove to be an attractive therapeutic target in treatment of this devastating
disease.
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Chapter 4
An Inducible Model System for Spatial and Temporal
Control of Spy1 Expression
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Introduction
A single transgenic mouse model allowing for constitutive overexpression of a protein of
interest undoubtedly provides an excellent model in which to study altered expression levels on
various tissue systems. The ability to induce expression and control it in a temporal and spatial
manner however, opens up more avenues of exploration and allows for more specific questions to
be answered (Gunther et al., 2002; Haruyama et al., 2009; Muller, 1999; Sun et al., 2007; Zhang
et al., 2010; Zhu et al., 2002). The reverse tetracycline transactivator system, rtTA, was developed
as a solution to some of the pitfalls associated with the tetracycline transactivator system (tTA),
allowing for inducible expression of a transgene upon administration of doxycycline (Gossen et
al., 1995). In the tTA system, the transgene of interest is on in the absence of doxycycline (Furth
et al., 1994). For the transgene to be turned off, doxycycline is administered which presents
problems when transgene activation is required again (Muller, 1999; Sun et al., 2007; Zhang et
al., 2010). Removal of doxycycline allows for transgene expression, however, induction of the
gene is dependent on removal of the substance from the organism’s system, thus rapid induction
of the transgene is not achievable. Using the rtTA system, transgene expression is induced upon
delivery of doxycycline allowing for rapid induction of gene expression. Upon removal of
doxycycline, gene levels have been shown to return to basal levels 24 hours after removal of
doxycycline (Blakely et al., 2005; Gunther et al., 2002). Thus, the rtTA system has proven to be a
more robust and effective system at inducing transgene expression during specified periods of
development.
Mammary gland biology has utilized this system and developed the MMTV-rtTA system.
This system has tighter control of transgene expression, is highly specific to the mammary gland
as compared to other MMTV models and demonstrates more homogenous expression through the
mammary gland (Gunther et al., 2002). Expression of the transgene can be seen as early as 6
hours after doxycycline induction and reach steady state levels by 48 hours (Gunther et al., 2002).
Removal of doxycycline returns transgene expression to basal levels 24 hours after withdrawal
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(Gunther et al., 2002). Additionally, levels of transgene expression can be titrated based on the
dose of doxycycline administered (Gunther et al., 2002). Thus, this system provides a model to
allow for specific spatial and temporal induction of a transgene while also allowing researchers to
induce transgene expression at varying levels, something which cannot be achieved using classic
transgenic model systems. The advantages of using an inducible system have been demonstrated
using the MMTV-rtTA promoter driving c-Myc overexpression within the mammary gland
(Blakely et al., 2005). Using this system, a 72 hour period during pregnancy was shown to be the
key stage of development that impairs the ability of mice to successfully nurse their pups if high
levels of c-Myc are expressed (Blakely et al., 2005). To further validate the inducible system, cMyc expression was turned on and was found to recapitulate the phenotype observed in the
MMTV-Myc mouse (Blakely et al., 2005). These findings further validate the use of the MMTVrtTA model as a valuable tool in studying altered gene expression at specified times of mammary
development.
We aim to utilize the MMTV-rtTA system to study the precise role of the cell cycle
regulator Spy1 in various stages of mammary development. Spy1 levels have been shown to be
tightly regulated during the course of development, with high levels corresponding to periods of
proliferation and apoptosis, and low levels corresponding to periods of differentiation (Golipour
et al., 2008). Overexpression of Spy1 via mammary fat pad transplantation leads to accelerated
development as well as the development of mammary tumours (Golipour et al., 2008). The
development of mammary tumours precludes studying the role of Spy1 in lactation. Previous data
has shown that overexpression of Spy1 in an in vitro setting led to abnormal morphology of the
cells when treated with differentiation stimuli, suggesting a key role for Spy1 during normal
mammary differentiation (Golipour et al., 2008). An inducible model system would allow us to
turn on Spy1 during key periods of mammary differentiation, such as during pregnancy and
lactation, and to investigate the precise period of development critical for Spy1 downregulation.
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Herein we describe the development of the Spy1-pTRE transgenic mouse. Crossing this
newly developed transgenic mouse with the MMTV-rtTA mouse, we have demonstrated
inducible expression of Spy1 within the mammary gland upon administration of doxycycline.
Additionally, we have data supporting that long term Spy1 expression does not alter mammary
development. This system will prove to be a valuable tool in the study of Spy1 in mammary gland
development.

157

Materials and Methods
Construction and Generation of Spy1-pTRE Transgene
Site directed mutagenesis was conducted to generate an XbaI site in Flag-Spy1A-pLXSN
(Porter et al., 2003). The pTRE-Tight caspase 3 (p12) : : n2 [TU#817] vector (Addgene 16084)
was subsequently digested with EcoRI and XbaI to remove the caspase 3 insert and allow for
ligation of the Flag-Spy1 coding sequence from the Flag-Spy1A-pLXSN vector into the pTRETight backbone.

Generation and Maintenance of Spy1-pTRE Mice and Maintenance of MMTV-rtTA Mice
The Spy1-pTRE vector was digested with XhoI to remove the vector backbone and
isolate the Spy1-pTRE transgene fragment. The resulting transgene fragment was sent to the
London Regional Transgenic and Gene Targeting Facility where pronuclear injections were
performed in B6CBAF1/J hybrid embryos. Identification of positive founders as well as
subsequent maintenance of the colony was performed using PCR analysis. The PCR reaction
conditions were as follows. A 25uL reaction containing 100ng of genomic DNA, 0.4uM forward
primer

[5’

GTGTACGGTGGGAGGCCTATATAA

3’],

0.4uM

reverse

primer

[5’

GTCATAGCCAAAAGATACTTGTCTGC 3’] and 12.5uL of New England Biolabs Master Mix
was prepared. PCR cycling conditions were as follows: 95°C for 2 minutes 30 seconds; 40 cycles
of 95°C for 45 seconds, 60°C for 45 seconds and 72°C for 1 minute 30 seconds, followed by a
final extension at 72°C for 10 minutes. Spy1-pTRE mice were maintained on the B6CBAF1/J
background and were also backcrossed with FVB mice to generate Spy1-pTRE mice on an FVB
background.
MMTV-rtTA mice were obtained from the lab of Dr. Roger Moorehead from the
University of Guelph, and were maintained on an FVB background. PCR analysis was utilized for
the identification of mice containing the MMTV-rtTA transgene. Briefly, 50ng of genomic tail
DNA was added to a 25uL reaction (1x PCR buffer, 2mM MgSO4, 0.2mM dNTP, 0.04U/uL UBI
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Taq Polymerase, 0.4uM forward primer [5’TGCAGAGCC AGCCTTCTTAT 3’ ], 0.4uM reverse
primer [5’ CCTCGATGGTAGACC CGTAA 3’]. PCR cycling conditions were as follows: 94°C
for 5 minutes, 36 cycles of 94°C for 30 seconds, 58°C for 30 seconds and 72°C for 45 seconds,
followed by a final extension of 72°C for 7 minutes.
Expression was induced by feeding mice food containing 2g/kg of doxycycline ad libitum
(Harlan Laboratories). Mice were maintained following the Canadian Council on Animal Care
Guidelines under the animal utilization protocol 10-16 approved by the University of Windsor.

Quantitative Real Time PCR Analysis
RNA was isolated from flash frozen tissue using the Qiagen RNeasy Plus Mini Kit as per
manufacturer’s instructions. cDNA was synthesized using Superscript II (Invitrogen), as per
manufacturer’s instructions. Real Time PCR was performed using Sybr Green detection (Applied
Biosystems) on a Viia7 Real Time PCR System (Life Technologies) and was analyzed using the
Viia7 Real Time PCR System software. Sequences for Flag-Spy1 and mouse GAPDH primers
were as follows:
Flag Spy1 Forward: 5’TGACAAGAGGCACAATCAGATGT 3’
Flag Spy1 Reverse: 5’ CAAATAGGACGCTTCAGAGTAATGG3’
Mouse GAPDH Forward: 5’ GATGCCCCCATGTTTGTGAT 3’
Mouse GAPDH Reverse: 5’ GTGGTCATGAGCCCTTCCA 3’

Whole Mount Analysis
Inguinal glands were collected and spread onto a positively charged slide. Slides were
immersed in Clarke’s Fluid (75% ethyl alcohol, 25% acetic acid) overnight. The following day,
glands were placed in 70% ethyl alcohol for 30 minutes at room temperature and were
subsequently left in Carmine Solution (0.2% carmine, 0.5% potassium sulfate) to stain ductal
structures overnight. Glands were placed into de-staining solution (1% hydrogen chloride, 70%
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ethyl alcohol) for 4 to 6 hours until the gland appeared to have been sufficiently de-stained. The
glands were subsequently dehydrated in ascending concentrations of ethyl alcohol for 15 minutes
each (70%, 95%, 100%) before being cleared in xylene overnight (or until glands were
sufficiently cleared). Glands were mounted with Permount toluene solution (Fisher Scientific)
and images were acquired using a Leica M205 FA stereo microscope (University of Windsor) and
captured using LAS V4.3 software.

Histology and Immunostaining
Briefly, inguinal glands were fixed in 10% neutral buffered formalin and were
subsequently dehydrated through a series of ascending ethanol concentrations, followed by
clearing in xylene. Following clearing in xylene, the tissues were embedded in paraffin wax and
sectioned into 5uM sections using the Leica RM2125RT. For immunohistochemistry, sections
were first rehydrated in a series of descending ethanol concentrations, followed by heat mediated
antigen retrieval with 10mM sodium citrate buffer pH 6.0. Next, endogenous peroxidase activity
was blocked using 3% H2O2 diluted in methanol, and sections were subsequently blocked using
MOM blocker (Biocare Medical; mouse secondary antibody) or 3% BSA-0.1% Tween-20 in 1x
PBS (rabbit secondary antibody). Sections were incubated in primary antibody diluted in
appropriate blocker overnight at 4°C. Following incubation in primary antibody, sections were
washed with 1xPBS and were incubated for 1 hour in a humidified chamber in secondary
antibody diluted in the appropriate blocker at 1:750. Sections were once again washed with
1xPBS and were treated with ABC reagent (Vectastain ABC

Kit) as per manufacturer’s

instructions. Sections were subsequently stained with DAB reagent (DAB Peroxidase Substrate
Kit, Vector Laboratories) as per manufacturer’s instructions, and were counterstained with
haematoxylin (Vector Laboratories). In a series of ascending ethanol concentrations, sections
were dehydrated and coverslipped using Permount toluene solution (Fisher Scientific). Images
were obtained using the LEICA DMI6000 inverted microscope with LAS 3.6 software.
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Haematoxylin and eosin stained slides were rehydrated in a series of descending ethanol
concentrations, and were then washed in distilled water. Sections were stained with haematoxylin
(Vector Laboratories), and were rinsed in running tap water for up to 10 minutes. Sections were
subsequently stained with eosin (Sigma Aldrich) and were dehydrated in a series of ascending
ethanol concentrations before being coverslipped using Permount toluene solution (Fisher
Scientific).
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Results
Spy1-pTRE transgenic mouse model generation and model validation.
The Spy1-pTRE transgene was cloned as described in materials and methods. Briefly, the
Flag-Spy1 human cDNA sequence was cloned into the pTRE-Tight vector, digested to remove
vector backbone, and sent to the London Regional Transgenic and Gene Targeting Facility.
Construction of this transgene will allow for inducible spatial and temporal expression of Spy1
under the control of the pTRE-Tight promoter (Figure 1A) upon administration of doxycycline.
The resulting Spy1-pTRE mice are crossed with the MMTV-rtTA mouse model generating pups
of four potential genotypes (Figure 1A). The MTB-Spy1 mouse will contain both the Spy1-pTRE
transgene and MMTV-rtTA transgene. This double transgenic mouse will overexpress Spy1
specifically within the mammary gland upon administration of doxycycline. Pups resulting from
the cross may also contain only one of the transgenes, or neither. These offspring are used as
controls as administration of doxycycline will not result in Spy1 overexpression.
Spy1-pTRE founders were identified via PCR analysis and germline transmission from
founder to offspring was also confirmed (Figure 1B).

Once germline transmission of the

transgene was confirmed, Spy1-pTRE mice were crossed with MMTV-rtTA mice to produce the
MTB-Spy1 mice and appropriate controls. 5 week old MTB-Spy1 mice and their control
littermates were administered doxycycline through their diet, and tissue from the inguinal glands
was collected 72 hours after beginning the doxycycline diet. To confirm that Spy1 expression is
indeed induced in this model, qRT-PCR analysis was performed (Figure 1C). The analysis
showed that after doxycycline administration, there is a significant increase in Spy1 expression
levels in the MTB-Spy1 mice as compared to their control littermates. Thus, this indicates that the
Spy1-pTRE transgenic model system is a reliable tool to study the effects of inducible spatial and
temporal overexpression of Spy1 on murine mammary gland development.
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Prolonged expression of Spy1 does not alter gross mammary gland morphology.
To study the effects of long term overexpression of Spy1 on normal mammary gland
development, MTB-Spy1 mice and control littermates of both genotypes were placed on a
doxycycline diet for one year. Mice from all genotypes were also allowed to undergo multiple
rounds of pregnancy as it is well known from other MMTV models that subsequent rounds of
pregnancy can lead to tumour formation (Stewart et al., 1984). In the MMTV-Myc model, all
mice develop mammary adenocarcinomas by the second or third pregnancy, highlighting the
importance of studying long term overexpression in parous mice (Stewart et al., 1984). Inguinal
glands were collected after 1 year, and qRT-PCR analysis was performed to determine if Spy1
levels were still elevated in MTB-Spy1 mice as compared to control (Figure 2A). Analysis
revealed that significantly elevated levels of Spy1 were maintained in the MTB-Spy1 mice even
after one year of induction. To test if elevated levels of Spy1 altered normal mammary
development, whole mount and immunohistochemical analysis was performed (Figure 2B, C). No
significant differences were noted in the gross morphology of MTB-Spy1 mammary glands as
compared to control. Additionally, even with multiple rounds of pregnancy, elevated levels of
Spy1 did not lead to tumourigenesis; therefore prolonged Spy1 overexpression does not affect the
development of the mammary gland.
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Discussion
Inducible transgenic model systems allow for tighter control and regulation of protein
expression, and open further avenues of study that a constitutive model does not allow (Sun et al.,
2007; Zhu et al., 2002). The Spy1-pTRE mouse model was generated to permit a more detailed
study of Spy1 overexpression on particular stages of mammary gland development. Crossing this
mouse with the MMTV-rtTA mouse generated the MTB-Spy1 mouse. Using the MTB-Spy1
mouse, Spy1 expression can be turned on either long term, or during discrete windows of
mammary gland development upon the administration of doxycycline. Upon withdrawal of
doxycycline, Spy1 expression is returned to its normal levels during that phase of development.
Prior to experimentation with this model, it first had to be demonstrated that all three of
the founder lines for the Spy1-pTRE mouse were capable of Spy1 overexpression once crossed
with the MMTV-rtTA mouse and administered doxycycline. Indeed we show that within 72
hours of doxycycline administration, we see a significant increase in Spy1 expression in MTBSpy1 mice. Further comparison with MTB-Spy1 control mice not on a doxycycline diet can be
used to further prove expression is induced in the presence of doxycycline. Thus, this proves that
this model effectively overexpresses Spy1 and will be an effective tool to study the effects of
altered Spy1 levels during discrete stages of development.
The first step was to determine if prolonged elevation of Spy1 levels altered normal
mammary gland development, and importantly, if it could induce spontaneous tumourigenesis.
MTB-Spy1 mice and their control littermates were left on the doxycycline diet for a period of one
year. During this time, cohorts of mice underwent multiple rounds of pregnancy. This
experimental design is pivotal to our understanding as the MMTV promoter is hormonally driven
and multiple rounds of pregnancy in an MMTV model can lead to tumourigenesis because
increased levels of hormones during pregnancy further elevate levels of the protein of interest
(Stewart et al., 1984). Although the mice were parous, none of the mice developed tumours
during the course of the treatment. When expression levels of Spy1 were examined at the end of
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the induction period, it was found that we do in fact see significantly higher levels of Spy1 in the
MTB-Spy1 mice indicating that long-term exposure to doxycycline does allow for prolonged
overexpression of Spy1 within the mammary gland. Although we did not see any tumour
development, it was still possible that normal development of the gland could be affected. Whole
mount and immunohistochemical analysis of the mammary gland was performed and no overt
gross morphological differences were noted, indicating that the overexpression of Spy1 alone is
not sufficient to induce developmental changes.
Previous data reported that the overexpression of Spy1 in vivo via mammary fat pad
transplantation led to altered mammary development (Golipour et al., 2008), however, using the
MTB-Spy1 model, prolonged overexpression of Spy1 does not lead to any alterations in
mammary development. This discrepancy can be explained by two possibilities. First, the
mammary fat pad transplantation experiment was performed in Balb/C mice and utilized the
HC11 cell line which is known to have a mutated p53 (Merlo et al., 1993). It is known that Spy1
is capable of overcoming DNA damage induced checkpoints and apoptosis (Barnes et al., 2003;
Gastwirt et al., 2006; McAndrew et al., 2009). It is quite possible that effects on normal
development were seen in the mammary fat pad transplantation model due to the interaction
between Spy1 and mutated p53, indicating that a second hit or alteration in protein levels is
required for Spy1 to affect development. Second, the MTB-Spy1 mouse generated from the Spy1pTRE and MMTV-rtTA cross is of a mixed background. The Spy1-pTRE mouse was generated
on a B6CBAF1/J hybrid background, and the MMTV-rtTA mouse is maintained on an FVB
background. The C57BL6/J mouse is known to be highly resistant to tumourigenesis and to the
effects of MMTV, thus the FVB strain is more commonly used in the generation of MMTV
mouse models (Beutner et al., 1996; Davie et al., 2007; Rollini et al., 1992). While the resulting
MTB-Spy1 mouse would therefore be of a B6CBAF1/J-FVB hybrid, perhaps the influence of the
C57BL6/J strain still does not allow for Spy1 to exert its effects on mammary development. To
test this possibility, the Spy1-pTRE mouse is currently being backcrossed onto the FVB strain.
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This will simplify breeding and will determine if the lack of phenotype is due to the influence of
mouse strain. Further investigation into these possibilities must be undertaken to determine the
precise effects of altered Spy1 levels on normal mammary development.
The Spy1-pTRE mouse model has been confirmed as a tool to induce specific
overexpression of Spy1 upon administration of doxycycline. This model provides an advantage
over traditional models as it allows for temporal and spatial control of induced expression. The
Spy1-pTRE mouse model will allow us to answer more specific questions about mammary gland
development, as well as enabling us to answer questions in other tissue systems, such as the brain,
simply by choosing a different tissue specific promoter to drive expression of rtTA. Thus, this
model will prove to be an excellent tool for future studies of the precise role of Spy1 in regulating
normal development and in the initiation and onset of tumourigenesis.
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Chapter 5
Development of a Gene Targeted Spy1 Model System
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Introduction
The advent of technology to render an endogenous gene inactive has greatly enhanced
our understanding of the normal functioning of hundreds of genes, which has facilitated the
treatment of a wide variety of human diseases (Bouabe and Okkenhaug; Capecchi, 2005). A
downfall of this strategy is embryonic lethality. Losing the function of many gene products early
in development will lead to failure of the embryo to thrive (Hakem et al., 1996; Hall et al., 2009).
While this can be beneficial in understanding the role of the gene in early stages of development,
it hinders our ability to study its function in other biological processes and diseases that develop
later in life. To overcome this pitfall, a strategy that allows for control over the timing and tissue
specificity of gene ablation was developed. The Cre/loxP system was first discovered in P1
bacteriophage, and it has now been successfully employed in the field of gene targeting to allow
for conditional gene knockout (Nagy, 2000; Sauer, 1998; Wagner et al., 1997). This system
involves the use of a transgenic animal which expresses Cre recombinase under the control of a
tissue specific promoter, and a gene targeted animal which contains loxP sites flanking a
functionally essential portion of the gene of interest (Hamilton and Abremski, 1984; Muller,
1999; Nagy, 2000; Voziyanov et al., 1999). The presence of the loxP sites will not affect gene
function thereby circumventing the issue of gene lethality. When these two mice are crossed
together, tissue specific expression of Cre recombinase will lead to removal of the essential part
of the gene leading to gene knockout. Understanding the basic function of a gene during normal
development facilitates our understanding of human disease development, progression and
ultimately, treatment. Thus the Cre/loxP system facilitates and enhances the study of the
essentiality of hundreds of genes, and has proven to be a valuable tool time and time again.
The study of cell cycle regulation has been enhanced through the use of gene targeted
approaches. Cell cycle regulators, such as cyclin dependant kinases (CDKs) and cyclins, play a
key role in regulating cell proliferation and it was thought that ablation of gene function would
result in embryonic lethality. This however, was not the case for all genes. Gene knockouts of
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CDK2, cyclin E, and CDK4 among others resulted in viable mice, and while these mice may have
had developmental defects such as sterility, it demonstrated that these genes were not essential for
viability of the organism (Berthet et al., 2003; Ciemerych and Sicinski, 2005; Geng et al., 2003;
Mendez, 2003; Rane et al., 1999). Knockouts of CDK1 however, resulted in embryonic lethality,
highlighting the importance of this CDK in the normal development of the organism (Santamaria
et al., 2007). One cell cycle regulator that has to date not been studied in a gene targeted system,
is the atypical cyclin-like protein Spy1. Spy1 can bind and activate CDK2 in absence of the
classical phosphorylation events, and can also directly bind to the CDK inhibitor p27 leading to
further activation of CDK2 (Cheng et al., 2005a; Karaiskou et al., 2001; McAndrew et al., 2007;
Porter et al., 2002; Porter et al., 2003). Overexpression of Spy1 shortens G1 phase of the cell
cycle and increases cellular proliferation, while depletion of Spy1 levels greatly reduces the rate
of cell proliferation and slows movement into M phase of the cell cycle, thus demonstrating that
Spy1 is an important part of the cell cycle machinery (Porter et al., 2002). To further highlight the
importance of Spy1 in normal cell cycle progression, Spy1 was initially discovered in Xenopus
oocytes, which are arrested at the G2/M transition during normal development (Lenormand et al.,
1999). It was discovered that injection of Spy1 into these oocytes leads to rapid maturation of the
oocyte and progression through the G2/M transition (Ferby et al., 1999; Lenormand et al., 1999).
It was also noted that expression of Spy1 was upregulated after stimulation with progesterone, the
hormone responsible for progression of Xenopus oocytes through meiosis (Ferby et al., 1999;
Lenormand et al., 1999). Ablation of Spy1 significantly delayed oocyte maturation upon
progesterone stimulation (Ferby et al., 1999; Lenormand et al., 1999). Taken together, these
results suggest that Spy1 may be required for oocyte maturation and could therefore play an
essential role in normal embryonic development.
While the studies in Xenopus oocytes have demonstrated the importance of Spy1 in
oocyte maturation, it remained to be determined if this role was conserved in mouse oocytes.
Indeed, injection of Spy1 mRNA into mouse oocytes arrested in prophase I resulted in germinal
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vesicle breakdown (GVBD), an essential step in resumption of meiosis (Terret et al., 2001).
Additionally, injection of Spy1 mRNA in early stage mouse embryos causes cleavage arrest and
inhibits polar body extrusion suggesting that it could act in M phase to inhibit the meiotic cell
cycle (Terret et al., 2001).
Based on our knowledge of the key role Spy1 plays in regulating normal cell proliferation
and oocyte maturation, one could hypothesize that a complete gene knockout of Spy1 could
render the embryo non-viable and lead to embryonic lethality, circumventing the study of the
essentiality of Spy1 in other tissue systems such as the mammary gland. To avoid the issue of
embryonic lethality, a conditional gene targeting approach has been employed to allow for the
conditional deletion of Spy1 in a tissue specific manner. Utilizing the Cre/loxP system, we sought
to generate a floxed mouse harbouring loxP insertions around the area of the Spy1 gene
responsible for its function, the Speedy-RINGO box. The Speedy-RINGO box is required for the
binding of Spy1 to CDKs, therefore, abolishing the ability of Spy1 to bind to CDK2 will render
the gene non-functional (Cheng et al., 2005a; Cheng et al., 2005b; Porter et al., 2002). Herein we
describe the gene targeting approach taken to generate the first conditional gene targeted mouse
for the Spy1 gene.
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Materials and Methods
Plasmids
The targeting vector for Spy1 was generated by Vega Biolab, and BAC clones
bMQ256e05 and bMQ185H8 were purchased from GeneService Sanger. Exon 4 of Spy1 was
flanked on either side by loxP sites placed in the intronic region of the gene. A neomycin cassette
was inserted in the targeted region adjacent to the 5’ loxP site in the opposing orientation to the
gene. A BamHI site was also introduced in the targeted region to aid in screening for correctly
targeted clones.
Probes for southern blot analysis of the 5’ and 3’ ends as well as for Neo incorporation,
were isolated from the appropriate mouse genomic DNA, or targeting vector respectively. The
isolated probe fragments were cloned into the pCR TOPO 2.1 Vector using the TOPO-TA
Cloning Kit (Invitrogen) as per manufacturer’s instructions. Following generation of the vectors,
probes can be readily isolated by digestion of the vector with EcoRI to isolate the probe
fragments for [α-32P]-dCTP labeling.

Gene Targeting
Electroporation of the targeting vector was performed by the London Regional
Transgenic and Gene Targeting Facility in R1 ES cells. Targeted clones were identified by
southern blot analysis as described below. Clones that were identified to have been correctly
targeted were injected into blastocysts to generate chimeric mice.

Southern Blot Analysis
10ug of genomic DNA in a 30uL reaction volume was digested overnight at 37°C with
BamHI, PstI or NdeI for 5’, 3’ or Neo screening respectively. The following morning, an
additional 1uL of the appropriate enzyme was added and the reaction was allowed to continue for
an additional 4 hours at 37°C. A 0.8% agarose gel was prepared without ethidium bromide and
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samples were run at 30 volts for 10 hours. Following the gel run, the gel was stained with
ethidium bromide in 1X TAE and imaged next to a UV ruler to measure migration of the ladder.
The gel was then washed twice with wash buffer 1 (1.5M sodium chloride, 0.5M sodium
hydroxide) for 30 minutes each followed by a 5 minute wash with distilled water. The gel was
then washed twice with wash buffer 2 (1M ammonium acetate, 0.02M sodium hydroxide) 30
minutes each. Overnight capillary action transfer using paper towels was then set up using
nitrocellulose membrane (Fisher Scientific; GE Nitrocellulose Membrane Nitropure 0.45uM).
Transfer buffer has the same composition as wash buffer 2. The following morning, the
membrane was left to dry on the bench for 1 hour before baking under pressure at 80°C. For
probe labelling, the appropriate probe was gel extracted using the Sigma GenElute Gel Extraction
Kit (Sigma Aldrich) as per manufacturer’s instructions, following digestion of the appropriate
vector with EcoRI to isolate the probe fragment. Once the probe was successfully extracted, the
membrane was placed in hybridization buffer (4X SET, 10X Denhardts, 0.1% sodium
pyrophosphate, 25mM Na3PO4, 0.2% SDS) for 1 to 2 hours at 65°C. The extracted probe was
labeled with [α-32P]-dCTP using the Promega Prime-a-Gene Labeling System (Promega) as per
manufacturer’s instructions. Probe was purified to remove unincorporated nucleotides using a
Sephadex G50 purification column. Purified probe was heated at 95°C for 5 minutes and added to
5mL of hybridization buffer heated to 65°C. Membrane was hybridized overnight at 65°C. The
following day, the membrane was washed 3 times 10 minutes at room temperature with low
stringency wash buffer (2xSSC, 0.1% SDS), followed by 3 10 minute washes at 65°C with high
stringency wash buffer (0.2X SSC, 0.1% SDS). Membrane was set up for a minimum of 3 nights
exposure with Super Sensitive Phosphor Screen (Perkin Elmer), and was subsequently imaged
using the Cyclone Plus Phosphor Imager (Perkin Elmer).
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Genotyping Procedure
Samples were screened for 3’ end loxP incorporation by PCR analysis. PCR was
conducted as follows: a 25uL reaction (1x PCR buffer, 2mM MgSO4, 0.2mM dNTP, 0.04U/uL
UBI Taq Polymerase, 0.4uM forward primer [5’ GATTCA AGTGGATTAACTCTGGGGACC
3’], 0.4uM reverse primer [5’GACAGAGAAAGTGTGTGTGTTGGAGG 3’] was prepared, and
PCR cycling conditions were 95°C for 10 minutes followed by 40 cycles of 95°C for 1 minute,
60°C for 2 minutes and 72°C for 1 minute followed by a final elongation at 72°C for 10 minutes.
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Results
SpdyA conditional knockout targeting vector design.
To examine the importance of Spy1 in development of the mammary gland, we sought to
generate a conditional knockout mouse via gene targeting of exon 4. LoxP sites were introduced
flanking exon 4 as illustrated in the targeting vector design in Figure 1A. Successful generation of
the targeting vector was verified using restriction enzymes illustrated on the targeting vector
verification map (Figure 1B). To detect successful homologous recombination, southern blot
analysis was utilized. Probes were designed outside of the arms of homology and were tested for
specificity by probing previously digested ES cell DNA with both the 5’ and 3’ probes. Probes
were deemed to be specific for the Spy1 sequence as seen in the representative images in Figure
1C.
To further validate events of successful homologous recombination, a southern blot
screening strategy to ensure the Neo selection marker was in the correct location in the gene was
designed (Figure 2A). The generated Neo probe was also tested for specificity to determine if it
would be suitable for screening (Figure 2B).This was accomplished by testing specificity of the
probe with ES cell DNA that had been previously digested with BamHI, which should yield a
1.5kb band once the Neo probe binds. Identification of the 1.5kb fragment indicates that the Neo
probe is indeed specific for its intended sequence.
To prepare for screening of the Spy1 floxed mice, primers were designed flanking the
loxP site located 3’ of exon 4 (Figure 2C). Designing primers in this location allows for detection
of the wild-type allele (lower band), the floxed allele (upper band) or the presence of both the
wild-type and floxed allele within the same mouse (Figure 2D).

179

180

181

Identification of ES cell clone demonstrating successful homologous recombination.
A total of 222 clones were generated from electroporation of the Spy1 targeting vector
into R1 ES cells. All clones were initially screened using the 5’ probe through a BamHI digest.
Out of the initial clones generated, 16 were identified as potentially having successful
homologous recombination by the presence of both the wild-type band at 18.5kb and the targeted
band at 6.3kb. These clones were then digested with PstI to enable screening with the 3’ probe to
check for proper homologous recombination on the 3’ end. One clone, 5-4C, was shown to be
successfully targeted on the 3’ end through the presence of the wild-type band at 6kb and the
targeted band at 4.8kb (Figure 3A). Based on the results from the initial southern blot screens, 54C was deemed to have undergone successful homologous recombination and the resulting ES
cells from this clone were injected into 3.5 day old C57BL/6 blastocysts. Prior to injection, clone
5-4C was re-grown for injection. DNA from the resulting population that was injected into the
blastocyst was received and screened once again for validation of successful homologous
recombination using all three of the designed probes for southern blot analysis (5’, 3’ and Neo).
Results from this final screen were surprising. Although clone 5-4C previously showed successful
recombination at both ends, the final screen after injection showed only the presence of the wildtype allele and no floxed allele (Figure 3B). Additionally, use of the Neo probe showed that the
Neo insert was not inserted in the correct location as the predicated size of the resulting fragment,
7.8kb, was not seen. Thus, this final analysis demonstrates that the chimeric mouse resulting from
the blastocyst injections was not correctly targeted, although initial analysis showed the presence
of both a wild-type and floxed allele on both the 5’ and 3’ ends of the targeted area.
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Discussion
The use of gene targeted animal models has helped to revolutionize our understanding of
the basic functions of many genes. Herein, we described an approach to conditionally knockout
the novel cell cycle regulator, Spy1. Spy1 was originally identified in a screen for Xenopus cDNA
that would confer resistance to UV radiation in a rad1 deficient strain of S.pombe (Lenormand et
al., 1999). It was found that Spy1 was present as maternal mRNA in Xenopus oocytes, and
injection of Spy1 RNA into Xenopus oocytes allowed for rapid progression through G2/M phase
of the cell cycle and oocyte maturation (Lenormand et al., 1999). Based on these findings, a full
knockout was not pursued as it was believed that the full knockout may be embryonic lethal, or
would cause phenotypes that would prevent the study of the loss of Spy1 on normal mammary
gland development, which is a system in which we sought to study the essentiality of Spy1.
Additionally, use of a conditional approach would allow for targeted spatial and temporal
expression of Cre recombinase in select tissues or cell populations, generating a model in which
the study of the essentiality of Spy1 in various systems could be studied without interference of
potential phenotypes in other systems.
The design of the Spy1 targeting vector presented some challenges. First, the Spy1 gene
has multiple start sites. To ensure full knockout is achieved upon Cre recombination, the targeted
location must be chosen carefully to ensure no functional protein remains. For this reason, exon 4
was targeted as this exon contains in it a large portion of the Speedy-RINGO box which is
essential for its binding to CDK2 (Cheng et al., 2005a; Cheng et al., 2005b; Porter et al., 2002).
Removal of the Speedy-RINGO box would ultimately render the Spy1 protein non-functional.
Additionally, the only remaining protein would be a portion of the N-terminus which contains
phosphorylation sites that target Spy1 for degradation. Thus any protein generated would
ultimately be non-functional due to the lack of the Speedy-RINGO box, and targeted for
degradation. In addition to the challenges presented by the Spy1 gene itself, further challenges
were presented by the presence of a gene encoding for non-coding RNA, Trmt61b. While this
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gene at present is not known to be translated, affecting the sequence of this gene could in and of
itself manifest as a phenotypic change in the development of the generated mouse. To ensure this
does not happen, the area targeted by the loxP sites is in an intronic region of the Trmt61b gene
diminishing the possibility of disruption to this non-coding RNA.
Once the targeting vector design was completed, the next critical step was ensuring the
screening strategy via southern blot analysis was specific and would be able to detect both the
wild-type and targeted alleles effectively. The strategy for screening the 3’ end of the targeting
vector also presented challenges in that a large portion of this end of the Spy1 gene shows
homology to a region of chromosome 1. All three probes designed for southern blot screening of
the resulting ES cell clones were tested and were shown to be specific and sufficient for detection
of the wild-type alleles indicating they would also be able to detect the targeted allele in the case
of successful homologous recombination.
Initial screening of the electroporated ES cells yielded one potential successfully targeted
clone, clone 5-4C. Having one successfully targeted clone demonstrates that the targeting
efficiency of the designed targeting vector was quite low. Additionally, having only one clone to
proceed with blastocyst injections is inherently risky as problems with growing up the clone,
aneuploidy or being unable to re-confirm the genotype means there is no fall back clone on which
to go back to. In this case, clone 5-4C was injected into C57BL/6 blastocysts and upon southern
blot analysis of the injected clone, it was found that the targeted allele was no longer present.
Only the wild-type allele was detected during the re-confirmation of clone 5-4C, indicating that
this clone was in fact not properly targeted and only contains part of the targeting vector inserted
randomly within the genome.
A number of possibilities exist to explain as to how correct targeting of a clone could
initially be seen and then upon re-confirmation is no longer present. The simplest explanation is
simply human error. Perhaps when the clone was picked from the plate to be re-grown for
injections, the wrong well was chosen. Given the large number of clones that are initially
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produced and screened, this very well could be a reasonable explanation for the result seen during
the re-confirmation of the clone. Another possibility could be due to a heterogeneous population
of ES cells within the clone. If wild-type cells were present in the clone and did not initially grow,
when the clone was grown back up, it is possible these wild-type cells had by this point acquired
resistance to Neomycin and overtook the culture. Additionally, the culture of ES cells is quite
difficult and it could be that the targeted cells differentiated and were ultimately lost (Tremml et
al., 2008). Due to the large number of possibilities to explain the loss of the targeted allele, it was
decided that the original targeting vector be re-examined and improved upon to improve the
chances of successful homologous recombination to improve targeting efficiency.
During the original design of the targeting vector, there was a noted discrepancy in the
published sequence of the Spy1 gene and the length of the 5’ homologous arm. The published
sequence is based on the C57BL/6 mouse strain while the strain of mouse being targeted is a
strain of 129. The targeting vector lacked a 1.5kb sequence as predicated based on the published
C57BL/6 sequence. Attempts to isolate this sequence from a second BAC clone failed, and based
on the predicated size of the wild-type fragment, it was determined that the 129 strain of mouse
does indeed lack this 1.5kb sequence. This shows the inherent variability between strains of mice
and highlights the importance of knowing the full sequence of the strain being targeted. To
further improve targeting efficiency, the CRISPR/Cas system will be employed.

The

CRISPR/Cas system makes use a system utilized by bacteria and archaea to seek out and
eliminate any invading viruses or plasmids (Sander and Joung, 2014; Yang et al., 2014). In this
system, a guide RNA (gRNA) targets the Cas9 endonuclease to a specific site within the genome
to generate a double stranded break (Sander and Joung, 2014; Yang et al., 2014). Once a double
strand break is produced, a knockout, knock-in, conditional allele or mutation may be introduced
at the site of the break and incorporated into the genome via DNA repair mechanisms such as
homologous recombination (Fujii et al.; Sander and Joung, 2014; Shen et al.; Wang et al.; Yang et
al., 2014; Yang et al.). To generate a targeted allele, Cas9 mRNA, two gRNAs and single
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stranded DNA containing the loxP site surrounded by arms of homology specific to the site of
double stranded break are injected (Sander and Joung, 2014; Yang et al., 2014; Yang et al.). This
system provides many advantages over the classic method of genome modification in generating
gene targeted mice as the timeline of completion is much quicker and multiple genes can be
targeted at one time (Wang et al.; Yang et al.). To utilize this new system, the full sequence of the
Spy1 gene in the 129 strain of mouse where targeting is to occur must be known. After analysing
the targeting vector closely, a 200bp insert was noted directly after the 3’ Frt site flanking the Neo
insertion cassette. This 200bp insert is located very close to exon 4 meaning that it could affect
the splicing of Spy1 and ultimately affect its function even prior to Cre recombination. It remains
to be determined however, if this 200bp insert is a by-product of the vector itself, or if this is
sequence specific to the 129 strain and not found in the C57BL/6 strain. To proceed with
CRISPR/Cas, the Spy1 sequence of the area in question in the R1 ES cells being used in targeting
will be sequenced to determine the full sequence of the Spy1 gene in this strain of mice.
If the sequence in question is indeed incorrect and will cause problems with proper gene
targeting, then the targeting vector design will need to be re-evaluated and a new strategy may
need to be developed and new targeting vector designed. Given the amount of time this may take,
alternate approaches to study the essentiality of Spy1 in various systems, such as the mammary
gland, are being evaluated. The generation of transgenic model systems is a much less time
consuming endeavour. Once cloning of the transgenic vector is completed, pronuclear injections
can be performed and screening for potential founders could occur in as early as 6 weeks from the
time of injection (Haruyama et al., 2009). Once founders are identified, they can immediately be
bred to expand the colony and analysis can begin much quicker than if gene targeting were to be
used. Transgenic model systems employing the use of shRNA are commonly used with much
success (Dow et al.). Using this approach, a transgenic vector containing the sequence for shSpy1
will be generated. The transgenic vector will utilize the pTRE-Tight promoter thereby allowing
for inducible temporal and spatial expression of shSpy1 upon administration of doxycycline.
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Transgenic mice expressing the reverse tetracycline transactivator, rtTA, under the control of
various promoters are readily available for use. Development of the pTRE-shSpy1 mouse model
will provide a system in which the essentiality of Spy1 can be studied. This system will not
provide complete knockout of Spy1, but instead, knockdown of Spy1 levels; thus it remains
possible that with small amounts of functional Spy1 present different phenotypes may be seen
with knockdown as compared to a full knockout. However, given the time required for the
generation of the conditional knockout mouse, the pTRE-shSpy1 transgenic mouse will become a
valuable tool.
The generation of a targeting vector to allow for the generation of the first Spy1
conditional knockout mouse presented many challenges. While there have been setbacks in this
process, the value of generating this model far outweighs any challenges. It is now clear that
further elucidating the sequence of Spy within the 129 strain is key to generating a functional
Spy1 conditional knockout. An shSpy1 transgenic mouse will provide a valuable tool in which to
study the essentiality of Spy1 in development while the finer details of the gene targeting project
are mapped out. Generating an in vivo system to study loss of Spy1 function will be key to fully
elucidating the precise role Spy1 plays in regulating developmental processes.
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Discussion and Future Directions
This thesis describes the generation of the first transgenic model systems to drive
expression of Spy1 in a temporally and spatially controlled manner. The advent of technologies to
generate transgenic and gene targeted models has revolutionized our understanding of the basic
molecular mechanisms which regulate developmental processes and ultimately progression to
carcinogenesis. No such models had previously existed for Spy1, therefore limiting research to in
vitro studies and transplantation of manipulated cells back into an in vivo setting. While these
techniques are commonly used in the literature and have proven to be reliable, the use of mouse
models inherently provides many advantages over other study systems. Inducing changes in
protein expression levels in a normal environment eliminates potential effects due to
immortalization of cells. Maintenance of an environment reflective of normal conditions also
prevents loss of extracellular signals from the local environment that typically affects the cellular
processes, playing important roles in influencing cell fate and cell cycle decisions.
Two transgenic model systems were generated. The MMTV-Spy1 mouse was designed to
target overexpression of Spy1 specifically to the mammary gland. Using the MMTV promoter,
we were able to study the effects of aberrant Spy1 expression on mammary development and
tumourigenesis. MMTV-Spy1 mice displayed normal mammary development and did not
develop spontaneous tumours, even after multiple rounds of pregnancy. Lack of an overt
developmental phenotype could simply be due to the strain of choice in generating this model.
MMTV-Spy1 mice were generated on a B6CBAF1/J background which are resistant to mammary
tumourigenesis (Beutner et al., 1996; Davie et al., 2007). The C57BL6/J strain is well
documented to be highly resistant to many forms of tumourigenesis. In addition, this strain is
known to be resistant to MMTV infection potentially due to differences in major
histocompatibility complexes which can lead to immune mediated resistance (Beutner et al.,
1996; Davie et al., 2007). It is plausible then that if backcrossed onto a susceptible strain of
mouse commonly used in the development of MMTV transgenic models, we may see an overt
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difference in mammary development and the onset of mammary tumourigenesis. The MMTVSpy1 mouse has been backcrossed ten generations onto an FVB background. Although
preliminary analysis shows only subtle differences similar to results seen on the B6CBAF1/J
background, it remains to be seen if over time and after repeated cycles of pregnancy, these mice
develop gross morphological changes and spontaneous mammary tumours.
Importantly, the highly resistant B6CBAF1/J MMTV-Spy1 mice showed increased
susceptibility to tumour formation when challenged with the carcinogen DMBA. Spy1 expressing
mice display a significant increase in the number of overall tumours and mammary tumours
formed over their control littermates when treated with DMBA. Since DMBA exerts its
carcinogenic properties by causing damage to the DNA, and Spy1 is known to override cellular
checkpoints and apoptotic pathways in response to DNA damage (Barnes et al., 2003; Das et al.,
1989; Gastwirt et al., 2006; McAndrew et al., 2009; Melendez-Colon et al., 1999), we
investigated whether the presence of exogenous levels of Spy1 elicited any effects on DNA
damage response signaling. Levels of p53 were examined after treatment with DMBA and were
found to be significantly elevated in MMTV-Spy1 mice. Additionally, a higher percentage of
cells were γH2AX positive. Increased levels of p53 could indicate a delayed or impaired DNA
damage response in response to DMBA treatment due to elevated levels of Spy1 which are
known to override DNA damage signaling checkpoints (Barnes et al., 2003; Gastwirt et al., 2006;
McAndrew et al., 2009). To further corroborate this, an increase in γH2AX indicates the presence
of unrepaired damage. Levels of γH2AX are proven to be a reliable marker of the amount of
DNA damage a cell has sustained or accumulated, and an increase in γH2AX

has been

demonstrated in various forms of cancer (Dickey et al., 2009). Taken together, increased levels of
both p53 and γH2AX indicate the DNA damage response is either delayed or inactive. The
inability of the cell to repair damage would lead to accumulation of damage over time
contributing to the onset of tumourigenesis.
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Surprisingly, aged male MMTV-Spy1 mice displayed a significant increase in the
number of spontaneous liver tumours. Previous reports have documented expression of MMTV
driven transgenes in male reproductive organs and salivary glands, although expression in the
liver has only been reported thus far in females (Callahan and Smith, 2000; Cardiff and Kenney,
2011; Wagner et al., 2001). We show a significant increase in Spy1 expression in aged male
MMTV-Spy1 livers, which correlates with increased tumour formation and lipid accumulation in
the liver. NASH is a fatty liver disease characterized by significant fat accumulation,
inflammation, injury and fibrosis which has the potential to develop into full blown HCC
(Dowman et al., 2010; Takahashi et al., 2012; The National Digestive Diseases Information
Clearinghouse, 2014). We show that MMTV-Spy1 male livers display an increase in lipid
formation, and a significant increase in nuclear size. Increased nuclear size could be due to either
increased ploidy or senescence (Gonzalez-Reimers et al., 1987; Nakajima et al., 2010). Since
elevated levels of Spy1 are known to increase rates of cellular proliferation (Porter et al., 2002),
perhaps increased levels of Spy1 in the liver could lead to increased DNA replication and
therefore increased DNA content. Assessing DNA content via flow cytometry through isolation
of primary hepatocytes, or immunohistochemical analysis using the Feulgen stain would allow us
to elucidate if the increase in nuclear size is due to increased DNA content. An increased number
of senescent cells could also explain the significant increase observed as nuclear size is known to
correlate with senescence (Nakajima et al., 2010; Rodier and Campisi, 2011). Importantly,
senescent cells are capable of promoting malignancy in certain cell systems highlighting the
important role the presence of these cells play (Krtolica et al., 2001). Most importantly, elevated
levels of p53 and its downstream target p21 were also noted in the livers of MMTV-Spy1 males.
Levels of p53 have been shown to be increased in cases of NASH correlating with higher degrees
of inflammation (Farrell et al., 2009; Panasiuk et al., 2006; Yahagi et al., 2004). An increase in
p21, which leads to cell cycle arrest and is correlated with the presence of senescent cells, was
also noted (Nakajima et al., 2010). Additionally, livers of MMTV-Spy1 mice also have elevated
197

levels of active caspase 3 indicating higher rates of apoptosis. Taken together, these results
indicate activation of the DDR in response to increased rates of tissue injury and inflammation.
Both male and female MMTV-Spy1 mice have increased susceptibility to tumour
formation in the liver and the mammary gland respectively. Interestingly, in both tissue types we
see elevated levels of the tumour suppressor p53 indicating stress response activation. We have
shown that under normal circumstances, an increase in p53 following damage acts to
downregulate expression of Spy1, allowing for inhibition of the cell cycle and for the appropriate
repair machinery to be activated. Our data suggests that after damage has been repaired, levels of
Spy1 begin to increase, presumably to contribute to the activation of CDK2 allowing for re-entry
into the cell cycle and subsequent cell cycle progression. In non-malignant cells, this would
prevent the accumulation of deleterious mutations or alterations and prevent Spy1 from sustaining
cell proliferation and survival. In cases of sustained elevation of Spy1 levels, this may in itself
serve as a stressor, causing aberrant proliferation of the cell. Sensing abnormal rates of
proliferation, levels of p53 increase to degrade Spy1 to slow down rates of cellular proliferation.
If Spy1 levels remain elevated, it may become a battle between the stress response signaling of
p53 and the ability of Spy1 to override these mechanisms to sustain enhanced cellular
proliferation. Under conditions of DNA damage or injury, if p53 is unable to keep levels of Spy1
in check, Spy1 will continue to sustain elevated rates of proliferation and enhance cell survival in
the presence of damage, ultimately leading to tumour initiation. In cases of p53 mutation or loss
of p53 resulting in compromised activity, elevated levels of Spy1 go unchecked significantly
increasing rates of proliferation and contributing to the onset of oncogenesis.
The ability of Spy1 to promote tumour initiation may then be dependent on its ability to
overcome p53 mediated checkpoints. Thus, loss or inactivation of p53 may be a contributing
factor in Spy1 tumour formation. To test this, the effects of overexpression of Spy1 and loss of
p53 need to be tested in an in vivo setting. This can be accomplished utilizing a variety of
experimental designs. First, knockdown of p53 could be induced in the mammary glands of
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MMTV-Spy1 mice via intraductal injection of siRNA. Intraductal injections have proven to be an
effective method of introducing drug or siRNA directly to the mammary epithelium (Krause et
al., 2013). While this is an effective method, one disadvantage is that expression of the siRNA
would not be stable meaning injections would need to be delivered on a regular basis to ensure
stable knockdown of p53. A more effective method to test the effects of p53 knockdown on Spy1
driven tumour development would be to cross the MMTV-Spy1 mouse model with the existing
p53 null mouse. The p53 knockout mouse is known to succumb to tumours such as lymphomas at
a short latency period (Donehower et al., 1992; Jacks et al., 1994). To overcome this, the MMTVSpy1 mouse could instead be crossed with the heterozygote p53 mouse meaning only one allele
would be lost. While this would be a far superior method than the use of intraductal injections, it
does pose some inherent problems. It is well documented that the MMTV promoter does not
drive expression of the transgene in a homogenous manner (Rao et al., 2014; Wagner et al.,
2001). This means that although knockdown of p53 would be observed in every cell of the
mammary gland, some of these cells would not be overexpressing Spy1 leading to a mixed
population of cells within the gland. To ensure that all cells contain both p53 knockdown and
Spy1 overexpression, a different transgenic system would need to be generated. Instead of using
the full p53 null mouse, the p53 floxed mouse could be used to introduce loss of p53 under the
control of the MMTV promoter. A new transgenic mouse containing both Cre recombinase and
Spy1 under the control of the MMTV promoter would be generated. Use of a bicistronic vector
would allow for simultaneous expression of both Spy1 and Cre under the control of the MMTV
promoter and would ensure all cells with Spy1 overexpression would also have loss of p53. The
use of bicistronic vectors in transgenic mice using the MMTV promoter has already been
successfully demonstrated and has proven to be a valuable model to test the expression or
knockdown of multiple genes within the same cell (Rao et al., 2014; Ursini-Siegel et al., 2008).
Crossing a bicistronic MMTV-Spy1-Cre mouse with the existing p53 floxed mouse would be a
more superior method than simply crossing the MMTV-Spy1 mouse and p53 null mouse. Using
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these models, the effects of reduced p53 activity on Spy1’s ability to promote mammary
tumourigenesis would be tested. Crosses could be done on either the B6CBAF1/J or FVBN/J
background to determine if loss of p53 activity can lead to spontaneous tumour formation in a
model expressing elevated levels of Spy1. If spontaneous mammary tumours do form, this would
prove that the ability of Spy1 to promote mammary tumour formation is dependent on loss or
mutation of p53. This would have a profound impact on our understanding of breast cancer
characterized by loss of p53. Patients with Li-Fraumeni syndrome have an increased
predisposition to the development of breast cancer caused by inheritable germline mutations in
p53 (Akashi and Koeffler, 1998). If Spy1 is capable of promoting tumour initiation after loss of
p53 function, it could prove to be an attractive therapeutic target specifically in this subset of
patients.
The effects of loss of p53 function in the development of HCC could also be tested
utilizing the MMTV-Spy1 mouse. Hydrodynamic tail vein injections have been demonstrated to
successfully deliver plasmid DNA and siRNA within the mouse, with concentrated expression in
the liver (Liu et al., 1999). Expression can be sustained with repeated injections to test the effects
of p53 knockdown on the development of NASH and HCC in the MMTV-Spy1 mouse model.
Using this approach, we would be able to determine if loss of p53 accelerates the development of
tumours in this mouse as currently spontaneous tumours are not noted until mice have reached
one year of age. It is plausible that loss of p53 function could accelerate this phenotype leading to
early disease and tumour onset.
To more specifically address the effects of Spy1 in liver disease and tumour formation,
the Spy1-pTRE mouse that I have generated could be crossed with an existing transgenic mouse
that drives expression of a transgene under the control of the albumin promoter specifically in
hepatocytes, the Alb-rtTA mouse (Liu-Chittenden et al., 2012). The Spy1-pTRE mouse provides
an inducible system that could be used for the study of elevated Spy1 levels in a variety of tissue
systems. Here we have described its use in the mammary gland by validating the model through
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crosses with the MMTV-rtTA mouse. Additionally, this mouse can be crossed with the NestinrtTA mouse to study the effects of Spy1 expression in subsets of populations within the brain
known to express Spy1. This is especially important given the role Spy1 is known to play in
driving brain tumour initiating cell populations in gliomas (Lubanska et al., 2014). To further
elucidate the role Spy1 plays in the development of NASH and HCC, we could drive expression
of Spy1 specifically within hepatocytes at various stages in development through the
administration of doxycycline. This would allow us to directly test the effects of aberrant Spy1
expression on liver development and would lead to higher levels of Spy1 than are seen in the
MMTV-Spy1 male livers as this would be driven in a liver specific manner, and not simply due to
leakiness or altered activation of the MMTV promoter. Using this system would allow us to better
elucidate the role of Spy1 in tumour initiation and combined with hydrodynamic tail vein
injection to knockdown p53, we would be able to determine the precise relationship between p53
signaling and activity and Spy1 mediated tumourigenesis.
Our data supports that Spy1 plays an essential role in mediating tumour initiation in cases
of aberrant or loss of p53 activity, and thus presents itself as a key player in promoting
oncogenesis. The essentiality of Spy1 in this process needs to be examined to elucidate the
complete molecular mechanism responsible for mediating these events. To this end, we have
described an approach for the generation of a gene targeted mouse that will allow for conditional
knockout of Spy1 in a tissue specific manner. Using this mouse, in conjunction with the MMTVCre mouse, we will be able to determine the essentiality of Spy1 both in normal development of
the mammary gland and in tumour initiation. Treatment of the Spy1 knockout mouse with
DMBA will allow us to monitor the onset of tumour formation to determine if loss of Spy1 leads
to increased tumour latency and decreased tumour formation. If this is the case, this would
indicate that Spy1 plays an essential role in promoting tumour formation and could thus be an
early indicator of propensity to develop breast cancer, making it an attractive diagnostic marker.
Similar types of studies could be conducted using the Alb-Cre mouse to knockout Spy1
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specifically within the liver. Using this approach we would be able to determine if Spy1 itself
leads to the onset of NAFLD and ultimately NASH. Generating a model in which the effect of
loss of Spy1 on development and tumourigenesis can be studied is an essential step in fully
elucidating the full molecular mechanism of these processes.
Using two different study systems, we have shown that elevated levels of Spy1 enhance
susceptibility to tumourigenesis. In both cases, increased levels of p53 were also found indicating
that overexpression of Spy1 could potentially act as a stressor, eliciting a stress response within
the cell. In response to stress, p53 is upregulated to try to prevent unrestrained cell proliferation
and survival of cells in the presence of damage. Increased p53 ultimately leads to a decline in
Spy1 levels in normal circumstances. With sustained elevation of Spy1, p53 may be unable to
reduce Spy1 to the physiological levels required to sustain normal rates of proliferation, and
cellular proliferation goes unchecked. If loss of p53 occurs, or activity is diminished, Spy1 is
capable of promoting proliferation in its absence and leads to uncontrolled cell proliferation and
survival in the presence of DNA damage. Over time, this will lead to the accumulation of
deleterious mutations and promote the initiation of tumourigenesis. Thus, understanding the
complex relationship between Spy1 and p53 mediated signaling is essential in understanding the
factors contributing to tumourigenesis. Further exploring and understanding this relationship will
open new avenues in the treatment of these diseases and will ultimately provide new therapeutic
targets and novel therapies in the treatment of oncogenesis.
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Appendix A- List of Primers
qRT-PCR Primers
Flag-Spy1
 Forward: 5’TGACAAGAGGCACAATCAGATGT 3’
 Reverse: 5’ CAAATAGGACGCTTCAGAGTAATGG3’
Human GAPDH
 Forward: 5’ GCACCGTCAAGGCTGAGAAC 3’
 Reverse: 5’ GGATCTCGCTCCTGGAAGATG 3’
Human p53
 Forward: 5’ CCTGAGGTTGGCTCTGACTGTAC 3’
 Reverse: 5’ TGGAGTCTTCCAGTGTGATGATG 3’
Human Spy1
 Forward: 5’ TTGTGAGGAGGTTATGGCCATT 3’
 Reverse: 5’ GCAGCTGAACTTCATCTCTGTTGTAG 3’
Mouse Albumin
 Forward: 5’ CTTAAACCGATGGGCGATCTCACT 3’
 Reverse: 5’ CCCCACTAGCCTCTGGCAAAAT 3’
 Primers sequence obtained from “Mammalian hepatocyte differentiation requires
transcription factor HNF-4α”
Mouse GAPDH
 Forward: 5’ GATGCCCCCATGTTTGTGAT 3’
 Reverse: 5’ GTGGTCATGAGCCCTTCCA 3’
Mouse Nestin
 Forward: 5’ GGCTTCTCTTGGATTTCCTGACCC 3’
 Reverse: 5’ TGGGCTGAGGACAGGGAGCAC 3’
Mouse p21
 Forward: 5’ GCCTGACAGATTTCTATCACTCCAA 3’
 Reverse: 5’ AGAGTGAGGGCTAAGGCCGA 3’
Mouse p53
 Forward: 5’CACAGCGTGGTGGTACCTTATG 3’
 Reverse: 5’ GGTTCCCACTGGAGTCTTCCA 3’
Genotyping Primers
MMTV-rtTA Genotyping
 Forward: 5’ TGCAGAGCC AGCCTTCTTAT 3’
 Reverse: 5’ CCTCGATGGTAGACC CGTAA 3’
MMTV-Spy1 Genotyping
 Forward: 5’ CCCAAGGCTTAAGTAAGTTTTTGG 3’
 Reverse: 5’ GGGCATAAGCACAGATAAAACACT 3’
Spy1-pTRE Genotyping
 Forward: 5’ GTGTACGGTGGGAGGCCTATATAA 3’
 Reverse: 5’ GTCATAGCCAAAAGATACTTGTCTGC 3’

207

Probe Generation for Southern Blot Analysis
3’Probe
 Forward: 5’
GCATGTACCGGTAGGAATGGAATTTAGTTGGTGGTAAAACACTTGCC 3’
 Reverse: 5’ GGCGCGCGTTTAAACTGTGTAAATTCCTAGACAGAAACACCTAC 3’
5’Probe
 Forward: 5’
GCATGTACCGGTCAACACCCGCCCCCCCCCACACATATGCACATCAATTTG 3’
 Reverse: 5’
GGCGCGCGTTTAAACGAGCCTGATTTTACATGAATAGTGACAGTAGGTGGTG
3’
Neo Probe
 Forward: 5’ GCCACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGC 3’
 Reverse: 5’ GTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAG 3’
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Appendix B: Detailed Protocols
I. Southern Blot Protocol
1) Digest 10ug of DNA overnight at 37C
- 30uL reaction volume total
o 3uL of buffer
o 1uL of appropriate enzyme
o 26uL of H2O + DNA
2) Following morning, add an additional 1uL of the appropriate enzyme and continue
digesting at 37C (for ~3-4hrs)
3) Prepare 0.8% agarose gel with NO ethidium bromide added
- Make 400mL of agarose for our big gel rigs
- When gel has solidified, remove tape and leave combs in gel; place in running
apparatus with combs still in gel and pour freshly made 1xTAE over gel; let gel sit in
buffer for ~30min before removing combs
4) Run DNA on 0.8% agarose gel O/N 30V for 10hrs
- Leave 2 spaces between ladder and first sample
- Combs have 38wells therefore can run 34 samples per comb if run 2 ladders
5) Place gel in glass baking dish and stain with EtBr in 1xTAE for ~15min while gently
shaking
6) Image the gel beside a UV ruler in order to measure migration of the ladder
- NOTE: to transfer gel into and out of glass baking dish use glass photo frame; slide
glass plate under the gel to gently lift gel without ripping the wells
7) Rinse gel in buffer 1 (made fresh that morning) 2x 30min each (rinsed in glass baking
dish)
8) Rinse with water for ~5min
9) Rinse gel in buffer 2 (made fresh that morning) 2x 30min each (rinsed in glass baking
dish)
10) Assemble O/N capillary action transfer apparatus
- Transfer buffer is buffer 2
- Membrane is nitrocellulose (Fisher (GE) WP4HY00010- NitroPure supported
nitrocellulose 0.45micron, 30cmx3m roll)
- Gel size is 8”x8”: paper towels, 3 sheets of filter paper and nitrocellulose paper
should be cut to this exact size
- Whatmann filter paper used in Western blot transfer is used as wick and filter paper;
wicks should be cut wider than 8” (~9-10”); use entire length of filter paper sheet for
wick
- Large Tupperware container with lid on and glass picture frame glass piece are used
as the base for the transfer platform (glass photo frame is used to provide level
surface to place the gel; glass is placed on top of the lid of the Tupperware container)
- 2 smaller Tupperware containers are used as the reservoirs on either side of the
transfer platform
- 3 wicks are wet with transfer buffer and placed on top of the platform with each end
hanging into the reservoirs on either side submerged as much as possible
- Use glass pipette to roll out air bubbles in wick
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Carefully place gel upside down onto the wick and try to keep wells intact (will need
to mark them later)
o Try to place gel centred on wick
o Remove air bubbles using glass pipette
o Trim off ladder and excess gel using razor
- Place nitrocellulose membrane on top of gel
o Once on gel can’t be moved
o Trim excess off if membrane is too wide (gel will be slightly smaller once
ladder is trimmed off)
o Roll out air bubbles
- Have 3 pieces of Whatmann filter paper cut to size; soak each one in transfer buffer
and place one at a time on top of the membrane removing air bubbles after adding
each one
- To prevent buffer from bypassing the gel surround gel with plastic wrap
o Tear off piece of plastic wrap, roll it and cut to size if need be and place
around all 4 edges of gel
o Usually stack 2 pieces on top of one another
- Need ~10cm stack of paper towels cut to size
o Place stack of paper towels on top of filter paper; ensure it is centred
- Put dry glass frame plate on top of paper towels
- Place weight on top of glass plate
o No heavier than 500g
o Ensure it is centred so stack of paper towels will not fall over
- Make sure reservoirs are filled with transfer buffer
- Transfer O/N
11) Disassemble transfer apparatus
- Stack of paper towels should be almost entirely wet and gel should be flat
- Remove gel and nitrocellulose together and mark wells with pencil on the membrane
12) Dry the membrane for 1hr on benchtop between 2 pieces of Whatman paper
13) Bake membrane between 2 pieces of Whatman paper, then all wrapped in aluminum foil
at 80C 20-25mg Hg for 2hrs
- Membrane should be slightly brown at edges and should no longer smell of the
transfer buffer
- Cut one of the corners of the membrane to orient later
- ***NOTE: after membrane has been baked, membrane can safely be stored until
needed for hybridization; doesn’t need to happen immediately after DNA has been
fixed to membrane
14) Pre-hyb membrane for 2hrs at 65C
- Hybridization buffer should be heated at 55C before hand
15) While membrane is in pre-hyb; label probe with αP32 dCTP (Perkin Elmer BLU513Z *
rest of catalog number is dependent on quantity ordered; 6000Ci/mmol)
- Probes are digested with appropriate enzyme to gel extract probe from vector (digest
2ug of vector to ensure sufficient yield and high enough quality DNA)
- Gel extract using Sigma Gel Extraction Kit following protocol from kit
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Label probe using Promega Prime-a-Gene Labeling System (U1100) following
protocol BUT double rxn
o Labeling 5x buffer 20uL
o Mixture of unlabeled dNTPS (dATP, dTTP, dGTP) 4uL
o Nuclease free BSA 4uL
o αP32 dCTP 6000Ci/mmol (100uCi) 5uL
o DNA polymerase 1 large fragment-Klenow 2uL
o DNA 50ng
o H20 up to 100uL (H2O + DNA=65uL)
 Denature DNA sample by heating at 95-100C for 2minutes; rapidly
chill the tube on ice
 Assemble reaction (add P32 last in hot lab; rest of reaction is
assembled in main lab since not hot)
 Incubate reaction at room temperature for 60minutes
16) Purify the probe
- Take 3mL syringe and remove plunger; place syringe in 15mL tube
- Place glass wool up to 1mL mark do not pack tightly
- Sephadex G50 beads prepared in advance no measurement, just pour some of the
Sephadex G50 powder into 50mL tube and add TE buffer; shouldn’t be too viscous,
solution will be cloudy
- Add Sephadex G50 beads (GE Healthcare Sephadex G50 fine 100ug 17-0042-01) on
top of glass wool up to ~1.5mL mark (add so that above that mark since need to spin
down); add to centre of syringe
- Spin at 1000rpm for 1min; check to make sure bead layer is at correct level, no
cracks and is level; if not, add more beads and spin again
- Once probe is labeled add to centre of column (100uL max/column)
o Before adding, cut lid off of 1.5mL tube and place in 15mL tube then put
syringe with prepared column back into 15mL tube so that the flow through
is collected in the 1.5mL tube
- Spin 1000rpm for 1min and collect flow through
- Since our scintillation counter is not accurate, Geiger both the purified probe and the
column (which contains unincorporated nucleotides) to ensure labeling was
successful
17) Add entire 100uL of purified probe to 5mL of hybridization buffer and incubate O/N at
65C
18) Wash the membrane 3x for 10min each at room temperature in low stringency wash
buffer
19) Wash the membrane 3x for 10 min each at 65C in high stringency wash buffer
20) Place membrane in film cassette wrapped in plastic wrap so that phosphor screen doesn’t
get wet; set up exposure with phosphor screen at room temperature; min 3 nights
exposure
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Wash Buffer 1-1L
87.66g
NaCl
20g
NaOH

Wash Buffer 2-2L
154.16g
NH4CH3COO
1.6g
NaOH

Hybridization Buffer-500mL
200mL
10X Set (4x final)
100mL
50X Denhardts (10X final)
5mL
10% sodium pyrophosphate (0.1% final)
37.9mL
0.33M Na3PO4 pH 6.9 (0.025M final)
5mL
10% SDS (0.2% final)
151.1mL
H2O
Low Stringency (cold) Buffer- 200mL
20mL
20X SSC
1mL
20% SDS
179mL
H2O

High Stringency (hot) Buffer-200mL
2mL
20X SSC
1mL
20% SDS
197mL
H2O

50X Denhardt’s Solution- 500mL
5g
Ficoll 400
5g
PVP
5g
BSA Pentax Fraction V
Bring up to 500mL with H2O, and filter through 0.45µm syringe using 60mL syringe and freeze
at -20⁰C in 45mL aliquots
10X SET- 1L
87.66g
NaCl (1.5M)
24.3g
Tris Base (0.2M)
20mL
0.5M EDTA (0.01M)
pH to 7.8 with HCl and fill to 1L with H2O
0.33M Na3PO4- 100mL
5.47g
Na3PO4
pH to 6.9 with HCl and fill up to 1L with Na3PO4
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Reagents:
Company
Fisher Scientific

Item Name
GE Nitrocellulose Membrane Nitropure
0.45uM 30cmx3m roll

Catalog Number
WP4HY00010

Sigma Aldrich

Glass Wool

18421-500G

GE Healthcare
Sciences

Sephadex G50 Fine 100ug

17-0042-01

Fisher Scientific

Hybridization Tubes

13-247-150

Promega

Prime-a-Gene Labeling System

U1100

Sigma

GenElute Gel Extraction Kit

NA1111-1KT

Perkin Elmer

dCTP P32 6000Ci/mmol 20mCi/mL

BLU513Z (remainder
of catalog number is
dependent on amount
of radiation ordered.
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Abstract
Background
Cell growth and proliferation are tightly controlled by the cyclic regulation of the cyclin
dependent kinases (Cdks). Cdks are positively regulated through interactions with regulatory
cyclin partners as well as being negatively regulated through interactions with Cdk inhibitors.
More recently, families of cyclin-like proteins have emerged with unique abilities to regulate the
Cdks. One of these proteins, Spy1A1 (SPDYA; herein referred to as Spy1), has demonstrated a
pivotal ability to directly bind and regulate both the Cdks as well as at least one Cdk inhibitor,
p27Kip1. Spy1 accelerates somatic cell growth and proliferation and has been implicated in a
number of human cancers including the breast, brain and liver. The physiological role for direct
interactions between Spy1 and the distinct binding partners Cdk2 and p27 have not been
addressed.
Methods
Herein we isolate key residues mediating the direct interaction with p27 and use mutants of Spy1
unable to interact specifically with either Cdk2 or p27 to study the effects on cell growth and
tumorigenesis.
Results
Disrupting the direct interaction with either Spy1 binding partner decreased endogenous activity
of Cdk2, as well as Spy1-mediated proliferation. However, only the direct interaction with p27
was essential for Spy1-mediated effects on p27 stability. In vivo neither mutation prevented
tumorigenesis, although preventing interactions with both p27 and Cdk2 slowed the rate of Spy1mediated tumorigenesis and decreased overall tumour volumes.
Conclusion
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These data support the conclusion that direct interactions with both p27 and Cdk2 contribute to
Spy1-mediated effects on cell growth. Hence, it is important to elucidate the dynamics of these
interactions and to consider these data when assessing functional outcomes.
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Introduction
Cell cycle regulation is an intricately controlled process that plays a critical role in all cell
fate decisions. The catalytic cyclin dependent kinases (Cdks) are dependent on the production and
destruction of their regulatory subunits, the cyclin family of proteins. Cyclin-Cdk complexes
undergo a series of well established post-translational modifications to assume a fully activated
state [1,2]. The G1/S cyclin-Cdk complexes are also negatively regulated through interactions
with the Cip/Kip family of Cdk inhibitors (CKI) which includes p27, p21 and p57. It is crucial
that Cdk regulation be tightly controlled to prevent the onset of tumorigenesis; in many forms of
cancer elevated Cdk2 kinase activity and decreasing levels of p27 correlate positively with
tumorigenic potential and negatively with patient prognosis [3,4]. The central requirement for
activated Cdks implicates these kinases as potential therapeutic targets, and indeed this approach
has shown tremendous potential in pre-clinical tumorigenesis models [5,6]. However with the
exception of hematological malignancies, Cdk inhibitor therapy has been largely disappointing in
the clinic [7,8]. Targeting metastatic ER+/HER2- have shown promise for select Cdk inhibitors
recently, but it is clear that thorough characterization of the active Cyclin-Cdk partners in select
patient populations will be necessary to optimize targeting [8,9] One factor that needs to be
considered when stratifying patient populations is the presence of ‘cyclin-like’ proteins capable of
activating the Cdks using very unique mechanisms [10,11]. Cdks bound to the Speedy/RINGO
class of cyclin-like proteins are not dependent on post-translational modifications for activation,
and they are less sensitive to inhibition by the Cdk inhibitors p21 and p27 [11,12].
One protein within the Speedy/RINGO class, Spy1A1 (SPDYA), herein referred to as
Spy1, is capable of binding to, and activating, both Cdk1 and Cdk2 leading to increased rates of
cell proliferation and inhibition of apoptosis when overexpressed [10,13,14]. The region
regulating Spy1 interactions with Cdks are within the highly conserved S/R Box and several
specific Spy1 residues have been identified to reduce binding affinity with Cdk2 in vitro [12].
217

Unlike any known cyclin proteins, Spy1 has also been shown to directly bind to the CKI p27,
ultimately leading to p27 degradation [15]. Spy1-p27 and Cdk2 can immunoprecipitate together,
supporting the rationale that they can form a trimeric complex, however Spy1 can also interact
with each protein directly in vitro [11,16]. Data suggests that in a trimeric complex Spy1
preferentially binds p27 to prevent its inhibitory interactions with Cdk2, and that Cdk2 binding to
Spy1 stabilizes this interaction and aids in the phosphorylation of p27 on T187, leading to p27
degradation [11,15].
Spy1 is elevated in the majority of breast carcinomas and Spy1 overexpression in the
mouse mammary gland induces rapid and invasive tumorigenesis [17,18]. Defining the
physiological role for direct interactions between Spy1-Cdk2 and Spy1-p27 in cell proliferation is
an essential step toward resolving the mechanism by which Spy1 promotes mammary
tumorigenesis.
This work isolates 4 key amino acids responsible for mediating the binding between Spy1
and p27. Using mutants of these sites we compare effects to a mutant form of Spy1 defective in
binding to Cdk2. Our data demonstrates that abrogation of binding between Spy1 and p27
significantly inhibits degradation of the CKI and subsequently reduces the proliferative capacity
of Spy1 in vitro. In opposition, abrogated direct binding to Cdk2 demonstrated little effect on
Spy1-mediated degradation of p27 or proliferative effects in the presence of the CKI. Preventing
interactions with either Cdk2 or p27 had comparable affects on endogenous activity of Cdk2 and
contributed to the basal effects of Spy1 on proliferation. Importantly, direct Spy1 interactions
with both p27 and Cdk2 play a role in mediating the rate of tumorigenic onset caused by Spy1.
However, disrupting either interaction alone did not prevent tumour formation. These data stress
that the prevalence and kinetics of these specific interactions in vivo will have significant effects
on the functional outcomes of Spy1 expression. These details become very important when
considering mechanisms of targeting Spy1, p27 or Cdks for drug therapy.
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Methods
Ethics statement. BALB/c mice were maintained following the Canadian Council on Animal Care
guidelines at the University of Windsor (protocol #06-19).
Cell culture. Human embryonic kidney cell line, HEK293 (ATCC) were maintained in DMEM
medium (Sigma) supplemented with 10% (vol/vol) fetal bovine serum (Hyclone). HC11, a nontransformed, immortalized BALB/c mouse mammary epithelial cell line (provided by Dr. C.
Shermanko; University of Calgary) were maintained in RPMI 1640 medium (Hyclone)
containing 10% (vol/vol) fetal calf serum (Sigma), supplemented with 5 µg/ml insulin (Sigma),
and 10 ng/ml EGF (Calbiochem). Both cell lines were maintained in 2 mM L-glutamine (Sigma),
penicillin (Invitrogen), and streptomycin (Invitrogen), and were cultured in a 5% CO2
environment. Cell counts were conducted with trypan blue exclusion and quantified using a
BioRad TC10 Automated Cell Counter.
Plasmid and mutagenesis. Creation of Myc-Spy1 in PCS3 was described previously [10]. Spy1PEIZ was generated by moving Flag-Spy1 from Spy1-PJT0013 [11] through EcoR1 and Xba1
restriction sites into the lentiviral PEIZ vector (provided by Dr. B. Welm, University of Utah).
Spy1-D90, Spy1-R170 and Spy1-R170-PEIZ were created in Myc-Spy1-PCS3 using Quik
Change PCR Multi Site-Directed Mutagenesis (SDM). Spy1-R170 mutation was made using
primers

#

A315

5'-

GTTAAGGGACCAGCTCTGGGATGCAATTGACTATGCGGCTATTGTAAGCAGG3'

and

#

A316

5'-

CCTGCTTACAATAGCCGCATAGTCAATTGCATCCCAGAGCTGGTCCCTTAAC-3'
;Spy1-D90

was

made

using

primers

GATTTCTTGTGGATGGCATGCTGCTGTAAAATTGC-3'

#A123
and

5'#A124

5'-

GTTAAGGGACCACTGGGATGSAAGACTATGCGGCTATTGTAAGCAGG 3', Spy1-R170219

PEIZ lentivirus plasmid was created by engineering an EcoR1 site upstream of Spy1 in Spy1PCS3

using

primers

#A532

CTTGATTTAGGTGACACTATAGAATTCAAGCTTGTTCTTTTTG-3’

5’and

CAAAAAGAACAAGTAGCTTGAATTCTATAGTGTCACCTAAATCAAG-3’.

#A533

5’-

Spy1-R170

was moved to PEIZ lentivirus vector via the EcoR1 and XbaI sites. Successful cloning in all cases
was determined by DNA sequencing (Robarts Sequencing Facility; Univ. of Western Ontario).
Immunoblotting (IB) and immunoprecipitation (IP). Cells were harvested and lysed in 0.1% NP40 lysis buffer (0.1% NP-40, 20mM Tris pH 7.5, 5mM 0.5M EDTA, 100mM NaCl in RO water)
containing protease inhibitors (100 ug/mL PMSF, 5 ug/mL aprotinin, 2 ug/mL leupeptin) for 30
min on ice. Bradford Reagent was used to determine the protein concentration following the
manufacturer’s instruction (Sigma). Aliquots of lysates containing 20-30 μg protein were
subjected to electrophoresis on denaturing SDS-10% polyacrylamide gels and transferred to
PVDF-Plus 0.45 micron transfer membranes (Osmonics Inc.) for 2 hr at 30 V using a wet transfer
method. Blots were blocked for 2 hr in TBST containing 3% non-fat dry milk (blocker) at room
temperature, primary antibodies were reconstituted in blocker and incubated overnight at 4°C,
secondary antibodies were used at a 1:10,000 dilution in blocker for 1 hr at room temperature.
Blots were washed three times with TBST following incubation with both the primary and
secondary antibodies. Washes were 6 min each following the primary antibody and 10 min each
following the secondary antibody. Chemilumiminescent Peroxidase Substrate was used for
visualization following the manufacturer’s instruction (Pierce). Chemiluminescence was
quantified on an Alpha Innotech HD2 (Fisher) using AlphaEase FC software.
For IP equal amounts of protein were incubated with primary antisera as indicated
overnight at 4°C, followed by the addition of 10 ul protein A–Sepharose (Sigma) and incubated at
4°C with gentle rotation for an additional 2 hr. These complexes were then washed three times
with 0.1% NP-40 lysis buffer and resolved by 10% SDS-PAGE.
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Transfections and infections. Cells were transfected overnight using polyethylenimine (PEI)
branched reagent Sigma (408727), 10 µg of DNA was mixed with 50 µL of 150 mM NaCl and 30
ug PEI for 10 min then added to a 10 cm tissue culture plate.
Lentiviral infections were carried out using a modified protocol from Welm et. al [19]. In
brief; PEI transfection of Lenti-XTM 293 producer cell lines (Cat. No. 632180, Clontech, CA)
was conducted as described above, 16 hr post-transfection, media containing viral particles was
concentrated, titred and stored at -80°C. Cells were screened for ZS-Green using flow cytometry.
HC11 infections were optimized using 2x105 cells/well in a 6-well plate to determine the
multiplicity of infection (MOI). HC11 cells were seeded with media lacking antibiotics for 18 hr,
media was removed and transfection media lacking antibiotics and serum added. Viral particles
were added in a final concentration of 8*105 transfection units (TU = MOI * cell number), and
polybrene was added to a final concentration of 10 ug/ml. Mixture was incubated for 4 hr,
followed by a media change to growth media lacking antibiotic.
Antibodies. The generation of Spy1 antibody was previously described [10]. Myc antibodies both
mouse (9E10) and rabbit (C19), HA (Y11 and F7) and p27 (F8) were purchased from Santa Cruz.
Actin antibody (MAB150R) was purchased from Calbiochem. HRP conjugated secondary mouse
antibody (A9917) and rabbit antibody (A0545) were purchased from Sigma.
Pulse chase. 16 hr post-transfection with indicated constructs, serum free media was replaced
with Cys-Met free media (D0422; Sigma) supplemented with dialyzed FBS (F0392; Sigma) for 1
hr. S35 was added to a final concentration of 500 µCi for 4 hr followed by 4 washes with 1X PBS
and supplementation with growth media containing 2 mM Cys-Met. Cells were lysed at indicated
time points, ran on an SDS-PAGE gel. Incorporated sulfur was visualized using a Cyclone
storage phosphor system and quantified using OptiQuant software (Perkin Elmer).

221

Kinase assays. Cells were transfected, cultured in 10% FBS and lysed in 0.1% NP-40 lysis buffer.
18 hr post-transfection IP was carried out as described above and precipitates were washed four
times prior to the addition of 50 μl of kinase buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1
mM DTT, 20 mM EGTA, 50 mM ATP, 10 μCi of [γ-32P]ATP) and 74 μg/ml H1 histone
(Boehringer Mannheim). Reactions were incubated for 10 min at 30°C, sample buffer was added
to stop the reaction and 50 μl of each sample were analyzed by 10% SDS-PAGE. Incorporated
phosphorylation was visualized using a Cyclone storage phosphor system and quantified using
OptiQuant software (Perkin Elmer). IPs were subsequently probed on the same membrane.
Fat pad transplants. HC11 cells infected and selected for the relevant lentiviral constructs were
injected into the cleared fat pad of the fourth mammary glands in 22-day old mice (250,000 cells
per gland) as previously described [17]. Tumor incidence was monitored every 2 to 4 days
beginning one week after surgery by palpitation of the gland. Glands were allowed to grow for 2
to 4 weeks following surgery. Tumour measurements were recorded using manual calipers and
tumour volume was calculated as length (mm) x width (mm) x height (mm). Collected glands
were either paraffin embedded for immunohistochemistry or flash frozen for protein, genomic or
mRNA analysis.
Results
Resolving key Spy1 residues mediating binding with p27.
Using a panel of Spy1 deletion mutants previously described [20] we began to narrow
down the region within the Spy1 protein that was necessary for p27 binding. Previously, it was
determined that truncation of Spy1 at aa 215 retained the ability to bind p27, while truncation at
aa 160 in Spy1 disrupted binding to p27 [15] (Fig. 1A; indicated beneath panel). We further
tested these results using deletion mutants (DM) of Spy1 where the indicated regions were
deleted (Fig. 1A). DMA represents a protein devoid of aa 1-57, DMB is devoid of aa 57-83,
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DMC lacks aa 83-145, DMG lacks aa 147-239 and DMZ lacks aa 241-286. We first determined
whether any of these Spy1 deletion mutants would result in abrogation of binding to p27. 293
cells were transfected with wild-type (WT) Spy1 or versions of the Spy1 protein harboring the
specified deletions (DMA-DMZ) (Fig. 1B). Cells were lysed and equal amounts of protein
immunoprecipitated with Myc antibody and analyzed by western blot. DMG failed to bind to p27,
demonstrating that aa 145-239 are required for the binding between Spy1 and p27. This was not
surprising given the large size of the deletion within DMG, as well as the previous results
suggesting the essentiality of this region for binding [15]. Although p27 interacts in different
ways with known partners, it was previously determined that p27 binding interactions favor
positively charged amino acids on the binding partner [21,22,23]. Alignment of the potential p27binding region within Spy1 from a number of different organisms noted a region of high
similarity containing a string of 4 highly conserved positive amino acids (Fig. 1C). Previous
binding interactions were found to depend on arginine interactions and were disrupted using
arginine to alanine substitutions [22,23]. Hence, we generated a mutant of Spy1 containing
alanine substitutions for arginines 170 and 174 (Spy1-R170) as well as a mutant containing
alanine substitutions for arginines 179 and 180 (Spy1-R179) (Fig. 1D).
Spy1-R170 and -179 do not bind to p27.
To test the necessity of these conserved arginine residues for binding to p27, Myc-tagged
Spy1-WT, Spy1-R170, or Spy1-R179 were transfected in combination with HA-tagged p27 in the
presence of MG132 (Fig. 2A). IP/IB studies demonstrate that Spy1-R170 and Spy1-R179 mutants
both reduce binding to p27 as compared to Spy1-WT binding (Fig. 2A). Reciprocally, IP with
Myc antibody isolated p27 when Spy1-WT was overexpressed but not the mutant Spy1 constructs
(Fig. 2B). It is notable that Cdk2 continued to bind to Spy1 in the presence of both p27-binding
mutations (Fig. 2B), which is consistent with previous results demonstrating that Cdk2 binds
more efficiently to Spy1 in the presence of overexpressed p27 protein [11]. We also examined the
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interaction between endogenous p27 and Spy1-WT or mutant constructs. Following IP for the
Myc-tagged Spy1 proteins, endogenous p27 protein was detected as part of a complex with Spy1WT but not with either of the Spy1 non-binding mutants (Fig. 2C). Collectively, these results
demonstrate that mutation of Spy1 at either arginines 170/174 or 179/180 abrogates binding
interactions with the CKI p27. These mutants will provide a valuable tool in assessing the specific
role for Spy1-p27 interactions in functional experiments.
Effect of Spy1 mutants on p27 degradation.
Direct binding of Spy1 protein to p27 enhances p27 degradation and subsequently activates Cdk2
kinase activity [11,15]. Importantly, Spy1 also directly binds to Cdk2 to activate kinase activity
and it is known that Cdk2 phosphorylation of p27 on T187 promotes p27 degradation [24]. To
determine whether the direct binding of Spy1 to p27 and/or Cdk2 is critical for Spy1-mediated
degradation of p27, we utilized 293 cells transfected with either the Spy1-p27 non-binding
mutants (Spy1-R170 and Spy1-R179) or the Spy1 mutant previously demonstrated to disrupt
interactions with Cdk2 (Spy1-D90) [12]. Lysates were monitored by IB (Fig. 3A; left panel) and
results over 3 separate experiments were quantified by densitometry (Fig. 3A; right panel). Cells
transfected with Spy1-WT and Spy1-D90 resulted in a significant reduction in overall p27 protein
levels as compared to cells overexpressing an empty vector control or the Spy1-p27 non-binding
mutants. To further confirm these results we used radioactive sulfur (S 35) incorporation in a pulse
chase assay, IP for p27, followed by IB and phosphor-image analysis to determine relative
stability of p27 protein levels over 3 separate experiments (Fig. 3B). IgG was used as a control for
the IP and lysates were used for control over transfections. Quantification of this data
demonstrates that Spy1-WT and Spy1-D90 significantly reduce the stability of p27 protein levels
over the empty vector control; however the Spy1-R170/R179 mutants were unable to
significantly impact p27 turnover. These data demonstrate that the direct binding between Spy1
and p27 is essential for Spy1-mediated effects on p27 protein turnover. To determine the relative
224

effects of direct interactions with Cdk2 or p27 on Cdk2 kinase activity, a histone kinase assay
was performed (Fig. 3C). Phosphor-quantification normalized to the Cdk2 IP demonstrated that
preventing interactions with either p27 or Cdk2 reduced kinase activity to that of control,
showing that each of these interactions is essential for Spy1-mediated activation of Cdk2.
Spy1 is known to override cell cycle inhibition by p27 [11]. To examine the effect of the
Spy1 mutants on p27-induced cell cycle arrest, cells were transfected with the indicated
constructs in the presence of p27 and cell number after 24 hr was assessed by trypan blue
exclusion (Fig. 4A). Cells transfected with the Spy1-p27 non-binding mutants showed a
significant decrease in the total cell number as compared to Spy1-WT, being comparable to that
of the empty vector control. Importantly, the Spy1-D90 resulted in a significant increase in the
total number of cells over the empty vector control, with numbers comparable to that of Spy1WT. These results demonstrate that the ability of Spy1 to override the inhibitory effects of p27 is
dependent on the direct interaction with p27. Measuring cell proliferation in the absence of p27
overexpression demonstrated that both Cdk2 and p27 binding mutants decreased Spy1proliferative effects, although neither mutant completely rescued the effect of Spy1
overexpression (Fig. 4B). These results support the conclusion that direct interactions with both
Cdk2 and p27 contribute toward Spy1-medicated proliferative effects.
Spy1 direct binding to both p27 and Cdk2 are important for Spy1-mediated tumorigenesis in vivo.
It has previously been shown that overexpression of Spy1 in vivo leads to accelerated rates
of mammary tumorigenesis [17]. To determine if this is dependent on Spy1’s interaction with
either Cdk2 or p27, fat pad transplantation was performed on the cleared inguinal mammary
gland of Balb/C mice using Spy1-WT expression on one side of the mouse and Spy1 mutants
defective for either Cdk2 binding (Spy1-D90) or p27 binding (Spy1-R170) on the opposite side.
One week following surgery, approximately 50-65% of all Spy1-WT glands had visible tumors
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while only 20% of all Spy1-D90 glands and 10% of all Spy1-R170 glands had visible tumors
(Fig. 5A). At day 21 post-transplant ~80-90% of all transplanted glands had detectible tumors,
with no difference in numbers between mutant or WT forms of Spy1. Mice were humanely
sacrificed at day 28 post-surgery due to the size and invasiveness of the Spy1-WT glands and
glands were removed and studied. There were significant differences in the overall tumor size
observed with Spy1-WT glands being much larger and more invasive than both the Spy1-D90
and Spy1-R170 tumors (Fig. 5B). These data indicate that Spy1 direct interactions with both p27
and Cdk2 are important for Spy1-mediated tumorigenesis in vivo. It further suggests that
inhibition of both of these functional pathways is required to significantly reduce tumorigenic
effects over time.
Discussion
Spy1 is an atypical Cdk activator known to increase cell proliferation and inhibit
apoptosis when overexpressed in mammalian cells [10]. In addition to directly binding and
activating Cdks, Spy1 is a binding partner for the CKI p27 [11]. In vitro and in vivo experiments
demonstrate that Spy1 directly binds and co-localizes with nuclear forms of p27, functioning to
override p27-mediated cell cycle inhibition [11]. Like Cyclin E/Cdk2, Spy1 overexpression is
also associated with an increase in phosphorylation of p27 at T187 leading to its proteasomal
degradation and enhanced cell cycle progression [15]. Whether the effects on p27 degradation are
mediated through the direct binding of Spy1 to Cdk2 or p27 was not previously known. To
address this question we first created and characterized two p27 non-binding mutants (Spy1-R170
and Spy1-R179). These mutants were used along with a Cdk2 binding mutant (Spy1-D90) that
has been previously described [16], in proliferation assays as well as in assays to assess p27
protein levels. We determined that direct binding of Spy1 to p27 was required to promote p27
degradation, as well as to override a p27-induced cell cycle arrest. The direct binding of Spy1 to
both Cdk2 and p27 were required for Spy1-mediated activation of Cdk2 and overall effects on
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cell proliferation. These data demonstrate that there are differences in the mechanism by which
Spy1-p27 and Spy1-Cdk2 drive cell proliferation and Cdk2 kinase activity.
Role of Spy1-p27 binding in tumorigenesis.
Elevated expression of Spy1 is found in many forms of human cancer [18,25,26,27,28]. In this
present study, we have demonstrated that abrogating direct interactions between Spy1 and either
p27 or Cdk2 significantly decreases the rate of tumorigenesis and overall tumour size in vivo.
Low levels of p27 protein has been implicated in many human cancers including breast [29] and
is found to correlate with poor patient outcome [29]. Constitutive activation of Cdk2 has also
been shown to result in mammary gland hyperplasia, fibrosis, and mammary tumors in a MMTV–
cyclin D1–Cdk2 derived cell line [30]. Given that Cdk2 targets p27 for degradation [31], it is a
valid hypothesis that these proteins are regulating each other; interestingly however, our data
suggests that direct interactions with both p27 and Cdk2 are important in driving the tumorigenic
activities of Spy1. Details on how these proteins function independently, as well as in a trimeric
complex, is required to fully resolve the physiological and pathological roles of these interactions.
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Figure legends
Figure 1. Generation of Spy1 – p27 binding mutants. (A) A schematic diagram of the Spy1
deletion mutants used for screening and their enzyme cut sites. The indicated regions are
selectively deleted in each Spy1 mutant construct (ie. DMA lacks region A, DMB lacks region B,
DMA lacks region C, DMG lacks region G, DMZ lacks region Z). Dotted line depicts the
truncation mutant of Spy1 previously determined to retain the ability to bind p27 [15]. The solid
line reflects the region previously shown to have lost the ability to bind p27. (B) 293 cells were
transfected with Myc-Spy1-PCS3 (WT) or the different deletion mutants DMA-DMZ depicted
above in the presence of HA-tagged p27 (HA-p27). Transfected cells were treated with MG132
(10M) for 14 hrs prior to harvest, lysates were immunoprecipitated with Myc antibody and
immunoblotted with HA antibody (upper panel) and Myc antibody (lower panel). This is one
representative experiment of 3. (C) Alignment of a highly conserved amino acid sequence within
the predicted p27 binding region from several species. Conserved positively charged residues to
be mutated are noted with a box. Amino acid #s are indicated after the species in brackets. (D)
Region G of Spy1 depicting the Arg. (R) residues which were mutated to Alanine (A) to create
Spy1-R170 and Spy1-R179 mutations.
Figure 2. R170 and R179 mutants of Spy1 abrogate binding to p27. 293 cells were transfected
with constructs indicated above the panels and treated with MG132 prior to lysis. Equal amounts
of protein was subject to IP/IB as indicated below each panel (upper panels). For each experiment
cell lysates were also run and blotted to demonstrate transfection efficiencies (lower panels). (A)
Overexpression of all constructs and IP for HA-tagged p27. (B) Overexpression of all constructs
and IP for Myc-tagged Spy1 constructs. (C) Transfection of Spy1-WT or mutant constructs and
analysis using endogenous p27. Cells were maintained in 2% serum containing media for 14 hr
following transfection to elevate endogenous p27 levels. All experiments reflect one
representative experiment of 3.
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Figure 3. R170 and R179 mutants inhibit p27 down regulation. 293 cells were transfected with
HA-tagged p27 in the presence or absence of Myc-tagged empty–vector (PCS3), Spy1-WT,
Spy1-R170, Spy1-R179 or Spy1-D90. (A) Lysates were blotted with HA (upper panel), Spy1
(middle panel) and Actin (lower panel) antibodies. Left panel is one representative blot of 3.
Right panel reflects densitometry of p27 levels normalized to actin over 3 separate experiments.
Error bars represent SEM. *p<0.05. (B) Pulse chase assay was conducted, followed by IP for
HA-tagged p27 and S35 incorporation measured by phosphor image analysis. Immunoblot using
IGg antibody was used as a control. Left panel is one representative experiment of 3. Right panel
represents quantification using OptiQuant software over 3 separate experiments. Error bars
represent SEM, *p<0.05 (C) Cdk2 IP from transfected lysates. Histone assay was conducted.
Left panel is one representative phosphorimage of 2. Right panel represents average phosphor
measurements over 2 experiments. Error bars represent SEM.
Figure 4. 293 cells were transfected with Myc-tagged empty–vector (PCS3), Spy1-WT, Spy1R170, Spy1-R179 or Spy1-D90 in the presence (A) or absence (B) of HA-p27. Cell numbers
were assessed using trypan blue exclusion and quantification over 3 separate experiments. Error
bars represent SEM. **p<0.01; *p<0.05. Right panels represent one representative blot of 3.
Figure 5.
Cleared mammary fat pads were transplanted with cells expressing Spy1-WT (WT) on the left
and either Spy1-R170 (R170) or Spy1-D90 (D90) on the right. (A) Graphic depiction of the
percent of mice remaining free from palpable tumours at time points following transplantation.
Treatments occurred in groups of 3 using 3 separate colonies of infected cells. Total sample size
= 45. Mann-Whitney, and Wilcoxon Matched Pairs Tests were performed (**p<0.01; *p<0.05).
(B) Mice were humanely sacrificed at the indicated time points and glands showing visible
tumors were isolated and measurements of height, length and width of the tumors were recorded.
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Total average tumour volume over 45 mice transplanted with either R170 or D90 (right gland)
and Spy1-WT (left gland) from three separate infections are depicted.**p<0.002; *p < 0.05.
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